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Abstract

Leptin is an adipocyte-derived hormone that regulates energy balance,

metabolism, and the neuroendocrine response to altered nutrition. Mice lacking lepti
(ob/ob) or its receptor (db/db) are massively obese and hyperphagic. They also have
increased triglyceride deposits in multiple peripheral organs, including the liver,

massively enlarged and steatotic. Leptin elicits a metabolic response that cannot be

explained by its anorectic effects alone. This response is characterized by weight l
depletion of lipid from peripheral tissues, and enhanced insulin sensitivity. The
mechanisms underlying these actions were largely unknown. This thesis addressed

leptin's metabolic effects on the liver, an organ with a critical role in lipid meta
and glucose homeostasis.
The relative contribution of central vs. peripheral leptin action on body weight,
neuroendocrine function, and lipid metabolism had not been tested genetically. To
address this question, mice with either neuronal (ObRSynIKO) or hepatocyte-specific
(ObRAlbKO) deletion of the leptin receptor were studied. ObRSynIKO mice were

massively obese and had neuroendocrine abnormalities resembling those of db/db mice,
whereas ObRAlbKO mice displayed normal body weight. ObRAlbKO mice had normal

liver triglyceride levels, while ObRSynIKO mice had enlarged fatty livers, indicatin

the liver abnormalities of ob/ob and db/db mice are secondary to defective leptin ac
the brain.

Microarrays were used to explore the basis for leptin's unique effects on the liver.

Genes with altered expression in ob/ob liver were identified, and gene expression wa

profiled following a time course of weight loss induced by either leptin treatment o

1

restriction. Cluster analysis demonstrated a unique transcriptional response to leptin,
distinct from pair-feeding. Based on these findings, an algorithm was developed to

identify and rank leptin-regulated genes for further functional analysis. The two mo

strongly leptin-regulated genes were stearoyl-CoA desaturase-1 (SCD-1) and insulin-l
growth factor binding protein-2 (IGFBP-2). SCD-1 was specifically repressed during
leptin-mediated weight loss, and mice lacking SCD-1 showed markedly reduced

adiposity on both a lean (abJ/abJ) and ob/ob background (abJ/abJ; ob/ob), despite hi

food intake. abJ/abJ; ob/ob mice also showed a complete correction of the hypometabo
phenotype and hepatic steatosis of ob/ob mice, suggesting that fatty acid oxidation

enhanced in the absence of SCD-1. Furthermore, both alcoholic and nonalcoholic fatty

liver disease secondary to lipodystrophy were markedly attenuated in SCD-1 deficient

mice. IGFBP-2 was specifically induced during leptin treatment. Double mutant IGFBP-

2~/~;ob/ob mice were partially resistant to leptin, suggesting that IGFBP-2 inducti
be necessary for the full spectrum of leptin's metabolic effects.
Thus, central leptin action coordinates a specific transcriptional response in the

liver, which mediates the metabolic effects of leptin. SCD-1 and IGFBP-2 both have a

role in leptin-mediated weight loss. Further study of these and other leptin-regulat
genes may further elucidate the molecular basis for leptin's unique effects on
metabolism.

C h a p t e r 1: Introduction

Obesity as a health problem

Medical and psychological effects of obesity
Obesity is an increasingly urgent medical and public health concern. The effects
of obesity and overweight have now permeated society. The diet industry generates

billions of dollars of revenue each year, with over 30% of adults in the United Sta

reporting that they are attempting to lose weight (Serdula et al. 1999; Friedman 200

Obesity has been estimated to cost citizens over $70 billion annually in both healt

costs and lost productivity (Wickelgren 1998). As further evidence of the far-reachi

effects of obesity, recent news stories have described a class action lawsuit again
food chains by a morbidly obese man (Reaves 2002), an expanding market in oversized
children's clothing (Erman 2002), and the banning of soda sales by the Los Angeles

school board in order to combat childhood obesity (Lota 2002). While these stories c
be viewed with a mixture of pessimism and alarm, an examination of the health

consequences and incidence of obesity illustrates the staggering scope of this issue
Obesity is associated with increased morbidity and mortality due to type 2
diabetes mellitus, coronary heart disease, cancer, hypertension, osteoarthritis,
cholelithiasis, and sleep apnea (Kopelman 2000). Actuarial studies have shown that
mortality and body weight are highly related. When smokers were removed from the
analysis, lowest mortality was found in those who are slightly underweight, with

mortality rising in parallel with body weight (Lew 1985). Results from the Nurses He

S t u d y o f ~ 1 1 5 , 0 0 0 w o m e n s h o w e d a direct relationship b e t w e e n b o d y weight a n d overall
mortality, as well as mortality specifically

Women Who Never Smoked (1499 deaths)
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Figure 1.1 Relative risk of death vs. body mass index.
Association between relative risk of death and BMI in women
who never smoked. Relative risk is directly related to BMI
(TakenfromManson et al.. 1995V

disease (Hubert et al. 1983). Further analysis of this population found that men with body
weight even 20% greater than normal showed elevated mortality (Garrison et al. 1983).
Obesity not only contributes to illness, but also carries with it a painful social
stigma in modern society. Overweight people are more likely to be thought of as unhappy
and as possessing negative personality traits (Hiller 1981). Studies have shown that obese
people are the victims of discriminatory attitudes and behavior in three major facets of

life: education, employment, and health care (Puhl and Brownell 2001). This
stigmatization contributes to psychological distress, poor self-esteem, and perhaps
worsening obesity (Myers and Rosen 1999).

Defining overweight and obesity
The most widely used metric for assessing overweight and obesity is body mass

index (BMI), which is equal to weight in kilograms, divided by the square of height i
meters. Other measures for defining obesity include waist circumference, skin fold
thickness, and bioimpedance (Kopelman 2000). BMI is highly correlated with body fat,

which is in turn, associated with adverse effects of obesity. W h e n analyzing B M I ,

however, a few caveats need to be considered. BMI does not distinguish lean mass fro

fat mass, nor does it describe the distribution of body fat, or take into account di

in body proportions. The World Health Organization classifies a BMI from 18.5-24.9 a
normal and healthy. Individuals with BMI from 25.0-29.9, 30.0-39.9, and >40 are
respectively classified as overweight, obese, and morbidly obese (Committee 1995;
Organization 1997). BMI is closely associated with the incidence of type 2 diabetes,

cholelithiasis, coronary heart disease, and hypertension, showing a linear relations
BMI < 30, but more of an exponential relationship for BMI above 30 (Willett et al.
1999). Data on women from the Nurses' Health Study and on men from the Health

Professionals Follow-up Study indicate that individuals with a BMI > 35 have a 20-fo

increased risk of developing diabetes, relative to individuals with BMI between 18.5
24.9 (Field et al. 2001).

Rising incidence of obesity
By any criteria, the incidence of obesity (BMI > 30) and overweight (BMI 25-

29.9) in the United States, other industrialized nations, and even in the developing

is increasing rapidly (Taubes 1998). The most recent data indicate that the prevalenc
overweight and obesity is 34% and 27% respectively in American adults (Yanovski and
Yanovski 2002). By comparison, according to the National Health and Nutrition
Examination Surveys (NHANES), only 12.8% of American adults met the criteria for

obesity in 1962 (Kuczmarski et al. 1994). Certain minority populations are affected a

much greater levels, with more than 10% of African-American women meeting the cutoff

for morbid obesity ( B M I > 40) (Flegal et al. 1998). Similar, but less severe trends have

also been observed throughout Europe, where recent estimates cite 15% of men and 22%
of women as obese (Project 1988). Among Pacific Islanders, rates of obesity are

markedly higher reaching a prevalence of greater than 60% in certain populations (Ho

et al. 1995; Shmulewitz et al. 2001). Rates of obesity have also risen in Japan, Kore
China, and Thailand, countries where obesity has not traditionally been a concern
(Popkin 1994).
Obesity is not only affecting adults in greater numbers, but is an increasing

concern in children and adolescents as well. Since 1976, the prevalence of overweigh

among children and adolescents in the US, has more than doubled (Troiano et al. 1995
(Yanovski and Yanovski 2002). This trend has been linked to a rise in the incidence

Type 2 diabetes and other sequellae of increased body weight in this age group (Sinh

al. 2002). In addition, early infancy, 5-7 years of age, and adolescence are critical
where the presence of obesity markedly increases the risk for obesity in adult life

1994). Thus, obesity not only impacts on health in children, but also predisposes the
a lifetime of health problems.

Causes of obesity

A consequence of environment or biology?
In basic terms, obesity, a disorder of energy homeostasis, develops when energy

intake exceeds energy expenditure. One view, popular among the public, is that obesi

the result of a lack of willpower and gluttony, coupled with extreme laziness. In to

consumer-driven society, Americans are bombarded with an array of "super sized," hig

calorie fast food. In addition, low fat foods are aggressively, and deceptively marketed as

a guilt-free alternative that can be consumed without consequences. The amenities of

modern society have not only led to higher caloric intake, but have also facilitated
decreased physical activity. Children in the US are spending increasing amounts of
leisure time watching television or playing video games, activities that have been

postulated to be partly responsible for the rise in childhood obesity (Robinson 2001)

Furthermore, low physical activity and reduced energy expenditure have been found to
risk factors for weight gain (Ravussin et al. 1988; Rissanen et al. 1991). The above
information supports an environmental basis for obesity, a hypothesis that has been
further bolstered by studies of migrant populations. Among Asian Americans, the

likelihood of overweight and obesity increases with the number of years spent in the

(Lauderdale and Rathouz 2000). Obesity is also more prevalent in American born than i
foreign-born individuals, and increases markedly in second and third generation
immigrants (Popkin andUdry 1998).
An alternative theory for the etiology of obesity posits that weight is maintained

by a precise physiological mechanism. Weight, whether normal or not, tends to remain
stable in most adult humans and other mammals, implying the existence of a precise

homeostatic circuit. Most adults gain a small amount of weight over the course of ea

decade, and calculations indicate that this trend requires that food intake and ener
expenditure match one another within 0.17% over this period (Weigle 1994).

Furthermore, when food intake is restricted to maintain a 10% reduction in body weig

energy expenditure decreases to offset this perturbation (Leibel et al. 1995). The in

stability in body weight led to the 'set point' hypothesis, which proposes that food

and energy expenditure are coordinately regulated to maintain a relatively constant body

weight (Harris 1990; Friedman and Leibel 1992). This hypothesis suggests the presenc

of afferent signals indicating the level of energy stores, which are sensed and inte

and then transduced into efferent signals controlling appetite and energy expenditur
Early physiology experiments indicated that the hypothalamus might be the central
integrator, where afferent signals are sensed and efferent responses are generated,

that adipose tissue might be the source of the afferent signal (Kennedy 1950; Kenned
1953). In support of this theory, lesions of the ventromedial hypothalamus lead to

hyperphagia and obesity, while lesions of the lateral hypothalamus result in increas
energy expenditure, decreased food intake, and weight loss (Hetherington and Ranson
1942; Powley and Keesey 1970).
The above discussion supports the view that body weight is determined by

environment and behavior, in conjunction with a precise homeostatic loop. Why then h
this physiological system not countered the rise in body weight associated with the

sedentary lifestyle and abundance of calories in modern society? According to the "t

genotype" hypothesis, in ancient hunter-gatherer societies, where food was scarce an

obtaining nutrients required significant energy expenditure, the ability to efficien
energy in the form of adipose tissue provided an adaptive advantage (Neel 1999).

Individuals capable of most efficiently storing energy in adipose tissue would be mo

likely to survive frequent periods of food deprivation, and in turn, pass these gene
their offspring. Now, thousands of years later, in an environment where calorically

foods are plentiful and technology has permitted a sedentary existence, the ready st

of energy as adipose tissue no longer serves a beneficial purpose, and instead contr

to the obesity epidemic. This hypothesis explains the recent rise in obesity and further
illustrates that this disorder is the result of an intricate connection between genes and
environment.

A genetic basis for obesity
While body weight can be heavily influenced by environment, obesity has a
definite genetic component. Twin studies, adoption studies, and patterns of familial
aggregation all support a genetic basis for obesity. An analysis of identical twins either
reared together or apart, found that the correlation in BMI was only slightly lower in
twins raised apart, than in those raised together (Stunkard et al. 1990). Furthermore, when
pairs of identical twins were subjected to periods of positive or negative energy balance,
the rate and proportion of weight gain, as well as the site of fat deposition, were more
similar within than between pairs (Bouchard et al. 1990). A large study of more than
100,000 individuals from either biologic or adoptive relationships found a BMI
correlation of 0.70 in monozygotic twins and 0.32 in dizygotic twins, which corresponds

to a heritability of 50-90% (Maes et al. 1997). This heritability coefficient is equivalent to
that for height and greater than those for many other traits considered to have genetic
underpinnings (Friedman 2000a). In order to reconcile the disproportionate prevalence of
overweight and obesity in westernized societies with this convincing genetic data, many
researchers have proposed that susceptibility to obesity is under genetic control and that
behavior and environment determine the phenotypic expression of these susceptibility
genes (Barsh et al. 2000).

Obesity can thus be viewed as a

Experiments
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complex, polygenic disease in which
genetic modifiers interact with the
environment to determine an individual's
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adiposity. However, rare, Mendelian
single gene disorders giving rise to
obesity in humans and rodents, have been
invaluable in elucidating the
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physiological basis for body weight
regulation. Recessive mutations in the
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Figure 1.2 Coleman's parabiosis experiments. These studies
suggested that ob encoded a soluble factor and that db
encoded its receptor (Taken from Coleman, 1978).

morbid obesity (Coleman 1978). These
mice weigh approximately three times more than normal littermates, with five times more
body fat. Parabiosis experiments, in which the circulations of two mice are fused,
suggested that the ob gene encodes a circulating factor regulating appetite and energy
expenditure and that db encodes its receptor (Figure 1.2) (Coleman 1978). When the
circulations of a wild-type and an ob/ob mouse are fused, the ob/ob mouse decreases its
food intake and loses weight, indicating that a soluble factor exists in wild-type mice,
which is absent in ob/ob mice (Figure 1.2, bottom panel). This factor also exists in db/db
mice, as indicated by weight loss in ob/ob mice parabiosed to db/db mice (Figure 1.2
middle panel). However, db/db mice are clearly resistant to this factor and overproduce it,
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because parabiosis of db/db and lean mice has no effect on db/db mice, but causes death
by starvation in wild-type animals (Figure 1.2, top panel).

A molecular basis for energy homeostasis

Leptin and the regulation of body weight
Coleman's hypothesis was validated with the positional cloning of the ob gene,

which was shown to encode an adipose tissue-derived, 16 kilodalton circulating hormo
named leptin (Zhang et al. 1994; Friedman and Halaas 1998). Leptin is also expressed

lower levels in the placenta, skeletal muscle, and gastric epithelium (Masuzaki et a

1997; Bado 1998; Wang 1998). In the ob2j mutant, an Etn transposon is inserted into t

first intron of the gene, generating hybrid RNAs, where the splice donor of the non-

coding first exon is joined to splice acceptors in the transposon, preventing the sy
of mature RNA (Moon and Friedman 1997). In the more commonly studied oblj mutant,

a nonsense mutation in the leptin gene leads to translation of a truncated protein t
not secreted into the circulation (Zhang et al. 1994). In this mutant, the levels of
are elevated, suggesting that leptin expression is under feedback control.
The initial data indicated that leptin might be the afferent signal in a negative

feedback loop regulating adiposity. Leptin is expressed in all adipose depots, and i

expression is increased roughly 20-fold in mice with hypothalamic lesions or in db/d

mutants (Maffei et al. 1995a). Plasma leptin levels are increased proportionately to

mass in obese mice and humans, and fall in both following weight loss (Maffei et al.
1995b; Considine et al. 1996).
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These results suggested that leptin
was an indicator of nutritional excess, with

20- A
18-

_ 163 1412~
high levels of circulating leptin signaling an•I
c 10tj 88 6animal to decrease food intake and increase
u. 240-

0

C57BU6J ob/ob

10

20 30

20 c C57BUKs db/db
18 j*fXA^vbA^ A ^
16
P-< ^ ^ - ^ s
14
12
108
642-

u-j

5

10 15

energy expenditure. Administration of leptin

80D

80,B

oU
7060501
40'

70,
by intraperitoneal injection or subcutaneous S 60!
¥ 50'
1 40infusion leads to a dose-dependent decrease -S" 30m 20in body weight and food intake in ob/ob and
W i l d - t y p e , b u t n o t d b / d b m i c e ( F i g u r e 1.3)

( C a m p f i e l d et al. 1 9 9 5 ; H a l a a S et al. 1 9 9 5 ;

100-

10

20 30

3020100-

10

15

Day

Figure 1.3 Effects of leptin administration, ob ob (A and B)
and db/db (C and D) mice received daily injections of leptin (5
u.g/g per day) (solid squares), daily injections of PBS (open
circles), or no treatment (solid tnanglcs) (Taken from Halaas
etal., 1995).

Pelleymounter et al. 1995; Stephens et al.
1995). In both ob/ob and wild-type mice, leptin-induced weight loss is specific to adipose
tissue, with no affects on lean body mass (Halaas et al. 1995; Pelleymounter et al. 1995).
Adenovirus-mediated leptin gene therapy also specifically depletes adipose tissue (Chen
et al. 1996a). Furthermore, leptin treatment improves hyperglycemia, hyperinsulinemia,
and hypercorticosteronemia in ob/ob mice (Halaas et al. 1995; Pelleymounter et al. 1995;
Stephens et al. 1995). When wild-type mice are treated with leptin, the reduction in food
intake only persists until the adipose tissue has been depleted, after which, food intake
returns to normal, without any weight being regained (Halaas et al. 1997). The signal
responsible for attenuating leptin's effects in wild-type mice remains unknown.
An alternate view of leptin's role is as a signal of nutritional deprivation, with low
leptin levels initiating an adaptive response to conserve energy, manifested by
hyperphagia, decreased energy expenditure, and shutdown of the reproductive and other
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endocrine axes, ob/ob mice, which lack circulating leptin, are hyperphagic and

hypometabolic and exhibit other characteristics of starvation, such as decreased bod
temperature, impaired immune function, and infertility (Coleman 1978). Concurrent

leptin administration largely corrects fasting induced changes in testosterone, lute

hormone, thyroxine, corticosterone, ACTH, and estrous (Ahima et al. 1996). Leptin als
corrects the starvation induced fall in serum growth hormone and can reverse the
immunosuppressive effects of starvation (LaPaglia et al. 1998; Lord 1998). Leptin

administration can restore fertility in female ob/ob mice (Chehab et al. 1996). Lept

effects on the reproductive axis are further evidenced by the early onset of pubert
leptin treated mice, and the delayed onset of puberty and cessation of ovulation in
extremely thin, hypoleptinemic women (Ahima et al. 1997; Chehab et al. 1997). In
addition, leptin injection into the third ventricle of ovariectomzied rats leads to
significant increase in plasma luteinizing hormone (Yu et al. 1997).
The above findings indicate that leptin's role may be to signal nutritional
deprivation to the endocrine system. However, leptin is also clearly important in

preventing weight gain in periods of nutrient excess. A broader view holds that lept
dynamically regulates appetite, energy expenditure, and neuroendocrine function to
maintain body weight within a narrow range.

Leptin signaling
A high-affinity leptin receptor (Ob-R) was identified from mouse choroid plexus
by expression cloning (Tartaglia et al. 1995). Ob-R was found to be a membrane

spanning receptor, related to the cytokine receptor family. Positional cloning of th
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m o u s e d b gene proved that it encodes O b - R , which has five alternatively spliced
isoforms, ObR (a-e) (Figure 1.4a) (Chen et al. 1996b; Chua et al. 1996; Lee et al. 1996).
Strains of db/db and fa/fa rats have been characterized and found to contain different
receptor defects (Philips et al. 1996; Lee et al. 1997; Li et al. 1998). C57B1/Ks db/db
mice contain an insert leading to an alternatively spliced transcript with a premature stop
codon, preventing the expression of Ob-Rb,
while other isoforms remain intact (Figure
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Figure 1.4 Leptin receptor isoforms and receptor
mutations in rodent models of obesity (a) The structure of
thefiveObR splice variants and (b) the nature of different
ObR mutations (TakenfromFriedman and Halaas. 1998V

cytoplasmic tail with consensus Jak-Stat binding motifs and three tyrosine residues that
are targets for phosphorylation by SH2 domain-containing proteins. Defective Stat
signaling was observed in cells transfected with the mutant receptor found in db/db mice
(Ghilardi et al. 1996). The role of the other isoforms is not presently known. Although
Ob-Ra can mediate signal transduction in vitro, an in vivo activity has not been
demonstrated (Bjorbaek et al. 1997). Ob-Ra and Ob-Rc are highly expressed in cerebral
microvessels and have been suggested to be involved in leptin transport into the CNS
(Banks et al. 1996; Hileman et al. 2002). Ob-Re is a soluble form of the receptor that
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binds leptin in the plasma and appears to facilitate leptin action (Li et al. 1998; Huang et
al. 2001).
Ob-Rb is expressed at high levels in hypothalamic neurons and has also been

detected in T cells, lymph nodes, vascular endothelium, and the jejunum (Chen et al.

1996b; Ghilardi et al. 1996; Lee et al. 1996; Lord 1998; Morton et al. 1998; Sierra-

Honigmann et al. 1998). Ob-Rb appears to be expressed, albeit at low levels, in most

other tissues (Ghilardi et al. 1996). In situ hybridization detected Ob-Rb in the ar
nucleus, dorsomedial hypothalamic nucleus (DMH), paraventricular nucleus (PVN),
ventromedial hypothalamus (VMH), and the lateral hypothalamus (LH), nuclei known to
be involved in regulating appetite and body weight (Hetherington and Ranson 1942;

Mercer et al. 1996b; Elmquist et al. 1997; Fei et al. 1997; Elmquist et al. 1998b). L

injection leads to a dose-dependent activation of Stat3 specifically in the hypothal
wild-type and ob/ob, but not db/db mice, detectable 15 minutes after administration

(Vaisse et al. 1996). Leptin also induces the hypothalamic expression of fos, a Stat3

target gene (Woods and Stock 1996). Leptin activates phosphatidylinositol-3-OH kinas
(PI(3)K) in hypothalamic neurons, and intracerebroventricular (i.e.v.) infusion of
inhibitors of this enzyme blocks leptin-induced anorexia (Niswender et al. 2001).
A number of molecules are also involved in attenuating leptin signal transduction.

Leptin receptor signaling requires Jak2 phosphorylation. Leptin binding induces tyro

phosphorylation of SHP-2, a phosphatase that decreases Jak2 phosphorylation, thereby
blunting leptin signal transduction (Carpenter et al. 1998; Li and Friedman 1998).
Protein-tyrosine phosphatase PTP1B also dephosphorylates Jak2 and mice lacking

PTP1B are hypersensitive to leptin, have increased levels of phosphorylated Stat3, a
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are resistant to obesity (Elchebly et al. 1999; Cheng et al. 2002; Cook and Unger 2002;

Zabolotny et al. 2002). Ob-R signaling is also negatively regulated by SOCS-3, a memb
of the suppressors-of-cytokine-signaling family of molecules (Bjorbaek et al. 1998).
The high levels of Ob-Rb expression in the hypothalamus and the leptin resistance

observed in rats with hypothalamic lesions indicate that leptin has direct effects o
brain (Satoh et al. 1997). I.C.V. administration of leptin reduces food intake at a

has no effect when delivered peripherally (Campfield et al. 1995; Stephens et al. 19
Halaas et al. 1997). Complete depletion of adipose tissue in wild-type mice requires

chronic i.c.v. infusion of only 3 ng/hr, whereas over 500 ng/hr are required when le

infused peripherally via a subcutaneous pump (Halaas et al. 1997). In addition, lepti

similar metabolic effects, whether delivered centrally or peripherally (Halaas et al
Kamohara et al. 1997). The leptin receptor, however, is broadly expressed and leptin
direct effects on some peripheral tissues. Leptin can modulate the immune system,
angiogenesis, and bone metabolism (Lord 1998; Sierra-Honigmann et al. 1998; Ducy et

al. 2000). Ob-Rb is expressed in a number of peripheral tissues and direct effects of
on T cells, macrophages, pancreatic 3-cells, muscle, and other cell types have been

reported (Shimabukuro et al. 1997a; Lord 1998; Kim et al. 2000; O'Rourke et al. 2001;

Minokoshi et al. 2002). Thus, the relative importance of leptin action on brain versu
peripheral sites is untested.

Neuronal circuitry regulating body weight

Leptin action in the brain modulates an increasingly complex neuronal circuit,
which regulates food intake and energy expenditure (Friedman and Halaas 1998;
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Schwartz et al. 2000). Ob-Rb expressing neurons in the arcuate nucleus receive inputs

from other hypothalamic nuclei as well as the cortex and amygdala (DeFalco et al. 200
In addition, hypothalamic nuclei expressing Ob-Rb have efferents that interact with
cortex, sympathetic and parasympathetic nervous systems, and pituitary.
The leptin receptor has been detected in a number of hypothalamic nuclei, such as
the arcuate nucleus, VMH, DMH, and PVN, and these nuclei express neuropeptides

which modulate food intake (Elmquist et al. 1997; Fei et al. 1997; Elmquist et al. 19

Key molecules in this neuronal circuit include neuropeptide Y (NPY) and agouti-relat
protein (AGRP), which stimulate food intake, and a-melanocyte stimulating hormone
(a-MSH) and cocaine- and amphetamine-regulated transcript (CART), which suppress
food intake. I.C.V. injection of NPY potently stimulates food intake, and NPY mRNA

upregulated in ob/ob mice and decreases following leptin treatment (Stanley et al. 1
Stephens et al. 1995). ob/ob mice lacking NPY show an attenuation of obesity with

decreased food intake and increased energy expenditure (Erickson et al. 1996). a-MSH

a cleavage product of the precursor pro-opiomelanocortin (POMC), whose cleavage also
generates (3- and y-MSH, as well as adrenocorticotropin (ACTH) and (3-endorphin. aMSH acts on melanocortin receptors (MC-R), with effects on feeding through the MC-3

and MC-4 receptors. Agonists of the MC-4 receptor inhibit feeding, while antagonists

stimulate feeding (Fan et al. 1997). Furthermore, MC-4 receptor knockout mice are obe

and leptin resistant, as are lethal yellow, agouti (Ay) mice, a mutant strain that e

expresses the agouti protein in brain, which acts as an MC-4 receptor antagonist (Lu

1994; Boston et al. 1997; Halaas et al. 1997; Huszar et al. 1997; Marsh et al. 1999)

AGRP was cloned as an endogenous inhibitor of melanocortin signaling, and ob/ob mice
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overexpress A G R P m R N A 8-fold (Ollmann et al. 1997; Shutter et al. 1997). In addition,
transgenic mice overexpressing AGRP are obese (Graham et al. 1997). CART decreases

food intake, and its expression is nearly undetectable in ob/ob mice, but can be ind
by leptin (Kristensen et al. 1998).
Leptin signals are transduced into a neuronal response, the general nature of

which is beginning to emerge. In the hypothalamus, Ob-Rb is expressed in functionall

distinct classes of neurons, the best characterized being neurons that co-express ei
NPY or a-MSH (Mercer et al. 1996a; Cheung et al. 1997). The orexigenic molecules
NPY and AGRP co-localize in arcuate nucleus neurons (Broberger et al. 1998; Hahn et

al. 1998). Furthermore, POMC and CART, both of which are anorexigenic, co-localize in

a distinct subset of arcuate nucleus neurons (Elias et al. 1998). NPY/AGRP neurons ar

inhibited by leptin, while POMC/CART neurons are activated by leptin (Stephens et al

1995; Schwartz et al. 1997; Thornton et al. 1997; Broberger et al. 1998; Hahn et al.

1998). These neurons are thought to innervate yet to be described higher order neuron
coordinating energy homeostasis.
The above model, however, is undoubtedly just one part of the higher order
circuitry, as numerous additional molecules also impact feeding behavior. Melanin-

concentrating hormone, galanin, orexin, peptide YY, and noradrenaline all increase f
intake, while cholecystokinin (CCK), corticotropin-releasing hormone (CRH), insulin,

glucagon-like peptide-1 (GLP-1), bombesin, urocortin, and serotonin all decrease food
intake (Friedman and Halaas 1998).
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Efferent pathways modulated by leptin
Early physiological studies demonstrated that lesions of the ventromedial

hypothalamus lead to hyperphagia and obesity (Hetherington and Ranson 1942; Elmquist

et al. 1999). When food intake in lesioned animals is restricted to the same levels a
controls, however, obesity still develops (Himms-Hagen 1989). Increased storage of

calories in the setting of normal food intake, indicates that these animals have red

energy expenditure. Thus, the brain serves a critical function in the coordination o

energy homeostasis. The role of leptin in this process is confirmed by decreased ene
expenditure in ob/ob mice (Boissonneault et al. 1978; Dauncey and Brown 1987).

Therefore, the leptin modulated neuronal circuit, through still undescribed higher o
neurons, is thought to regulate energy homeostasis.
Energy expenditure can be divided into three main components: obligate energy
expenditure required for basic cellular function, physical activity, and adaptive
thermogeneis (Lowell and Spiegelman 2000). Adaptive or facultative thermogenesis, is
defined as heat production in response to environmental temperature or diet. Energy
expenditure is generally measured by oxygen consumption, which can then be used to
caculate metabolic rate. Oxygen consumption or metabolic rate increases acutely

following feeding, as well as after chronic overfeeding (Shibata and Bukowiecki 1987
Sims and Danforth 1987; Levine et al. 1999). Food restriction, on the other hand is

associated with a decrease in metabolic rate (Leibel et al. 1995). These alterations,
counter-productive during dieting, serve to maintain weight within a narrow range.
Leptin has clear effects on energy expenditure and is thought to exercise its
effects, in part, through the autonomic nervous system. Treatment with ^-adrenergic
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receptor agonists causes lipolysis and an increase in energy expenditure (Galton and Bray
1967; Davies 1968; Landsberg et al. 1984). Brown adipose tissue and skeletal muscle

play a major role in adaptive thermogenesis, and these tissues are highly innervated

the sympathetic nervous system. Decreased sympathetic output has been proposed to be
responsible for the development of obesity (Bray and York 1998). Sympathetic outflow

to brown adipose tissue is decreased in ob/ob mice (Young and Landsberg 1983). Lepti
increases norepinephrine turnover in brown fat (Collins et al. 1996). The leptin-

dependent rise in sympathetic activity to brown adipose tissue increases the express
the uncoupling protein, UCP1 (Scarpace et al. 1997; Scarpace and Matheny 1998).
Uncoupling proteins disrupt the mitochondrial proton gradient causing energy to be

dissipated in the form of heat, rather than channeled into the formation of ATP. The
importance of brown adipose tissue to body weight homeostasis is indicated by the

development of obesity in mice with genetic ablation of brown fat (Lowell et al. 199
UCP1 knockout mice, however, are not obese, perhaps due to compensation by other
UCP isoforms (Enerback et al. 1886). Ectopic overexpression of UCP1 in white adipose

tissue, on the other hand, protects mice from obesity (Kopecky et al. 1995). While UC

is expressed specifically in brown adipose tissue, UCP2 is expressed in most tissues

UCP3 is expressed in muscle and brown adipose tissue (Boss et al. 1997; Fleury et al
1997; Gimeno et al. 1997; Gong et al. 1997; Vidal-Puig et al. 1997).
Measurement of nerve activity following leptin treatment demonstrates dose-

dependent increases in sympathetic output to brown adipose tissue, kidney, hindlimb,
the adrenal gland in wild-type, but not in obese Zucker rats, which have a mutation

leptin receptor (Haynes et al. 1997). Sympathetic output acts on P-adrenergic recepto
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of which there are three well characterized types, (31, |32, and 03. Activation of these

receptors leads to intracellular activation of protein kinase A (PKA) and cyclic AMP

(cAMP), and these molecules are involved in energy homeostasis (McKnight et al. 1998)
Disruption of RII(3, one of the regulatory subunits of PKA, leads to an increase in

catalytic units of PKA, with greater avididity for cAMP. Despite normal food intake,

these mice are lean, and show decreased triglyceride storage in white adipose tissue

elevated metabolic rate, and resistance to dietary obesity (Cummings et al. 1996). Th

P3-adrenergic receptor has been proposed to play a particularly important role in en
expenditure and body weight homeostasis, as its stimulation decreases adiposity and

leptin expression (Collins and Surwit 1995; Mantzoros et al. 1996). The selective p3-

adrenergic agonist CL316243 is effective at treating obesity and diabetes in rodents

et al. 1999). In addition, a knockout of the P3-adrenergic receptor leads to a mild i
in adiposity (Susulic et al. 1995). Confirmation of the importance of P-adrenergic
receptors, as opposed to an unknown target, in the regulation of body weight was

difficult, however, due to functional redundancy of the different receptor types. Tr

mutant mice lacking all three P-adrenergic receptors have recently been generated a

demonstrate reduced metabolic rate and massive obesity on a high-fat diet, indicatin
these receptors are required for diet-induced thermogenesis (Bachman et al. 2002)
Leptin also modulates energy expenditure through effects on the hypothalamic-

pituitary axis. Leptin regulates many aspects of hypothalamic-pituitary function, so
which are involved in energy homeostasis (Yu et al. 1997). Thyroid hormone modulates

energy expenditure, with low levels associated with decreased metabolic rate and hig
levels associated with increased metabolic rate (al-Adsani et al. 1997). Leptin
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administration can prevent fasting-induced suppression in thyroid hormone levels, by
blunting the suppression in prothyrotropin releasing hormone RNA levels in the
hypothalamic PVN (Ahima et al. 1996; Legradi et al. 1997). Elevated glucocorticoid

levels, as in Cushing's syndrome, are associated with increased fat deposition. In fa
transgenic mice overexpressing lip hydroxysteroid dehydrogenase type 1 (lip HSD-1)
have increased adipose tissue levels of corticosterone and develop visceral obesity
features of the metabolic syndrome (Masuzaki et al. 2001). Glucocorticoid levels are
elevated in ob/ob and db/db mice, and obesity in these animals is improved by

adrenalectomy or treatment with glucocorticoid antagonists (Naeser 1973; Freedman et

al. 1986). Elevated glucocorticoid levels are unique to ob/ob and db/db mice, whereas
other forms of rodent obesity are not associated with elevated corticosterone (Bray

York 1979). As further evidence for the role of leptin in modulating corticosterone l

fatless A-ZIP/F-1 lipoatrophic mice, which are deficient in circulating leptin, also
hypercorticosteronemia (Haluzik et al. 2002). Leptin has been shown to lower
glucocorticoids both by direct action on the adrenals and via the hypothalamic PVN
(Bornstein et al. 1997; Huang et al. 1998; Cherradi et al. 2001).
The growth hormone (GH) axis is also perturbed in obesity (Scacchi et al. 1999).

In humans, plasma GH is inversely related to measures of adiposity, and in humans an

rodents, obesity is also associated with reduced plasma insulin-like growth factor I

I), which is downstream of GH (Rudman et al. 1981) (Copeland et al. 1990; Zhou et al

1998a). In obese Zucker rats, GH levels and pulsatility are severely decreased, due t
decreased hypothalamic growth-hormone releasing factor (GRF) and an impaired

pituitary response to GRF (Finkelstein et al. 1986; Tannenbaum et al. 1990). Transgen
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rats expressing a low level of human G H show suppression of endogenous G H secretion

and pulsatility and develop massive obesity and insulin resistance (Ikeda et al. 1997
Double-labeling immunohistochemistry detected ObR in some hypothalamic neurons
containing GH-releasing hormone (GHRH) (Hakansson et al. 1998). Administration of a

leptin antiserum to rats leads to decreased GH secretion, suggesting that leptin, ma

part, regulate GH secretion (Carro et al. 1997). Furthermore, central leptin infusion

stimulates spontaneous pulsatile GH secretion, as well as secretion in response to G
(Tannenbaum et al. 1998).

Metabolic effects of leptin

Differential actions of leptin and food restriction
Leptin regulates energy expenditure by exerting specific and unique metabolic
effects. These effects are likely due to modulation of sympathetic outflow and
neuroendocrine activity, as well as direct actions of leptin on peripheral tissues.
deficient in leptin (ob/ob) or resistant to its action (db/db, fa/fa) are markedly

hyperphagic and morbidly obese. However, the effects of leptin deficiency are not pu
the result of increased caloric intake, as food restricted ob/ob mice still develop
(Coleman 1978). Replacement of leptin in ob/ob mice leads to the specific depletion

fat mass, whereas food restriction depletes both fat and lean mass (Halaas et al. 19

Pelleymounter et al. 1995; Halaas et al. 1997). ob/ob mice that have been food restr
to the level that leptin treated mice voluntarily consume (pair-fed) show smaller

decreases in body weight and size of adipose depots (Levin et al. 1996). In addition
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restriction is associated with a compensatory decrease in energy expenditure, which does

not occur in response to leptin-induced hypophagia (Halaas et al. 1997). Finally, whe

food restriction leads to a rise in serum free fatty acids, leptin-mediated weight l

associated with a rise in free fatty acids or ketones, suggesting a unique mechanism
fatty acid oxidation (Chen et al. 1996a; Shimabukuro et al. 1997a). Taken together,

data confirm that leptin's effects on body weight are not due to its anorectic effec
but must also require actions on peripheral metabolism.

Effects on lipid metabolism
In the absence of effective leptin action, triglyceride not only accumulates in

adipose tissue, but also in other peripheral sites such as liver, skeletal muscle, h
pancreatic islets. One dramatic manifestation can be seen in ob/ob liver, which is
massively enlarged and steatotic, with numerous lipid-filled vacuoles apparent on

histological examination (Figure 1.5). This build-up of lipid in non-adipose tissues

lipotoxicity, which contributes to insulin resistance and organ dysfunction in the o
state (Unger 2002). Increased intracellular lipid in insulin-responsive tissues is
increasingly appreciated as being critical to the development of insulin-resistance
diabetes (McGarry 1992; Shulman 2000). In addition, lipid accumulation in islets is

involved in islet hypoplasia and destruction in advanced diabetes, via increased syn

of the apoptotic mediators nitric oxide and ceramide, and reduced levels of Bcl-2, a

inhibitor of apoptosis (Lee et al. 1994; Shimabukuro et al. 1997b; Shimabukuro et al
1998a; Shimabukuro et al. 1998b; Shimabukuro et al. 1998c).
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Figure 1.5 Hepatomegaly and fatty liver in ob/ob mice. (A) Photographs of freshly
dissected livers, wild-type on left and ob/ob on right. The ob/ob liver is 3-4x larger
and has a shiny appearance, consistent with lipid accumulation. (B) Hematoxylin and
eosin stained liver sections demonstrate vacuolation throughout ob/ob liver, suggestive
of lipid accumulation and fatty liver disease.

Given the deleterious consequences of lipid accumulation in peripheral tissues,
evidence suggests a role for leptin in the control of lipid homeostasis in nonadipose
tissues (Unger 2002). When caloric intake exceeds energy expenditure, leptin levels rise
to prevent deposition of lipid in peripheral sites. In states of leptin deficiency or leptin
resistance, however, this action is defective and lipotoxic disease develops. In support of
this hypothesis, leptin treatment, significantly more so than pair-feeding, rapidly reduces
lipid in non-adipose sites by decreasing triglyceride formation and increasing free fatty
acid oxidation (Shimabukuro et al. 1997a). Islets isolated from hyperleptinemic rats, as
compared to islets isolated from pair-fed or untreated rats, show a markedly increased
ratio of fatty acid oxidation to esterification (Zhou et al. 1997). Relative to control and
pair-fed samples, these islets demonstrate increased expression of acyl CoA oxidase
(ACO) and carnitine palmitoyltransferase-I (CPT-I), enzymes involved in fatty acid
oxidation, as well as increased expression of UCP-2. In addition, islets from both leptin
treated and pair-fed rats show a comparable reduction in the expression of acetyl-CoA
carboxylase (ACC) and glycerol-3-phospate acyltransferase (GPAT), enzymes involved
in fatty acid biosynthesis and esterification (Zhou et al. 1997). Adipose tissue
demonstrates a similar pattern of gene expression in hyperleptinemic animals, along with
loss of expression of the adipocyte markers fatty acid binding protein-2 (aP2), tumor
necrosis factor a, and leptin, and appearance of the preadipocyte marker Pref-1 (Zhou et

al. 1999).
The biochemical pathways mediating leptin's effects on fatty acid oxidation are
beginning to be elucidated. The nuclear hormone receptor PPARa, which regulates many
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of the enzymes of fatty acid oxidation, has been proposed to coordinate this

transcriptional program (Aoyama et al. 1998). Hyperleptinemia in wild-type, but not f
rats, induces the expression of PPARa, ACO, and CPT-I in peripheral tissues, genes
which likely mediate the effects of leptin (Zhou et al. 1998b; Zhou et al. 1999).

Administration of leptin to PPARa knockout mice leads to a smaller reduction in adip

depots and a smaller depletion in liver triglyceride, confirming that this pathway i

required for the lipopenic effects of leptin (Lee et al. 2002). In muscle, leptin has

found to stimulate fatty acid oxidation, both directly and secondary to signaling in
brain. These actions are mediated through activation of a2 AMP-kinase, which
phosphorylates and inhibits acetyl-CoA carboxylase (ACC) (Minokoshi et al. 2002).

Inhibition of ACC leads to reduced levels of malonyl CoA, which is required for fatt
acid biosynthesis and also inhibits the mitochondrial carnityl palmityl transferase

the rate-limiting step in the import and oxidation of fatty acids in mitochondria (M

et al. 1977). Thus, malonyl CoA is considered to be a crucial metabolic control point

with reduced levels leading to decreased fatty acid biosynthesis and increased fatty

oxidation (Ruderman et al. 1999). This mechanism also accounts for the lean phenotype
and increased fatty acid oxidation in mice lacking acetyl-CoA carboxylase 2 (AbuElheiga et al. 2001). However, activation of a2 AMP-kinase is not associated with

increased leptin-mediated fatty acid oxidation in all tissues. While leptin stimulat
acid oxidation in liver and heart, a2 AMP-kinase is not activated, suggesting that
alternative mechanisms can also explain leptin's lipopenic actions (Atkinson et al.
Lee et al. 2002).
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Leptin's effects on lipid metabolism are not solely the consequence of enhanced

fatty acid oxidation, but are also due to decreased lipogenesis. ob/ob and db/db mic

enlarged steatotic livers (Yen et al. 1976; Koteish and Diehl 2001). The fatty liver
part, the result of an increased rate of hepatic lipogenesis, which is also thought

contribute to the development of obesity (Kaplan and Leveille 1981). Leptin treatmen

normalizes the hepatomegaly and associated elevations in hepatic lipid (Levin et al

1996). Analysis of ob/ob livers by 13C NMR after five days of leptin treatment revea
decreased de novo fatty acid synthesis, which is supported by biochemical assays
showing decreased ACC and fatty acid synthase (FAS) activity (Cohen et al. 1998).
Thus, by modulating gene expression and the pathways of fatty acid biosynthesis and

oxidation, leptin confines storage of triglycerides to adipose tissue and prevents l
disease during states of overnutrition.
More recently, leptin's metabolic effects have been shown to be important in

lipodystrophies, a rare set of diseases characterized by complete or near-complete l
adipose tissue (Garg 2000; Reitman et al. 2000). In the absence of adipose tissue,

ingested nutrients are deposited as triglycerides in liver, muscle, and other periph

tissues leading to severe insulin resistance and diabetes. Transgenic overexpression

white adipose tissue of either nuclear sterol regulatory element-binding protein-lc
SREBP-Ic tg) or a dominant negative protein preventing the binding of certain bZIP

transcription factors (A-ZIP) produces mice with a near complete absence of adipose

tissue, along with marked hepatic steatosis, insulin resistance, and hyperglycemia (

et al. 1998; Shimomura et al. 1998a). In the near-absence of adipose tissue, circulat

levels of leptin and other adipose-derived factors are extremely low, and a deficie
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one or more of these factors has been hypothesized to be responsible for disease.
Treatment of aP2-SREBP-lc tg lipodystrophic mice with physiological doses of leptin

for 12 days led to a complete normalization of hepatic steatosis and glucose and ins
levels, while pair-feeding had much more modest effects (Shimomura et al. 1999c).

Originally, treatment of A-ZIP mice (which have a more severe phenotype) with lepti
produced more modest effects on the diabetic phenotype (Gavrilova et al. 2000b).

However, later studies showed that supraphysiological levels of leptin can correct t
phenotype in these mice (Ebihara et al. 2001). In addition, surgical implantation of

from wild-type mice, but not from ob/ob mice, can fully rescue the phenotype of A-ZI
mice (Gavrilova et al. 2000a; Colombo et al. 2002). While these findings do not rule

a role for other adipose factors, leptin clearly plays a crucial role in depleting p

triglyceride and correcting diabetes in these mice. Based on these findings, a lepti
was initiated in lipodystrophic humans, resulting in marked reductions in appetite,
hepatic steatosis, muscle triglyceride, diabetes, and hypertriglyceridemia (Oral et

2002; Petersen et al. 2002). As lipodystrophy is a side effect of antiretroviral ther

HIV, leptin therapy may become useful for this growing population of patients (Estra
et al. 2002).

Effects on carbohydrate metabolism
Leptin also has well-documented effects on glucose metabolism, ob/ob and db/db
mice are hyperglycemic and hyperinsulinemic, with marked insulin resistance. The
hyperglycemia and hyperinsulinemia of ob/ob mice are corrected with leptin

administration, and leptin treatment leads to a greater reduction in glucose, insuli
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hepatic glycogen than pair-feeding (Pelleymounter et al. 1995; Levin et al. 1996).

Obesity is associated with hyperinsulinemia, which is the body's attempt to compensa

for worsening insulin resistance. After a certain threshold, the capacity of the pan

islets is exceeded, at which point, hyperinsulinemia fails to compensate for insulin

resistance, and hyperglycemia and diabetes become fully evident. Thus, the modulatio

of glucose metabolism by leptin is influenced by a complex interplay between obesity

leptin, and insulin. Leptin receptors are expressed in pancreatic P cells and treatm

islets inhibits insulin secretion by activating ATP-sensitive potassium channels (Ki

et al. 1996; Harvey et al. 1997; Kieffer et al. 1997). As well as inhibiting insulin

secretion, leptin counters hyperinsulinemia by decreasing the expression of preproin
mRNA in ob/ob islets (Seufert et al. 1999a). Leptin has similar effects on insulin

secretion and gene expression in islets from human donors (Seufert et al. 1999b). As

insulin, in turn, increases the expression of leptin mRNA, the existence of an adipo

axis has been proposed, where insulin stimulates leptin production, and leptin, in t

inhibits insulin production (Saladin et al. 1995). Therefore, leptin's effects on glu
metabolism may, in large part, be mediated via its interactions with insulin.
A number of studies, however, point to a more specific role for leptin in

carbohydrate metabolism. When streptozotocin-induced, insulin-deficient diabetic rat

were treated with leptin for 12-14 days and studied with a hyperinsulinemic-euglycem
clamp, leptin, independent of its effects on food intake, restored euglycemia and
peripheral insulin sensitivity, and improved post-absorptive glucose metabolism

(Chinookoswong et al. 1999). Transgenic overexpression of high levels of leptin leads
a complete disappearance of white fat and increased glucose metabolism and insulin
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sensitivity (Ogawa et al. 1999). These mice are strikingly different from lipoatrophic

mice, which also have no fat, but instead develop steatosis and severe diabetes (Moi
al. 1998; Shimomura et al. 1998a).

Acute treatment with leptin, either as a five hour intravenous or i.c.v infusion, or

even as a single microinjection into the ventromedial hypothalamus, similarly increa
glucose uptake and turnover in skeletal muscle and brown adipose tissue. Leptin

stimulated glucose uptake was diminished in denervated muscle, pointing to centrally

orchestrated sympathetic output as a mediator of these effects (Kamohara et al. 1997

Minokoshi et al. 1999). The increased glucose turnover and uptake occurred in the set

of decreasing hepatic glycogen and constant plasma insulin and glucose, suggesting t
leptin acutely increases hepatic gluconeogenesis from glycogen to compensate for
enhanced glucose turnover (Kamohara et al. 1997). An acute intravenous infusion of

leptin in ob/ob mice also increased glucose uptake and turnover in brown adipose, he

and brain, but not in white adipose or skeletal muscle. This protocol did not influe
hepatic lipid metabolism, but did stimulate hepatic glucose production, and was
associated with increased activity of glucose-6-phosphatase (G6Pase) and decreased
activity of phosphoenolpuruvate carboxykinase (PEPCK) (Burcelin et al. 1999).
An acute leptin infusion in lean rats clamped at physiological hyperinsulinemia,

however, found no difference in glucose uptake and glycogen synthesis between leptin

treated and control animals. In this study, leptin enhanced insulin suppression of h
glucose production and redistributed intrahepatic glucose fluxes such that the
contribution from glycogenolysis was reduced and that from gluconeogenesis was

enhanced, changes marked by decreased levels of glucokinase RNA and increased levels
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of P E P C K R N A (Rossetti et al. 1997). This group reported the s a m e findings with i.c.v.
leptin, again indicating that leptin's effects on glucose metabolism are centrally mediated
(Liu et al. 1998). A subsequent insulin clamp study compared the effects of 8 days of
leptin and pair-feeding on glucose metabolism and showed that leptin enhanced insulinmediated inhibition of hepatic glucose production with a similar repartitioning of glucose
fluxes, while also increasing insulin stimulated peripheral glucose uptake. Relative to
food restriction, chronic administration of leptin also decreased expression of glucokinase
and increased expression of G6Pase and PEPCK (Barzilai et al. 1997). While the insulin
clamp experiments suggest that leptin mainly augments insulin action, the shift in glucose
fluxes and the changes in gene expression in a direction counter to that induced by insulin
alone, indicate that leptin has novel effects on glucose metabolism, independent of
insulin. 13C NMR studies demonstrated that five days of leptin treatment in ob/ob mice
increases hepatic gluconeogenesis and also increases the rate of hepatic glycogen
synthesis, in part by increasing the activity of glycogen synthase (Cohen et al. 1998).
Discrepancies exist in these studies, which may be due to the use of different assay
techniques and rodent species, or due to different effects of leptin in lean and insulinresistant obese animals or following acute versus chronic administration

Other mediators of energy homeostasis
While leptin is critical in the regulation of energy homeostasis, a number of other
circulating factors also act in endocrine pathways involved in energy metabolism. Insulin,
which is secreted by pancreatic P cells, acts peripherally, as an anabolic hormone,
stimulating glucose uptake and lipogenesis. However, insulin also crosses the blood-brain
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barrier, and insulin receptors are expressed in brain regions involved in feeding (Baskin

et al. 1988; Baura et al. 1993). High insulin levels reduce food intake and body weig

while low levels stimulate food intake (Woods et al. 1979; Sipols et al. 1995). Mice

a neuronal-specific knockout of the insulin receptor are hyperphagic and develop die
induced obesity (Bruning et al. 2000). Similarly, rats with decreased levels of

hypothalamic insulin receptors are hyperphagic and insulin resistant (Obici et al. 20
The recently identified hormone ghrelin, is synthesized by the stomach and the

hypothalamus, and acts as a ligand for the growth hormone secretagogue receptor (GHS

R) (Kojima et al. 1999). Ghrelin not only induces growth hormone secretion, but also

stimulates food intake, with peripheral or central administration causing weight gai

to hyperphagia and reduced utilization of fat (Tschop et al. 2000; Wren et al. 2000;

Nakazato et al. 2001; Wren et al. 2001). Interestingly, plasma ghrelin levels rise af

dieting, but remain low following gastric bypass surgery, explaining the vastly diff
success rates of these two weight loss treatments (Cummings et al. 2002).
A number of adipose-derived factors, in addition to leptin, have peripheral
metabolic effects, challenging the traditional view of adipose tissue as a passive
repository of triglyceride (Trayhurn and Beattie 2001). Levels of TNFa, a factor
mediating cachexia, are increased in different rodent models of obesity, and

neutralization of TNFa increases peripheral glucose uptake in response to insulin (O

et al. 1987; Hotamisligil et al. 1993). TNFa causes insulin resistance by inducing se
phosphorylation of insulin receptor substrate 1 (IRS-1), converting IRS-1 into an

inhibitor of insulin receptor tyrosine kinase activity (Hotamisligil et al. 1996). T

inhibitory form of IRS-1, which can attenuate signaling through the insulin receptor
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observed in muscle and adipose tissue from obese fa/fa rats (Hotamisligil et al. 1996).
Deletion of the TNFa gene or the two genes encoding its receptor improved insulin

sensitivity in lean mice, diet-induced obese mice, gold-thioglucose injected mice, a

ob/ob mice, further supporting the pivotal role of TNFa in obesity-associated insuli
resistance (Uysal et al. 1997; Ventre et al. 1997). Others, however, have found that

than contributing to insulin resistance, TNF receptors protect against obesity-relat
diabetes (Schreyer et al. 1998).

Other factors include resistin, which is secreted from adipose tissue and circulates

at increased levels in models of dietary and genetic obesity (Kim et al. 2001; Step

al. 2001). Treatment of mice with resistin leads to impaired glucose tolerance and i
action, while administration of anti-resistin antibodies improves hyperglycemia and
insulin resistance in diet-induced obese mice (Steppan et al. 2001). The specific

physiological role of resistin, however, awaits the identification of its site of ac
the generation of a knockout mouse. Acrp30 (adipocyte complement related protein of
30kDa or adiponectin) is an abundant serum protein that can form large oligomers

(Scherer et al. 1995). Treatment of mice with a proteolytic cleavage product of Acrp

induces fatty acid oxidation and weight loss (Fruebis et al. 2001). In addition, Acr

inhibits hepatic glucose production, augments hepatic insulin action, and reverses i

resistance due to lipoatrophy and obesity (Berg et al. 2001; Combs et al. 2001; Yam
et al. 2001). Obese type 2 diabetics have low adiponectin levels and adiponectin

mutations have been associated with diabetes (Weyer et al. 2001; Kondo et al. 2002).
Two separate groups have generated adiponectin null mice, and in one study, but not

the other, adiponectin deficiency leads to diet-induced insulin resistance (Ma et al
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Maeda et al. 2002). Thus, the precise function of Acrp30 remains to be elucidated. Other

adipose-derived factors including angiotensinogen, adipsin, acylation-stimulating pr

haptoglobin, retinol-binding protein, interleukin 6, plasminogen activator inhibitor

tissue factor also play important, but less well-defined roles in inflammation, meta
and energy homeostasis (Trayhurn and Beattie 2001).
In addition to adipose tissue, other peripheral tissues such as liver, muscle, and
pancreas may also secrete factors that modulate peripheral metabolism. Myostatin is

secreted from skeletal muscle and negatively regulates muscle mass, as mice and catt
lacking myostatin display muscle hypertrophy and hyperplasia (Grobet et al. 1997;

McPherron et al. 1997; McPherron and Lee 1997). In addition, myostatin null mice have
reduced adiposity, in the setting of normal food intake, and double mutant ob/ob or

mice also lacking myostatin show a partial correction of obesity and diabetes (McPhe

and Lee 2002). Systemic overexpression of myostatin, on the other hand, induces muscl
and fat wasting, resembling cachexia (Zimmers et al. 2002).

Leptin and body weight homeostasis in humans

Human obesity mutations
The scarcity of identified human mutations in the leptin circuit supports the

premise that obesity is the result of a complex constellation of genetic and environ
factors, many of which have yet to be elucidated. While a number of genetic studies

identified linkages to loci contributing to obesity in humans, monogenic forms of ob

are rare (Barsh et al. 2000). However, study of these mutations illustrates a remarka

similarity to the homologous mouse mutants. Mutations in the human ob gene are thoug
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to be rare, as numerous studies in obese subjects have failed to detect any mutations

(Maffei et al. 1996; Barsh et al. 2000). Thus far, two kindreds with homozygous loss-

function leptin mutations have been identified, displaying hyperphagia, morbid obesi
and hypogonadotropic hypogonadism (Montague et al. 1997; Strobel et al. 1998). One

family has been identified with a mutation producing a truncated leptin receptor, a

these patients have a similar phenotype to individuals lacking leptin, with the addi

presence of growth retardation and central hypothyroidism (Clement et al. 1998). Unl

rodents with mutations in leptin or its receptor, cold intolerance, severe diabetes,
increased glucocorticoid production have not been reported in human mutants. Two

children with a phenotype of obesity, adrenal insufficiency, and hypopigmentation h

also been identified and shown to have loss-of-function POMC mutations (Krude et al
1998). Obese humans with dominant mutations in the MC-4 receptor have also been

described, and this is the most commonly mutated gene in human obesity, with 3-5% o
humans with BMI > 40 estimated to have mutations in this gene (Vaisse et al. 1998;
et al. 1998; Hinney et al. 1999).
The identification of humans with loss-of-function mutations in leptin or POMC

suggests that hormone replacement therapy might be an effective treatment. One of th
leptin-deficient probands has been treated with leptin for over a year with daily
subcutaneous injections, with a notable decrease in body weight and appetite, along
pubertal progression (Farooqi et al. 1999). The successful use of leptin therapy in

children indicates that leptin is capable of enacting the same physiological respon
humans as in mice.
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Leptin and the pathogenesis of obesity
Although specific mutations in the leptin loop are rare in humans, both obesity
and other eating disorders are associated with perturbations in circulating leptin.

Modulation of circulating leptin levels, in a manner that would have been adaptive i

prehistoric times where nutrients were scarce, is now maladaptive and contributes to

high failure rate of dieting. Weight loss in overweight individuals is associated w

decrease in leptin levels, which consequently stimulates appetite and reduces energy

expenditure, tending to restore body weight to its original value (Leibel et al. 199

Maffei et al. 1995b; Considine et al. 1996). Low dose leptin administration during d

can prevent these effects associated with falling leptin, and may help dieters maint

reduced body weight (Rosenbaum et al. 2002). Alterations in circulating leptin level
also involved in the pathogenesis of anorexia nervosa. These patients have very low

leptin levels, and the rapid rise in leptin following refeeding may play a role in t
disorder by diminishing appetite before normal weight is reached (Casanueva et al.
Mantzoros et al. 1997).
Human obesity, though largely polygenic, is stll characterized by altered leptin
physiology and can be broadly categorized as resulting from either inappropriately
leptin levels or leptin resistance. These two possibilities can be distinguished by

measurement of plasma leptin. With the exception of ob/ob mice and rare human cases,

leptin levels are high in most rodent and human obesity, illustrating the prevalenc

leptin resistance in the pathogenesis of obesity (Maffei et al. 1995a; Maffei et al.

Considine et al. 1996). Rodent models have facilitated examination of leptin resista

a molecular level. Peripheral and central administration of leptin to Ay, New Zealan
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obese (NZO), and diet-induced obese (DIO) AKR/J mice confirmed their resistance to
leptin (Halaas et al. 1997; Van Heek et al. 1997). Ay mice are totally resistant to

peripheral and i.c.v. doses of leptin, suggesting that signaling through the MC-4 r
is necessary for the response to leptin and for maintenance of normal body weight

(Halaas et al. 1997; Marsh et al. 1999). NZO mice are resistant to peripheral leptin,
respond normally to centrally delivered leptin, indicating that this polygenic form

obesity may be the result of impaired leptin transport into the CNS (Halaas et al. 1

In obese, hyperleptinemic humans, a decreased cerebrospinal fluid to serum leptin ra

has been noted, supporting the existence of a saturable system for leptin transport

brain, defects in which might account for leptin resistance (Caro et al. 1996; Schwa

al. 1996). Although DIO mice respond to central leptin, they show peripheral resista

requiring high doses to effect weight loss (Halaas et al. 1997; Van Heek et al. 1997

mice are normally lean, but become obese when fed a high-fat diet, while other strai
can maintain a stable weight on such a diet (West et al. 1992). Determining the
mechanism whereby a high fat diet, on certain genetic backgrounds, contributes to

obesity, would be highly relevant to human obesity, judging by the increased prevale
of obesity in populations consuming high fat, western diets. One proposed mechanism

diet-induced obesity holds that a palatable, high-fat diet causes a temporary weight

which is then normally lost. In susceptible individuals, however, the increased lept
levels associated with weight gain could desensitize the leptin response and bring
new 'set-point' at a higher weight (Friedman and Halaas 1998).
Decreased leptin synthesis or secretion could also lead to obesity. Although most
obese humans are hyperleptinemic, 5-10% have relatively low leptin levels, pointing
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decreased leptin as being relevant in a subset of obesity (Maffei et al. 1995b; Considine et

al. 1996). Relatively low leptin levels have been detected in Pima Indians, prior to
development of obesity (Ravussin et al. 1997). ob/ob mice carrying a human leptin

transgene, expressing constitutively low levels of leptin, develop a marked obesity,

is not as severe as that in ob/ob mice, and which can be similarly corrected by lept

administration (Ioffe et al. 1998). In addition, humans with partial leptin deficien
tend to develop increased adiposity (Farooqi et al. 2001).

Molecular targets for the regulation of body weight

Current and future obesity therapy
Given the immense health burden of obesity, finding new, effective treatments is
imperative. While the public would welcome a therapy that could eradicate obesity,

studies indicate that even a 10% weight loss can decrease complications from obesit

such as diabetes, hypertension, and hyperlipidemia, and increase longevity (Goldstei

1992). Currently, the most widely used interventions are diet and exercise, weight l
drugs, and bariatric surgery (Yanovski and Yanovski 2002).
Considering the overwhelming prevalence of weight regain following dieting and

the risks of surgery, pharmacotherapy for obesity seems to be a reasonable approach.

Both leptin and drugs targeting components of the leptin circuit are currently in c

trials (Crowley et al. 2002). While leptin treatment of obese humans leads to a dose
dependent weight loss, its effects are rather modest, which is to be expected since
obese humans are leptin resistant (Heymsfield et al. 1999). However, leptin appears

far more effective in treating leptin-deficient obese and lipodystrophic patients, a

39

also be useful in obese individuals with inappropriately low levels of leptin (Farooqi et al.

1999; Farooqi et al. 2001; Oral et al. 2002). The development of novel therapies for
obesity requires a fuller understanding of the physiological basis of body weight

regulation. As leptin is a central mediator of energy homeostasis, further elucidati
effects on appetite and metabolism will shed light on the biology of obesity.

Specific aims

This thesis aims to further define the molecular basis for leptin's metabolic
effects. The effects of leptin on the liver are the focus here, due to this organ's

role in coordinating peripheral metabolism. The physiological role of central versu
peripheral sites of leptin action was examined using tissue-specific knockout mice
(Chapter 3). These studies indicated that central action of leptin is critical for

on body weight and hepatic lipid metabolism. Next, transcriptional profiling was use

identify molecular targets of leptin's specific effects on peripheral metabolism (C
4). Using a novel computational approach, genes whose expression was specifically
modulated during leptin-mediated weight loss were identified. One of these genes,

stearoyl-CoA desaturase-1 (SCD-1) was shown to be required for leptin-mediated weig
loss (Chapter 5). ob/ob mice lacking SCD-1 were resistant to obesity and showed a

correction of the hypometabolic phenotype and hepatic steatosis characteristic of le
deficiency. Mice lacking SCD-1 were also found to be resistant to alcoholic and

nonalcoholic fatty liver disease (Chapter 6). Other leptin-regulated genes were als

identified and studies on the role of insulin-like growth factor binding protein-2 (
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2) in leptin-mediated weight loss are presented (Chapter 7). Finally, a summary of the
findings and directions for future research are discussed (Chapter 8).
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Chapter 2: Materials a n d M e t h o d s

Materials and Methods from Chapter 3
ObR floxed mice. A 12 kb genomic clone containing the first coding exon of ObR was
isolated. A single loxP element was PCR amplified from the plasmid pNeoTKLox. The

oligonucleotide primers were engineered to introduce a BamHI-Ncol double restriction

site at one end and a BamHI site at the other end. Following digestion with BamHI, t

product was ligated into the BamHI site of the genomic clone, resulting in the clone
BNLOXB with a single LoxP site upstream of the first exon. A loxP-Neo-HSV-TK-LoxP
element was isolated by digesting pNeoTKLox with BstXI and Sail. The fragment was
blunt-ended and cloned into Bgl-II digested blunt-ended BNLOXB. This clone, denoted

ObR-lox-SSl-lox, was double digested with Aflll and Kpnl, blunt-ended, and re ligate

generate the targeting vector. The excised 500 bp Aflll-Kpnl fragment was used as Pr

1. The targeting vector was linearized with Sail and electroporated into 129/SV ES c
Cells were selected with G418 and surviving clones were screened for homologous

recombination. Positive clones were transiently transfected with the Cre recombinase
expressing plasmid, p0G231 (kindly provided by S. O'Gorman) (O'Gorman et al. 1997).

Cells were then subjected to gancyclovir selection and surviving clones were checked
Southern blotting using Probe 2, which is within exon 2, to confirm the deletion of

Neo-HSV-TK cassette (Type II deletion). ES cells with the correct genotype (ObRflox/

were injected into C57B1/6 blastocysts, and resulting chimeras were bred with C57B1/

mice to obtain germline transmission. ObRflox/+ mice were crossed to generate the li
O b R floxed mice, denoted ObRflox/flox.
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O b R null mice. ObRflox/+ mice were crossed with transgenic adenovirus EIIA cre mice

(kindly provided by H. Westphal) (Lasko et al. 1996). Since Cre is expressed early in
embryogenesis in this line, progeny were screened by Southern blotting with Probe 2

germline Cre-mediated deletion of the first coding exon (Type I deletion). These mic

with the genotype ObRA/+, were crossed to produce homozygous ObRA/A mice, designated
ObR null mice.
Conditional deletion of ObR. Neuron-specific deletion of ObR was achieved using

synapsinl-Cre transgenic mice (Synl-Cre(+)) (kindly provided by J. Marth) (DeFalco e

al. 2001; Zhu et al. 2001). Hepatocyte-specific deletion was achieved using albumin-c
transgenic mice (Alb-Cre(+)). The Alb-Cre transgene (Figure 3.5A) was constructed
using plasmid NB, which contains 2 kb of the albumin promoter-enhancer (kindly
provided by R. Palmiter) (Pinkert et al. 1987). A 2 kb fragment containing the Cre-

recombinase gene and a nuclear localization and polyadenylation signal was excised f
a separate plasmid by digesting with Bglll and blunt-ending and then digesting with
Kpnl. This fragment was cloned into KpnI-EcoRV digested plasmid NB downstream of

the albumin promoter-enhancer. The resulting plasmid was digested with Notl and Kpnl

to release the 4 kb transgene, which was gel purified and injected into fertilized e
from C57/B16 x CBA (Fl) mice to produce transgenic mice. The presence of the
transgene in both (Synl-Cre(+)) and (Alb-Cre(+)) mice was verified by PCR and
Southern blotting. Tissue-specific knockout mice were generated by two successive
crosses (Figure 3.2a). First, ObRA + mice were crossed with either synapsinl-Cre

transgenic mice (Synl-Cre(+)) or albumin-cre transgenic mice (Alb-Cre(+)) to generat
ObR^, Synl-Cre(+) mice or ObR^, Alb-Cre(+) mice. These mice were then mated to
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0bRfiox/fiox mice tQ generate mice with the genotype O b R ^ A Synl-Cre(+) or O b R ^ A
Alb-Cre(+), hereafter designated ObRSynIKO and ObRAlbKO respectively. Mice with the
following genotypes were also generated: (1) ObR^A Synl-Cre(-) and ObR^0", Alb-

Cre(-) (heterozygotes), (2) ObRflox/+, Synl-Cre (+) and ObRflox/+, Alb-Cre (+) (refe

as wild type), and (3) ObRflox/+, Synl-Cre (-) and ObRflox/+, Alb-Cre (-) (referred t

wild type). All animals here, and those described in other chapters, were housed unde
controlled temperature (23° C) and lighting (12 hours of light, 0700-1900 hours; 12
of dark, 1900-0700) with free access to food and water, unless otherwise indicated.
procedures were in accordance with the guidelines of the Rockefeller University
Laboratory Animal Research Center.
Assay of Cre specificity. Genomic DNA was prepared from multiple tissues from
0bRfW+ SynI.Cre (+) and obRflox/+ Alb-Cre (+) mice and 200 ng was PCR amplified

using primers flanking the first coding exon of ObR. A schematic of the primer locat

is shown in (Figure 3.2b). In tissues expressing Cre recombinase, exon 1 is excised a

single loxP site remains, generating an ObRA allele. While primers 1 and 3 can ampli
product from the ObRA allele, the primers are separated by too great a distance for

amplification to occur in the ObR ox or ObR+ (wild-type) alleles. As a control, prim

and 2 were used to amplify both the ObRflox and ObR+ alleles from all tissues. The O
allele produces a slightly smaller product due to the absence of loxP sequence. The
primer sequences are as follows: primer 1-5' GTCACCTAGGTTAATGTATTC 3',
primer 2- 5' TCTAGCCCTCCAGCACTGGAC 3', primer 3- 5' GCAATTCATATC
AAAACGCC 3'.
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Assay of Cre efficiency. T o determine the degree of Cre-mediated recombination, O b R

expression levels from all ObRSynIKO and ObRAlbKO mice and a sample of mice with all
other possible genotypes were quantitated using Taqman® real time PCR. Total RNA
was isolated from ObRSynIKO and ObRAlbKO mice and reverse transcribed into cDNA
using random hexamers with Reverse Transcription Reagents from Roche (Branchburg,
NJ). Expression levels were determined using 25 ng of each cDNA sample assayed in
duplicate and amplified with the ABI Prism 7700® Sequence Detection System (Perkin
Elmer Applied Biosystems, Foster City, CA). The location of primers and fluorescent

probes is indicated in Figure 3.3b. As amplification occurs, the probe is cleaved, r
in a signal from a reporter dye that is directly related to the amount of amplicon.
were derived from sequences in the 5' untranslated region (forward) and the second
coding exon (reverse). The fluorescent probe, labeled with the FAM dye, contains
sequence located within the first coding exon. When this exon is deleted, the probe

cannot be cleaved, and no signal is generated. As a control for input amount, each c
sample was also amplified using primers and a probe, labeled with the VIC dye, for

cyclophilin. The sequences of the primers and probes are as follows: ObR- probe 5' A
CCACATAGAATTTCTGACACATCATCTTTC 3', forward primer 5' AGGAATCGTT
CTGCAAATCCA 3', reverse primer 5' TATGCCAGGTTAAGTGCAGCTATC 3';
cyclophilin- probe 5' ACACGCCATAATGGCACTGGTGG 3', forward primer 5' TGT
GCCAGGGTGGTGACTT 3', reverse primer 5' TCAAATTTCTCTCCGTAGATGGA
CTT 3'. Data were analyzed with the ABI Sequence Detector® software. Every set of

reactions contained a set of four serial two-fold dilutions of the same liver cDNA s

which was used to generate a standard curve for both ObR and cyclophilin. Amounts of
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each transcript were calculated from the standard curve and levels of O b R were corrected
for levels of cyclophilin (ObR level/ cyclophilin level).
Body composition analysis. Body composition was analyzed as previously described

(Halaas et al. 1995). Carcasses were weighed and then oven dried in a 90° C oven unt

weight was constant. The total body water was calculated as the difference between t
weights before and after drying. The carcass was then homogenized in a blender and
duplicate aliquots were extracted with a soxhlet apparatus using a 3:1 mixture of
chloroform:methanol. The extracted homogenate was dried overnight and weighed to
calculate fat and lean mass.

Neuropeptide expression levels. Neuropeptide levels were quantitated by Taqman® real
time PCR from individual hypothalami. Expression levels were measured in the obese
ObRSynIKO mice, heterozygote controls, and in female ObR null mice. Primers and
probes were made for AGRP, NPY, MCH, POMC, and CART. The sequences of the
primers and probes, labeled with 5' FAM and 3' TAMRA, are as follows: AGRP- probe
5' TCCACAGAACCGCGAGTCTCGTTC 3', forward primer 5' CTTTGGCGGAGGTG
CTAGA 3', reverse primer 5' GGACTCGTGCAGCCTTACACA 3'; NPY- probe 5' CA
GAAAACGCCCCCAGAACAAGGC 3', forward primer 5' CACC AG AC AG AG AT AT
GGC A AG A 3', reverse primer 5' TTTCATTTCCCATCACCACATG 3'; POMC- probe
5' CAGTGCCAGGACCTCACCACGGA 3', forward primer 5' TGCTTCAGACCTCC
ATAGATGTGT 3', reverse primer 5' GGATGCAAGCCAGCAGGTT 3'; CART- probe
5' CACTGCGCACTGCTCCAGCG 3', forward primer 5' CGAG AAGA AGT ACGGCC
AAGTC 3', reverse primer 5' CCGATCCTGGCCCCTTT 3'; MCH- probe 5' AGGTGT
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A T G C T G G G A A G A G T C T A C C G A C C 3', forward primer 5' G G A A G G A G A G A T T T T
GACATGCT 3', reverse primer 5' GCAGGTATCAGACTTGCCAACA 3'.
Neuroendocrine function. After sacrifice, mice were exsanguinated and blood was

collected on EDTA. Plasma was collected after centrifugation and used for all assays
Leptin levels were determined using an ELISA kit from R&D Systems (Minneapolis,
MN). Insulin levels were determined using an ELISA kit from Alpco Diagnostics
(Windham, NH). Glucose levels were determined using the Trinder reagent from Sigma

(St. Louis, MO). Triglyceride levels were determined using an enzymatic kit from Wak

Diagnostics (Richmond, VA). Corticosterone, estradiol, testosterone, and thyroxine l
were determined using RIA kits from ICN (Costa Mesa, CA).
Liver triglyceride quantitation. 40-100 mg of liver from each mouse was homogenized
4 ml of chloroform-methanol (2:1). 0.8 ml of 50mM NaCl was added to each sample.

Samples were then centrifuged for 5 minutes at 3000 rpm. The lower phase was removed
and duplicate 50 jil aliquots were evaporated under N2 gas and then assayed for

triglycerides using the Trinder reagent from Sigma (St. Louis, MO). Values are expre
as ug triglyceride / mg liver.
Statistical analysis. Data here, and throughout this thesis, are expressed as means
minus standard error of the mean (SEM). Unless otherwise indicated, significance was

evaluated using the unpaired Student's t test. Significance of correlation coefficie
evaluated using the t test for correlation.
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Materials and Methods from Chapter 4
Mice. Eight to ten week-old, female C57B1/6J ob/ob or lean littermate mice (ob/+ or

referred to as wild-type) from the Jackson Laboratory (Bar Harbor, ME) were used for
expression studies and weight loss time courses.

RNA isolation. All mice were sacrificed in the middle of the light cycle and livers
removed and rapidly frozen in liquid nitrogen. Total RNA was prepared from frozen
livers using Trizol reagent (Invitrogen, Carlsbad, CA).
Northern blotting. 10-20 (Xg of total RNA was separated by denaturing formaldehyde

electrophoresis and transferred by capillary blot to positively charged nylon membr
as described (Ausubel et al. 1999). Blots were hybridized with a32-P labeled PCR
amplified cDNA probes. To control for equal loading, 18S RNA was stained with

ethidium bromide or blots were hybridized with a32-P labeled cyclophilin cDNA probes

Time course. The time course experiment has been previously described (Soukas et al.
2000). All data presented in this thesis use material from this time course or an

independent time course performed under identical conditions. Mice were individually

caged and allowed to acclimate for a number of days prior to the start of the experi

Alzet 2002 mini-osmotic pumps (Alza, Palo Alto, CA) were filled with PBS (free-fed a
pair-fed groups) or 400 ng/ml leptin (Amgen, Thousand Oaks, CA), and implanted

subcutaneously under anesthesia. RNA and plasma were isolated from ob/ob mice treat

with subcutaneous leptin (infusion rate of 4.8 >ug/24 hours via an Alzet miniosmoti

pump) for 2, 4, and 12 days, untreated ob/ob mice, and free-fed ob/ob mice that rece

saline. As an additional control, RNA and plasma were isolated from saline-treated o
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mice that were pair-fed to the leptin treated group also for 2, 4, and 12 days of treatment.

The pair-fed group was staggered one day behind the other two groups and fed an amo
equal to the average amount of food consumed by the leptin treated group over the
previous 24 hours. Body mass and food intake were measured each morning. The body
weight and food intake of these groups of mice is shown in Figure 4.2.
Liver histology and triglyceride quantitation. Liver histology was kindly performed

Dr. K. Sokol at the Rockefeller University Laboratory Animal Research Center. Livers

were fixed in 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin
Liver triglyceride levels were determined by thin layer chromatography : gas
chromatography (TLC:GC), as described below.

Microarrays and data analysis. RNA from the livers of these animals was prepared and
hybridized to Affymetrix murine 6500 Gene Chips according to established methods

(Affymetrix, Santa Clara, CA). Data were analyzed using a AT-means clustering algori
(Hartigan 1975; Kohonen 1997; Soukas et al. 2000). This computational method groups

genes with similar patterns of expression over the time course experiment. For inclu

in the cluster analysis, a gene had to meet pre-established selection criteria, base

empirical observations from Northern blots. Specifically, genes were included that w
given either an I (increased) or D (decreased) score by the Affymetrix GeneChip 3.1

software and that met one of the following cutoffs in at least two samples: (i) fold

> 2.0 and average difference change > 250, (ii) fold change > 1.5 and average diffe
change > 500, (iii) fold change > ~1.5 and average difference change > 100.

Western blotting. Nuclear SREBP protein levels were measured as previously described

(Soukas et al. 2000). Following treatment with saline, leptin, or saline with pair-fe
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as described above,freshlivers were rinsed in ice cold saline supplemented with I m M
DTT and 0.5 mM PMSF. Livers were minced with a razor blade and homogenized with
10 strokes of a dounce homogenizer in NDS buffer (10 mM Tris at pH 7.5, 10 mM NaCl,
60 mM KCI, 0.15 mM spermine, 0.5 mM spermidine, 14 mM P-mercaptoethanol, 0.5
mM EGTA, 2 mM EDTA, 0.5% NP-40, 1 mM DTT, and 0.1 mM PMSF) supplemented
with complete protease inhibitors at 4° C (Roche, Indianapolis, IN). The NP-40

concentration was raised to 1% and nuclei were pelleted by centrifugation at 700g f
minutes. Nuclei were then washed once with NDS buffer (1% NP-40), pelleted at 500g
for 5 minutes, resuspended in 1 volume of 1% citric acid, lysed (by the addition of

volumes of 0.1 M Tris, 2.5% SDS, and 0.1 M DTT), sonicated, and heated to 90°C for 5
min. Western blotting was performed using nuclear extract, according to previously
established methods (Sambrook et al. 1989). SREBP was detected using 5g/ml rabbit
anti-mouse SREBP-1 (kindly provided by M. Brown, University of Texas Southwestern
Medical Center, Dallas, TX). Bound antibodies were detected using an HRP-conjugated

anti-rabbit IgG secondary antibody (Organon Teknika, West Chester, PA) and visualize
using enhanced chemiluminescence plus reagents (Amersham, Buckinghamshire,
England).

Statistical analysis. Data are expressed as means plus or minus SEM. Significance wa
evaluated using the unpaired Student's t test.

Materials and Methods from Chapter 5

Identifying and ranking leptin-regulated genes. In order to prioritize leptin-regula

genes for detailed functional analysis, we developed an algorithm to identify and ra
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genes that are specifically repressed by leptin. This algorithm ranked genes based on the

extent to which their expression was (1) increased in ob/ob liver compared to wild t

(2) repressed by leptin treatment, and (3) different between leptin treatment and pa

feeding. Specifically, we selected genes, which met the above criteria for cluster a

whose expression was increased in ob/ob relative to wild-type and corrected by lepti

administration. The selected genes were then scored using the following two criteria

the magnitude of the difference in expression between the untreated ob/ob sample and

day 12 leptin treated sample and (2) the magnitude of the distance between the lepti

expression profile and the pair-fed expression profile. The above distance was defin
be the Euclidean distance between the normalized 3-dimensional vectors composed of

2, 4, and 12 day leptin-treated and pair-fed profiles. To combine the two scores, th

were ranked according to both parameters and then the pair of ranks was averaged for

each gene. This final average rank served as the score for each gene. Genes with the
lowest scores are those most strongly leptin-regulated.
Northern blotting. Membranes were hybridized with a32-P labeled cDNA probes made

using the untranslated region of SCD-1, which specifically hybridizes to SCD-1 and n

SCD-2 (Ntambi et al. 1988; Kaestner et al. 1989). To control for equal loading a cDN
probe for the small mitochondrial RNA pAL-15 was used.

SCD activity assay. These assays measure the conversion of [1-14C] stearoyl-CoA to [

14C] oleate, as previously described (Miyazaki et al. 2000). Tissues were homogenized
10 volumes of buffer A (0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, 1 mM PMSF,
pH 7.4). The microsomal fractions (100,00 x g) were isolated by sequential
centrifugation. Reactions were performed at 37°C for 5 min with 100 |0.g protein
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homogenate and 6 u M of [1-14C] stearoyl-CoA (60,000 rpm), 2 m m N A D H , 0.1 M TrisHCl, pH 7.2. After the reaction, fatty acids were extracted and methylated with 10%

acetic chloride/methanol. Saturated and monounsaturated fatty acid methyl esters wer
separated by 10% AgN03-impregnated TLC using hexane:diethyl ether (9:1) as
developing solution. The plates were sprayed with 0.2% 2',7'-dichloroflourescein in

ethanol, and the lipids were identified under UV light. Fractions were scraped off o
plate and radioactivity was measured using a liquid scintillation counter.
Lipid Analysis. Total lipids were extracted from liver with Folch solvent
(chloroform/methanol 2:1). At the start of the liver extraction, internal standards

triglyceride, cholesteryl ester, and phosphatidyl choline were added to quantitate e

lipid class (Nu Check Prep, Elysian, MN and Sigma, St. Louis, MO). The lipid classes

the liver extract were separated by thin layer chromatography using silica gel G and

developing solvent of hexane/diethyl ether/acetic acid (60:40:1). The fatty acids in
lipid class were methylated with fresh 5% methanolic HCI and analyzed with a gas
chromatograph (model 5890, Hewlett-Packard, Palo Alto, CA) equipped with a 100m x
0.25mm SP2560 fused silica capillary column (Supelco, Bellefonte, PA).
Mouse crosses. Asebia (abJ/abJ) mice were obtained from the Jackson Laboratory (Bar

Harbor, ME). These mice have a spontaneous deletion of the first four exons of the S
1 gene and express no SCD-1 RNA or protein (Gates and Karasek 1965; Zheng et al.
1999). Double mutant abJ/abJ; ob/ob mice were generated by two successive crosses.
First, abJ/abJ mice (mutation arose spontaneously in Balb/cJ mice) (more detailed
background strain information is available on the internet at
http://www.informatics.jax.org/external/ festing/mouse/docs/ABJ.shtml) were crossed
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ob/+ (C57B1/6 background). Then, progeny were intercrossed to generate the following

groups of mice: (1) double mutant mice (abJ/abJ; ob/ob), (2) ob/ob controls (abJ/+; o
and +/+; ob/ob), (3) asebia mice (abJ/abJ; ob/+ and abJ/abJ; +/+), and (4) controls
(abJ/+; ob/+, abJ/+; +/+, +/+; ob/+, and +/+; +/+). ob genotypes were determined by
PCR amplifying genomic DNA using the forward primer 5' GACTTCATTCCTGGG
CTTCA 3' and the reverse primer 5' TCTGTGGAGTAGAGTGAGGC 3' and the

following cycling conditions: 94°C 5 min, 40 x (94°C 1 min, 55°C 1 min, 68°C 2 min),

68°C 7 min. The 247 bp PCR product was then digested with Ddel (a Ddel site is added

by the ob mutation) and run on a 3% agarose gel. The wild-type allele shows a 152 bp

and 32 bp band and the ob allele shows 105 bp, 47 bp, and 32 bp bands. For practical
purposes only the 152 bp and 105 bp bands were used to determine genotypes, ab
genotypes were determined by Southern blotting of Ncol digested genomic DNA. Blots
were hybridized using an a32-P labeled SCD-1 exon 5 probe, PCR amplified from cDNA
using the forward primer 5' TGTGCTTCATCCTGCCCACG 3' and the reverse primer
5' GATTGAATGTTCTTGTCGTAGG 3' and the following cycling conditions: 94°C 5
min, 35 x (94°C 30 sec, 60°C 30 sec, 72°C 1 min), 72°C 7 min. ab/ab, ab/+, and +/+
genotypes showed characteristic banding patterns.
Carcass analysis. Carcass analysis was done as described above.
Food intake. 12-18 week old were individually caged and allowed to acclimate for 1
week. 24-hour food consumption was measured over 8 consecutive days, and these

values were averaged for the mice in each group. Food intake for males and females w
indistinguishable and was therefore pooled.
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Oxygen consumption. 14-16 week old mice were placed in an O x y m a x indirect
calorimeter (Columbus Instruments, Columbus, OH) and allowed 2 hours to acclimate.

The calorimeter was calibrated and operated according to the manufacturer's instruct
Measurements were taken for 5 hours during the middle of the light cycle. The first
reading was discarded, and the total V02 was determined by averaging the other 19

readings. The resting V02 is the average of all readings that are one standard devia
below the total V02, as these readings represent periods of inactivity.
Plasma assays. Leptin levels were measured by ELISA (R&D Systems, Minneapolis,
MN). P-hydroxybutyrate levels were measured using an enzymatic assay (Sigma, St.
Louis, MO).
Liver histology and triglyceride quantitation. Liver histology was kindly performed

Dr. T. Scase at the Bobst Hospital of the .Animal Medical Center (New York, NY). Liv

were fixed in 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin

Liver triglyceride levels were determined as described above, with a monor modificat

one drop of Triton X-100 was added to each aliquot prior to evaporating under N2 gas.

VLDL production assay. Mice were fasted for five hours prior to injection with tylox

(Triton-1339) (Sigma, St. Louis, MO) as previously described (Merkel et al. 1998). Mi
were injected via the tail vein with 0.5 mg/kg tyloxapol dissolved in saline at a
concentration of 0.15 g/ml. Tail bleeds were done just before injection (tO) and 45
minutes following injection. Plasma triglycerides were assayed using an enzymatic
reagent (Sigma, St. Louis, MO). The slope of the line denotes the rate of VLDL
production.
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Fatty Acyl CoA Levels. Mice had their food removed at the beginning of the light cycle
and were studied 6-10 hours later. Mice were anesthetized with an intraperitoneal
injection of ketamine/xylazine. Livers were freeze-clamped in situ using tongs that
been cooled to -70°C and were stored at -80°C. Tissues were homogenized and long
chain fatty acids were extracted and analyzed by LC/MS/MS analysis using a tandem
mass spectrometer (Applied Biosytems, Foster City, CA) as previously described
(Neschen et al. 2002).

Statistical Analysis. Data are expressed as means plus or minus SEM. Significance wa
evaluated using the unpaired Student's t test.

Materials and Methods from Chapter 6
Alcohol Studies. Group housed, 5-7 week old male and female abJ/abJ and littermate
control mice (abJ/+ or +/+) were acclimated to alcohol by the introduction of a 10%

ethanol solution in addition to regular drinking water. After 1 week (time 0), regul
drinking water was removed and mice were only given 10% ethanol to drink. Groups of
mice were sacrificed after 3 and 5 weeks of ethanol consumption. As a control, non-

alcohol fed, age-matched abJ/abJ and littermate control mice (abJ/+ or +/+) were als
studied. To measure food intake and alcohol consumption, 8-10 week old ab /ab and

littermate control mice (abJ/+ or +/+) were individually caged, and food and alcohol

intake were recorded weekly. Total caloric intake was based on a caloric value of 5
kcal/ml for pure ethanol and 4 kcal/g for mouse chow.
Lipodystrophy Studies. Double mutant abJ/abJ;aP2-SREBP-lc transgenic mice were
generated by two successive crosses. First, female abJ/abJ mice (strain information
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described above) were crossed to male aP2-SREBP-lc transgenic mice obtained from the
Jackson Laboratory (Bar Harbor, ME) (C57B16/J x SJL strain). Then abJ/+;aP2-SREBP1c transgenic male progeny were crossed to abJ/+ female progeny to generate the

following groups of mice: (1) double mutant mice (abJ/abJ;aP2-SREBP-lc tg), (2) aP2SREBP-Ic tg controls (abJ/+;aP2-SREBP-Ic tg and +/+;aP2-SREBP-Ic tg), (3) asebia

mice (abJ/abJ), and (4) controls (abJ/+ and +/+). Genotyping was performed by genomi
PCR for the transgene and by Southern blotting for SCD-1.
Liver histology and triglyceride quantitation. Liver histology was performed at the
Hospital of the Animal Medical Center (New York, NY). Livers were fixed in 4%

paraformaldehyde, sectioned, and stained with hematoxylin and eosin. Liver triglycer
levels were determined as described above, except for the additional step of adding
drop of Triton X-100 to each aliquot prior to evaporating under N2 gas.

Statistical Analysis. Data are expressed as means plus or minus SE. Significance was
evaluated using the unpaired Student's t test.

Materials and Methods from Chapter 7
Northern Blotting. C57B1/6J, ob/ob, db3J/db3J, dbKh/dbKh, NZO, Ay, and AKR/J mice

were obtained from the Jackson Laboratory (Bar Harbor, ME). The AKR/J mice (strain i

susceptible to dietary obesity) were not diet-induced, ob/ob tg mice were maintained

the Rockefeller University Laboratory Animal Research Center (Ioffe et al. 1998). All
mice were 8-12 weeks old. Liver RNA was isolated from 2-3 animals of each genotype,

sacrificed in the fed state or after a 48 hour fast. IGFBP-2 RNA levels were determi

by Northern blotting, as described above, using an a32-P labeled PCR amplified IGFBP
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c D N A probe. Equal loading was confirmed by ethidium bromide staining of 18S R N A or
by hybridization with a cyclophilin probe.
Mice. IGFBP-2";ob/ob mice were generated by two successive crosses. ob/+ mice

(C57B1/6J strain) obtained from the Jackson Laboratory (Bar Harbor, ME) were crossed
to IGFBP-2'- mice (129/ReJ x C57B16/J) generated and maintained at the Robert Wood

Johnson Medical School / University of Medicine and Dentistry New Jersey (Piscataway

New Jersey) (Wood et al. 2000). IGFBP-2+/';ob/+ progeny were intercrossed to generate
a line of IGFBP-2'/';ob/+ mice. These mice were intercrossed to generate IGFBP-2'''

;ob/ob mice, ob/ob controls (C57B16/J strain) were obtained from the Jackson Laborat
(Bar Harbor, ME).

Leptin Administration. Leptin treatment was performed as described above for Chapter
Mice were individually caged and allowed to acclimate for more than a week prior to

start of the experiment. Alzet 2002 mini-osmotic pumps (Alza, Palo Alto, CA) were fi
with PBS (saline group) or 400 ng/ml leptin (Amgen, Thousand Oaks, CA), and

implanted subcutaneously under anesthesia. Groups of ob/ob and IGFBP-2'''; ob/ob mic

were treated with subcutaneous leptin (infusion rate of 4.8 (xg/24 hours via an Alze

miniosmotic pump) or PBS for 10 days. For ob/ob mice, n = 4 for saline (all males, ag
start of experiment = 76 days) and n = 6 for leptin (4 females and 2 males, average

start of experiment = 66 ± 3.2 days). For IGFBP-2'';ob/ob mice, n = 4 for saline (al

females, average age at start of experiment = 103.8 ± 8.6 days) and n = 5 for leptin
females, average age at start of experiment = 103.6 ± 8.3 days).
Plasma Assays. Leptin levels were measured by ELISA (R&D Systems, Minneapolis,
MN). Glucose levels were measured using an enzymatic assay (Sigma, St. Louis, MO).
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Statistical Analysis. Data are expressed as means plus or minus S E M . Significance was
evaluated using the unpaired Student's t test.
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C h a p t e r 3: Selective Deletion of Leptin R e c e p t o r in N e u r o n s L e a d s to
Obesity

Introduction

Leptin is an adipocyte hormone that functions as an afferent signal in a negative
feedback loop that regulates energy balance (Zhang et al. 1994; Friedman and Halaas

1998; Spiegelman and Flier 2001). Mice with mutations in leptin (ob/ob) or its recept

(db/db) are hyperphagic and severely obese (Tartaglia et al. 1995; Chen et al. 1996b

et al. 1996). These mutant mice also manifest a large number of metabolic and endocr

abnormalities including diabetes, hypercortisolemia, infertility, and cold intoleran
(Coleman 1978; Coleman 1982). ob/ob and db/db mice also have enlarged, steatotic

livers (Yen et al. 1976; Koteish and Diehl 2001). The fatty liver is in part a result
increased rate of hepatic lipogenesis, which is also thought to contribute to the
development of obesity (Kaplan and Leveille 1981).
Treatment of ob/ob mice with leptin reduces food intake and body weight and

corrects the metabolic and endocrine defects associated with leptin deficiency. Lept
treatment also normalizes the hepatomegaly and associated elevations in hepatic
glycogen and lipid (Levin et al. 1996). Infusions of leptin into wild type mice at
physiological amounts results in a dose dependent reduction in food intake and body
weight (Campfield et al. 1995; Halaas et al. 1995; Pelleymounter et al. 1995). This

metabolic response to leptin in both ob/ob and wild type mice is novel and is not so

consequence of its anorectic effects (Soukas et al. 2000). Intracerebroventricular le
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has similar effects, but at much lower doses, suggesting that leptin has direct effects on
brain (Campfield et al. 1995; Halaas et al. 1997).
The leptin receptor, which has five splice variants (ObRa-e), is broadly expressed,

however, and the relative importance of leptin's effects on brain vs. peripheral sit

unclear (Ghilardi et al. 1996; Fei et al. 1997). This distinction is of importance be
leptin deficiency is associated with myriad abnormalities in many tissues including

While leptin has been suggested to act directly to deplete triglycerides, the contri

these actions to body weight homeostasis, deposition of lipid in peripheral sites, a
neuroendocrine function in vivo is untested (Shimabukuro et al. 1997a; Minokoshi et

2002). In order to determine the role of leptin action in the central nervous system

periphery, we are systematically deleting ObR in a tissue-specific fashion using the
loxP system. Here we present data from mice with either neuronal (ObRSynIKO) or
hepatocyte-specific (ObRAlbKO) deletions of ObR.
Among the ObRSynIKO mice, the extent of obesity was negatively correlated with
the level of ObR in hypothalamus and those animals with the lowest levels of ObR

exhibited an obese phenotype. The obese mice with low levels of hypothalamic ObR als
show elevated plasma levels of leptin, glucose, insulin, and corticosterone. The

hypothalamic levels of AGRP and NPY are increased in these mice. These data indicate

that leptin has direct effects on neurons and that a significant proportion, or perh
majority, of its weight reducing effects are the result of its actions on brain. To

possible direct effects of leptin on a peripheral tissue, we also characterized ObRA
mice. These mice weigh the same as controls and have no alterations in body
composition. Moreover, while db/db mice and ObRSynIKO mice have enlarged fatty
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livers, ObRAlbKO mice do not. In summary, these data suggest that the brain is a direct

target for the weight reducing and neuroendocrine effects of leptin and that the liv

abnormalities of ob/ob and db/db mice are secondary to defective leptin signaling in
brain.

Results

Generation of tissue-specific knockout mice
We have used the Cre-loxP system to generate mice with tissue specific deletions
of ObR (Gu et al. 1994). The construction of the targeting plasmid is described in
Chapter 2 (Materials and Methods) (Figure 3.1a). The first coding exon of ObR was
flanked by loxP sites. This exon contains the signal sequence and deletion of it by
mediated recombination was predicted to inactivate all splice variants. Following
transfection into mouse embryonic stem (ES) cells, 3/72 G418-resistant clones had

undergone homologous recombination (Figure 3.1b). The targeting cassette was deleted
by transiently transfecting one of the homologous recombinant ES cell lines with a
plasmid expressing Cre recombinase and screening for clones with a type II deletion

(Figure 3.1a). Clones with the correct genotype, ObRflox/+, were confirmed by Southe
blotting and injected into C57B1/6 blastocysts (Figure 3.1c). Breeding of chimeras
confirmed that animals with a germline insertion of loxP sites into ObR had been
generated. Mice homozygous for the floxed allele, ObRflox/flox, were generated by
crossing ObRflox/+ animals.
ObRflox/flox mice were viable, fertile, and indistinguishable from wild-type or

ObRflox/+ mice indicating that the insertion of loxP sites into the introns flanking
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Figure 3.1 L o x P targeting of the O b R locus. Gene targeting was used to insert loxP sites on either side of
the first coding exon of O b R (A) Restriction maps (from top to bottom) of the genomic locus, targeting
vector, homologous recombinant, and the type II and type I deletion alleles Probe 1, located outside the
targeting construct, was used to screen for homologous recombinants Probe 2, located in the second coding
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(D) Body weight at 8 weeks of age of O b R ^ and littermate control (ObR^4) mice. Data represent the mean
+/- S E M of at least 9 animals of each genotype and gender. *, p < 0.02, **, p < 0.001 in an unpaired Student's t test.

coding exon did not interfere with O b R function. To determine whether Cre-mediated

deletion of the first coding exon results in a null allele, ObRflox/+ mice were cros

transgenic mice expressing Cre at an early embryonic stage (Lasko et al. 1996). Mice

with the genotype ObR +, heterozygous for a germline deletion of the first coding e
(Type I deletion), were generated and mated to produce homozygous ObRA/A mice, also
referred to as ObR null mice (Figure 3.1c). ObR null mice are massively obese and

indistinguishable from db3J/db3J mice, which are also null for all ObR isoforms (Fig
3.1d) (Lee et al. 1997). These data confirm that the floxed allele is wild type and
deleted allele is null, thus validating the targeting strategy.

Neuron-specific ObR knockout
Neuron-specific ObR knockout mice, designated ObRSynIKO were generated by
two successive crosses (Figure 3.2a, and described in Materials and Methods). These

mice carry one floxed and one null allele so that Cre-mediated inactivation of only
allele, rather than two, is sufficient to delete ObR in a given cell. The ObRSynIKO
were compared to littermate controls with the genotype ObR^*10", Synl-Cre(-), also

referred to as heterozygotes. These mice were used as controls because some phenotyp

changes have been observed in db/+ mice (Coleman 1979). Data were also obtained from

lean littermates with the genotypes ObRflox/+, Synl-Cre (+)or ObRflox/+, Synl-Cre (-

of which are referred to as wild type. Genotypes of all mice were determined using P
and Southern blotting.
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Figure 3.2 Cre-mediated recombination specifically in the brain of ObRSynIKO mice.
(A) The breeding strategy that was used to generate O b R A ' K O mice and littermate controls
is shown. ObRAlbKO mice (described below) were generated using the same strategy.
(B) Genomic D N A was prepared from several tissues from ObRflov", Synl-Cre(+) mice and
P C R .amplified using primers flanking thefirstcoding exon of O b R . The locations of the primers
are shown on the schematic below the gel. In tissues expressing the Cre recombin.ase, exon 1 is
excised and a single loxP site remains, generating an O b R A allele. While primers 1 and 3 can
amplify a product from the O b R A allele, in the ObRtlox or O b R " (wild type) D N A , the primers
are separated by a distance too great for amplification to occur. A s a control, primers 1 and 2 were
used to amplify both the ObRflox allele and the O b R + alleles from all tissues. The O b R + allele
produces a slightly smaller product due to the absence of loxP sequences.

In the synapsinl-Cre transgenic line, expression of Cre recombinase is controlled

by the rat synapsin I promoter. This promoter has been shown to drive Cre expression

specifically in neurons (Hoesche et al. 1993). Crossing Synl-Cre+ mice to LacZ indic

transgenic strains showed that Cre activity was first detectable at El2.5 and restri

brain, spinal cord, and the dorsal root ganglion, and absent from astrocytes and gli
et al. 2001). To confirm the tissue specificity of Cre-mediated recombination, a
qualitative PCR assay was developed that was capable of detecting recombination

between the lox sites flanking the first coding exon of ObR in genomic DNA. In ObRfl
synapsinl-Cre (+) mice, Cre-mediated recombination was restricted to brain,

hypothalamus and spinal cord (Figure 3.2b). As previously indicated by reporter gene

expression in Synl-CAT transgenic mice, low level recombination was also seen in tes
(data not shown).
The weight of the ObRSynIKO mice was compared to that of heterozygous mice at

four months of age. While the weights of ObRSynIKO mice, on average, were no differe

than heterozygotes, in both sexes a subset of the ObRSynIKO mice had an increased bo
weight (Figure 3.3a). The percent body fat of these mice (shown in yellow) was more

than 3 standard deviations greater than the average percent body fat of heterozygote

(Figure 3.3a). This suggested the possibility that the extent of the knockout of ObR
variable and that the most obese ObRSynIKO animals had the lowest levels of ObR. In
order to assess the efficiency of Cre-mediated recombination, real time PCR assays
(Taqman®) were performed to quantitate ObR RNA using cDNA prepared from

individual hypothalami (Livak et al. 1995). Previous data have suggested that in neur
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Figure 3.3 O b R R N A levels. (A) The distribution of body weight and percent body fat for male
and female ObRSynIKO mice at 16 weeks of age is shown. Those mice with less than 1 5 % of O b R
R N A (as identified in Figure 3 B ) are shown in yellow. (B) Expression levels were determined using
T a q m a n ® real time P C R with the jABI Prism® 7700 Sequence Detection System. The locations of
primers and fluorescent probe .are as indicated. Primers were derived from sequences in the 5'
untranslated region and the second coding exon. The fluorescent probe is located within the first
coding exon 1. W h e n this exon is deleted, no signal is generated. A s a control for input amount, each
c D N A sample was also amplified using primers and a probe for cyclophilin. Data were analyzed with
A B I Sequence Detector® software and the levels of O b R were normalized to cyclophilin. Levels are
represented as the percentage of the levels in ObRfloA Synl-Cre(+) .and ObRflra/+, Synl-Cre(-) wild
type mice. Data represent the m e a n +/- S E M . A t least 13 animals were analyzed for each genotype.
p values for comparisons between genotypes are indicated.

O b R is expressed at highest levels in hypothalamus and at much lower levels in other

brain regions. This assay detected all forms of the leptin receptor. ObRflox/+, Synl

and ObR ° +, Synl-Cre(-) mice had equivalent levels of ObR expression, and thus both
genotypes were designated as wild-type (Figure 3.3b). As expected, ObR^A Synl-Cre

(-) mice, which have one allele inactivated in the germ line, have 50% as much RNA a
wild type mice (p < 0.006). The average level of ObR RNA was significantly lower in
ObRSynIKO mice than in ObR^A Synl-Cre (-) heterozygote littermates (30% vs. 50% of
wild type respectively, p = 0.004). Moreover, while many of the ObRSynIKO mice had
levels of ObR RNA that were indistinguishable from heterozygotes, a subset of the

ObRSynIKO mice had markedly reduced levels of ObR. These results confirmed that Cremediated recombination is variable, and indicated that in many animals there is no
evident recombination.
We next considered whether the most obese ObRSynIKO animals (i.e. percent

body fat 2.5 standard deviations greater than heterozygotes) had lower levels of ObR
RNA than the lighter ones. Analysis of the data indicated that percent body fat and

weight were significantly increased in each of six animals in which ObR RNA was less
than 15% that of wild-type (shown in yellow in Figure 3.3a) (p < 0.005 for percent

fat, p < 0.05 at all ages greater than 5 weeks for body weight). This confirmed that

significant deletion of ObR is associated with an obese phenotype. Furthermore, in t

cases where the deletion is most extreme, a severely obese phenotype is evident. Two
ObRSynIKO females and one ObRSynIKO male had a greater than 97% reduction of ObR
RNA and each weighed more than 50 grams at sacrifice, weights that approach, but do
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not equal, that of db/db mice. In these studies, as well as studies of the ObRAlbKO mice
(see below), there were no lean mice with hypothalamic ObR RNA levels less than 15%

that of wild type, and there were no obese mice (obese defined as percent body fat >
SD above heterozygotes: 30.5% for males, 47.8% for females) with RNA levels greater

than 15%o that of wild type. These data suggest that a near normal body weight can b
maintained until markedly reduced levels of ObR in hypothalamus are evident. In all
following studies, the phenotype of the animals with <15% wild type levels of
hypothalamic ObR RNA was compared to heterozygotes. These mice are referred to as
obese ObRSynIKO mice.
The weights of the obese ObRSynIKO mice were significantly increased relative to

heterozygotes at all time points greater than 5 weeks of age (p < 0.05). At 5 months
age, males and females weighed 35% and 66% more than heterozygotes respectively.

(Figure 3.4a). The increase in body weight was associated with increased adipose tis

mass and, as is also the case in ob/ob and db/db mice, decreased lean body mass (Tab
3.1). At sacrifice, the percent body fat of ObRSynIKO mice was 39% in males and 60%
females, compared to 15% in male heterozygotes and 26% in female heterozygotes.
The obese ObRSynIKO mice were also analyzed with respect to a number of other
abnormalities associated with the db/db mutation (Table 3.1). Plasma leptin

concentrations were elevated 5.8-fold in obese ObRSynIKO males (p < 0.05) and 8.3-f

in obese ObRSynIKO females (p < 0.0001) and were highly correlated with percent bod

fat (r = 0.82, p < 0.01, t test for correlation). In addition, plasma insulin was in
6-fold in obese ObRSynIKO males (p < 0.05) and 16.1-fold in ObRSynIKO females.

Glucose was increased 2.3-fold in ObRSynIKO females (p < 0.005), and was unchanged i
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Figure 3.4 Obesity in a subset of ObRSynIKO mice. Significant obesity was evident in those
ObRSynIKO mice that had 1 5 % or less O b R R N A in the hypothalamus than wild type mice.
(A) Weight curves of male and female ObRSynIKO mice (solid squares), heterozygote littermates
(open squares), and O b R null mice (solid triangles). Mice were weighed weekly from 5 weeks of
age. Data represent the mean +/- S E M of 4 male and 2 female ObRSynIKO mice and 7 male and 9
female heterozygote littermates. For both sexes, ObRSynIKO vs. heterozygotes, p < 0.05 at all ages
and ObRSynIKO vs. O b R null, p < 0.05 at all ages. (B) Expression levels of A G R P , N P Y , P O M C ,
and C A R T were determined by Taqman ® and are expressed as normalized to cyclophilin. Levels
were measured in ObRSynIKO, heterozygotes, and O b R nulls, n = 5 for heterozygotes, n = 6 for
knockouts, and n = 3 for null mice.

Body Composition and Neuroendocrine Function in O b R ^ ' K O and ObRAlbKO Mice
ObR^'KO
ObR^'Het
ObRAlbHet
ObRAlbKO
Percent Fat Mass
Males
15.4+/-0.8 (8)A
39.4 +/- 0.7 (4)
14.0+/-1.5 (4)
13.2+/-0.5 (5)
Females
25.8+/-0.9(10)*
60.1 +/-1.5(2)
15.4+/-0.9 (7)
15.6+/-1.1 (5)
Percent Lean Mass
Males
19.7+/-0.6 (4) 25.7 +/- 0.2 (8)A
30.2 +/- 0.8 (4)
30.2 +/- 0.8 (5)
Females
12.7+/-1.2 (2) 22.6+/-0.3 (10)A 28.0 +/- 0.7 (4)
27.5 +/- 0.7 (5)
Percent Water Mass
Males
59.0 +/- 0.6 (8)A
40.9 +/- 0.3 (4)
55.8+/-1.3 (4) 56.6 +/- 0.6 (5)
51.6+/-0.6(10)A
Females
27.2 +/- 0.3 (2)
56.6 +/- 0.9 (4)
56.9 +/- 0.7 (5)
Leptin (ng/mL)
Males
73.8 +/- 8.5 (4) 12.7+/-0.4 (10)B 13.1 +/-0.8(9)
13.9+/-0.7 (15)
6.7+/-0.2(12)B
Females
125.0+/-0.7 (2) 15.1 +/-0.8(12)A
12.7+/-0.9 (6)
Insulin (ng/mL)
Males
17.1 +/-2.1 (4) 2.8 +/- 0.2 (8)B
1.9+/-0.1 (9)
1.6+/-0.1 (6)
Females
40.1 +/-6.5(2)
2.5 +/- 0.2 (8)
0.8+/-0.1 (4)
0.7+/-0.1 (5)
Glucose (mg/dL)
Males
158.3 +/- 9.3 (4) 165.3 +/- 4.9 (10) 80.3 +/- 2.3 (7)
89.1 +/-2.5(8)
282.6 +/- 32.3 (2) 123.1 +/- 4.7 (8)4 87.3 +/- 3.9 (5)
91.9 +/- 2.0 (9)
Females
Corticosterone (ng/mL)
63.4+/-2.7 (11)
238.5+/-17.9 (4) 134.9+/-40.2 (3) 54.0+/-4.2 (6)
Males
469.4 +/- 32.7 (2) 195.9 +/-16.1 (8)B 208.8+/-25.1 (5) 108.5+/-9.3 (9)
Females
Estradiol (pg/mL)
ND
ND
3.9 +/- 0.3 (2) 6.8 +/- 0.8 (3)
Females
^ < 0.005 vs. knockout, BP< 0.05 vs. knockout, NDNot Determined

Table 3.1 B o d y composition and neuroendocrine function in ObRSynIKO and O b R A l b K O mice.
After sacrifice, the subset of significantly obese ObRSynIKO mice and the subset of O b R ^ K O mice
with less than 3 0 % O b R R N A as well as heterozyogte littermates were exsanguinated and plasma was
collected for the following assays. M l plasma was collected from mice sacrificed at 1200 hrs under free
feeding conditions. Average ages for ObRSynIKO and O b R ^ K O mice sampled here are 26 weeks and 23
weeks. All data represent the m e a n +/- S E M , with the sample size indicated in parentheses (A, p < 0.005,
B, p < 0.05 in an unpaired Student's t test).

ObRSynIKO males. Plasma corticosterone was elevated 1.8-fold in ObRSynIKO males and
2.4-fold in ObRSynIKO females (p < 0.05). The elevation in plasma glucose and the

greater elevation in corticosterone specific to females could be due to the fact tha
females analyzed had a lower level of ObR RNA and were more obese. Of note, an

increased plasma corticosterone is unique to ob/ob and db/db mice, whereas other for

of rodent obesity are not generally associated with elevated corticosterone (Bray an

York 1979). Mutations in leptin or its receptor are also associated with infertility

leptin has been shown to influence the hypothalamic-pituitary-gonadal axis (Chehab e

1997). Consistent with this, obese female ObRSynIKO mice had 43% reductions in plasma
estradiol. Male ObRSynIKO mice, however, did not have reduced levels of plasma

testosterone. This sexual dimorphism is consistent with the fact that leptin deficie

a more profound effect on female reproduction than male reproduction (Ewart-Toland e

al. 1999). Finally, plasma thyroxine and triglycerides were not significantly differe
between mutant and control mice (data not shown).
Despite the marked obesity in this subset of ObRSynIKO mice, these animals still
weighed less than mice with germline deletions of ObR (Figure 3.4a, p < 0.05 at all
These data suggest either that the knockout was incomplete even in the most obese

animals or that leptin also acts at peripheral sites to reduce weight. To further as

extent of the knockout in brain, levels of a number of hypothalamic neuropeptides we

examined using Taqman assays (Figure 3.4b). Defective leptin signaling is associated
with increased levels of hypothalamic AGRP, NPY, and MCH RNA and reduced levels
of POMC and CART RNA (Stephens et al. 1995; Qu et al. 1996; Ollmann et al. 1997;
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Shutter et al. 1997; Thornton et al. 1997; Kristensen et al. 1998). Comparisons of
heterozygotes to obese ObRSynIKO mice showed that AGRP and NPY levels were
increased, while POMC and CART levels showed a trend towards being reduced. While
the reduction in POMC and CART RNA levels is not significant, the levels of these
RNAs are only modestly decreased in ob/ob and db/db hypothalamus. MCH levels were
indistinguishable between heterozygous mice, ObRSynIKO mice, and ObR null mice. The

reported 80% increase in MCH RNA in ob/ob mice is also more modest than the reported
increases in AGRP and NPY RNA (Qu et al. 1996). While the levels of AGRP and NPY

were increased in the obese ObRSynIKO mice, they were less elevated than in null mic
This suggests that, despite the low levels of ObR RNA in these mice, some ObR
expressing neurons remained.

Hepatocyte-specific ObR .knockout
The data here indicate that leptin has direct effects on brain but leaves open the

possibility that leptin also has direct effects on peripheral tissues. To assess a p

role of ObR in liver, a peripheral tissue that has been suggested to be a direct tar
leptin action, mice with a hepatocyte-specific knockout of ObR were generated
(ObRAlbKO). These mice were generated using the same breeding strategy as described

for ObRSynIKO mice (Figure 3.2a). The albumin promoter was used to direct hepatocyte-

specific expression of Cre recombinase (Figure 3.5a) (Pinkert et al. 1987). Genomic P

performed on multiple tissues from ObRflox/+ albumin-Cre (+) mice confirmed that cre

mediated recombination was restricted to liver (Figure 3.5b). In contrast to ObR ynKO

mice, ObRAlbKO mice did not manifest an increased weight even in those animals where
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Figure 3.5 Normal body weight and liver phenotype in O b R A l b K O mice. (A) Schematic of
Albumm-Cre transgene. (B) Genomic D N A was prepared from several tissues from ObR""**,
Alb-Cre(+) mice and P C R amplified using primersflankingthefirstcoding exon of O b R as
described in Figure 5.2B. (C) Weight curves of male and female ObRAJbKO mice (solid squares)
and heterozygote littermates (open squares). Mice were weighed weekly from 5 weeks of age
Data represent the mean +/- S E M of 9 male and 11 female O b R ^ K O mice and 23 male and 23
female heterozygote littermates. For both sexes, O b R A l b K O vs. heterozygotes, p values were
not significant at all ages (D) Photographs offreshlydissected livers from representative mice
with the given genotypes. (E) Liver triglycerides (mg triglyceride ' gram liver) were determined
for O b R ^ K O mice with < 3 0 % of wild type O b R RN.\ and heterozygote controls. Data represent
the mean +/- S E M of 6 male and female Ob.RAlbKO mice, 5 male and 5 female heterozygote
nsrtrols.. sad 6 siale and 3 female O b R null mice. For both sexes, p < 0.05 for O b R A l b K O and

the levels of O b R R N A in liver (as measured using the aforementioned Taqman assay)
were reduced to less than 30% wild type levels (9/12 males, 11/16 females analyzed)
(Figure 3.5c). As the liver is composed of a number of different cell types, and 80%

the mass is accounted for by hepatocytes, this likely represents a near complete del
in hepatocytes (Weibel et al. 1969; Gumucio et al. 1996). Inspection of the weight
distributions showed that no ObRA KO mice manifested an increased weight. Body

composition was analyzed to determine whether hepatocyte-specific deletion of ObR ha

a subtle effect on body partitioning in ObRAlbKO mice. Water mass, lean mass, and fa

mass were all unchanged in these animals (Table 3.1). In both sexes, plasma leptin l

were within the normal range as were insulin, glucose, and corticosterone. While db/

and ObRSynKO mice have enlarged fatty livers characteristic of leptin deficient mice

livers of ObRAlbKO mice were grossly normal (Figure 3.5d). Wet liver weight and live
weight as a percentage of body weight were also unchanged between ObRAlbKO mice
and heterozygotes (data not shown). Quantitation of liver triglycerides showed no

difference between ObRAlbKO mice and heterozygote controls, while levels in ObR null

mice were significantly elevated relative to both of these groups (p < 0.05) (Figure

These data indicate that ObR expressed in hepatocytes is not likely to play a signif

role in body weight homeostasis or the hepatic steatosis associated with the db muta
and that the liver abnormalities observed in ob/ob and db/db mice are secondary to
defective leptin signaling in the brain.
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Discussion

In this study, two possible sites of leptin action were evaluated by analyzing the

phenotype of mice with neuron and hepatocyte-specific knockouts of the leptin recept

These data provide direct genetic evidence that leptin signals via direct effects o

neurons. Separate data from studies of dbKls/dbKls mice indicate that the specific a

of the ObRb form of the receptor results in a phenotype indistinguishable from lept
deficiency, demonstrating that ObRb is absolutely required for the weight reducing

effects of the hormone (Tartaglia et al. 1995; Chen et al. 1996b; Lee et al. 1996). O

the only isoform that has all of the motifs necessary for signal transduction and is
expressed at high levels in brain and a number of other tissues.
These findings suggest that leptin exerts its weight reducing and some, or perhaps

all, of its neuroendocrine effects via interactions with the ObRb form of the recep

specific classes of neurons in brain. This is consistent with the high potency of le

administered i.c.v. and the anatomic distribution of ObRb (see below) (Campfield et

1995; Halaas et al. 1995). This conclusion is also consistent with data from experim

where an NSE-ObRb transgene was able to partially complement the phenotype of db/db

mice (Kowalski et al. 2001). However, in this study ObRb was overexpressed 30-fold i
all neurons, with some leakiness in peripheral tissues.
The phenotype of the obese ObRSynKO, while significant, did not reach that of
ObR null mice. However, in these animals, hypothalamic AGRP and NPY levies, while
increased, were still not as high as in null mice suggesting that there were still

residual ObR expressing cells. This leaves open the possibility that a truly complet

brain-specific knockout (i.e. deletion of ObR on every neuron) could recapitulate t
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obese phenotype of O b R null mice. The generation of such a knockout might require the
simultaneous use of multiple different neuron-specific cre expressing lines.
In some studies, the expression of ObRb in brain was reported to be restricted to
the hypothalamus, possibly implicating the hypothalamus as the principal target of
leptin's weight reducing effects. In hypothalamus, ObRb is enriched in the arcuate,

ventromedial, dorsomedial, and paraventricular hypothalamic nuclei, all of which are

known, based on studies of animals with stereotactic lesions, to play a role in regu

food intake and body weight (Hetherington and Ranson 1942; Elmquist et al. 1997; Fei

al. 1997; Elmquist et al. 1998a). However, in other studies, ObRb expression has also

been reported in other brain sites including the brainstem, thalamus, and cerebellum

possibility that one or more of these extrahypothalamic brain sites play important r

the regulation of body weight can be tested using region-specific or neuron-specific
promoters to drive Cre expression in localized brain areas and specific cell types.

hypothalamus, ObRb is expressed in functionally distinct classes of neurons, the bes

characterized being neurons that co-express either NPY or °=MSH (Mercer et al. 1996a
Cheung et al. 1997). Both of these neuropeptides exert potent effects on food intake
body weight. Experiments to test the effects of ObR deletion in these two types of

neurons may allow an analysis of the functional importance of these two neuropeptide

downstream effectors of leptin signaling and could establish the extent to which the
two cell types by themselves can fully account for the neural response to leptin.
A number of studies have suggested that leptin also has direct effects on liver
(Shimabukuro et al. 1997a; Kim et al. 2000). The data presented here indicate that
hepatocyte-specific deletion does not have any observable effects on body weight or
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composition and does not result in any gross liver pathology. Furthermore ObRAlbKO

mice have equivalent amounts of liver triglycerides as controls, indicating that the

phenotype of db/db mice is secondary to defective leptin signaling in brain. However
hepatocyte-specific deletion may have less obvious effects on hepatic lipid and
carbohydrate metabolism. In addition, these findings do not exclude the possibility
hepatocyte ObR by itself serves functions, such as modulating leptin turnover.
While these findings suggest that neurons are required for leptin's effects on body
weight, they do not exclude the possibility that leptin also directly acts on other
peripheral targets. In addition to regulating food intake, body weight, and the
neuroendocrine axis, leptin can also modulate the immune system, bone turnover,

angiogenesis, and lipid metabolism (Lord 1998; Sierra-Honigmann et al. 1998; Ducy et
al. 2000; Atkinson et al. 2002; Minokoshi et al. 2002). Indeed, ObRb is expressed in
number of peripheral tissues and direct effects of leptin on T cells, macrophages,
pancreatic B-cells, skeletal muscle, heart, and other cell types have been reported

(Shimabukuro et al. 1997a; Kim et al. 2000; O'Rourke et al. 2001; Atkinson et al. 200

Minokoshi et al. 2002). Other forms of ObR (ObRa, c, d, e) may play a role in transpo

of leptin across the blood brain barrier and choroid plexus, sites that express high
of ObR. The function of ObR at these and other sites can now be assessed by crossing

ObR ox ox mice to transgenic lines that express Cre in a tissue-specific fashion. Su
studies should allow an assessment of the relative role of direct effects of leptin

tissues vs. indirect effects via signaling in brain. In conclusion, these findings i

that the brain is a direct target for the weight reducing and neuroendocrine effects
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leptin and that the liver pathology of ob/ob and db/db mice is secondary to defective
leptin signaling in neurons.
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Chapter 4: Leptin-specific Programs of G e n e Expression in Liver

Introduction

The adipocyte-derived hormone leptin functions as the afferent signal in an
endocrine loop regulating energy homeostasis. Mice with mutations in leptin (ob/ob)

its receptor (db/db) exhibit marked obesity, hyperphagia, and endocrine abnormalitie

(Zhang et al. 1994; Tartaglia et al. 1995; Chen et al. 1996b; Lee et al. 1996). When

administered to wild-type and ob/ob mice, leptin causes significant reductions in fo

intake and body weight (Campfield et al. 1995; Halaas et al. 1995; Pelleymounter et
1995). These findings have implicated leptin as a key regulator of energy balance
(Friedman and Halaas 1998). Current evidence indicates that the brain is a critical

leptin action, suggesting that leptin modulates a neuronal circuit that controls foo
and peripheral metabolism (Chapter 3)(Cohen et al. 2001). At present, however, the

components of this neuronal circuit and the nature of the efferent signals from the

nervous system that regulate metabolism in response to leptin are not well characte
Leptin elicits a metabolic response that cannot be explained by its effects on food
intake alone. When the food intake of an ob/ob mouse is restricted to the amount of

voluntarily consumed by a leptin-treated mouse (pair-fed), the pair-fed animal loses

significantly less weight than a leptin treated counterpart (Levin et al. 1996). Ani

treated with leptin also exhibit a number of physiological differences from food-re
animals. While pair-feeding causes the breakdown of both lean and fat mass, leptin

treatment selectively reduces fat mass (Halaas et al. 1995; Pelleymounter et al. 19
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Halaas et al. 1997). In addition, leptin treatment does not produce an increase in

circulating free fatty acids and ketone bodies typical of starvation (Chen et al. 19

Shimabukuro et al. 1997a). Leptin treatment also eliminates the compensatory drop in
energy expenditure induced by starvation (Halaas et al. 1997). In aggregate, these

findings suggest that leptin causes weight loss by enacting a novel metabolic progra
distinct from food restriction on both a physiological and molecular basis.
The mechanism underlying leptin's unique metabolic effects is likely to involve
modulation of gene expression in metabolically active organs such as liver, adipose

tissue, and muscle. In order to more fully characterize this metabolic response, dat
presented here on leptin-specific programs of gene expression in liver. First, we
examined the effects of total leptin deficiency on gene expression, by using

oligonucleotide microarrays to compare ob/ob to wild-type liver. Next, gene expressi

was analyzed in ob/ob liver over a time course of leptin replacement and pair-feedin

identify unique profiles of gene expression characteristic of each state. Finally, t

transcriptional regulation of clusters of genes with leptin-specific patterns of exp
was examined.

Results

Comparison of gene expression in ob/ob and wild-type liver by oligonucleotide
microarrays
Initially, suppressive subtractive hybridization was used to compare gene

expression in ob/ob and wild-type liver (Diatchenko et al. 1996). Although this meth

successfully identified a few clones with altered expression in ob/ob liver, high-de
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microarrays permit a more comprehensive and high-throughput analysis of gene
expression, allowing one to compare the RNA levels of thousands of genes
simultaneously (Brown and Botstein 1999; Lockhart and Winzeler 2000). Using
Affymetrix murine 6500 Gene Chips, we examined the expression of roughly 6500 genes
in the livers of ob/ob and lean littermate control mice. Based on the GeneChip 3.1

Software, 177 genes were upregulated and 98 genes were downregulated in ob/ob liver.
Table 4.1 shows all genes with more than 3-fold altered expression in ob/ob liver.
The gene most upregulated in ob/ob liver was apoliprotein A-IV (17.5-fold), which

functions in HDL metabolism. Many of the other molecules overexpressed in ob/ob live

are involved in lipid and carbohydrate metabolism, which was expected since ob/ob mi

demonstrate increased hepatic lipogenesis and gluconeogenesis (Yen et al. 1976; Kapl

and Leveille 1981; Yoon et al. 2001). The gene most downregulated in ob/ob liver was

insulin-like growth factor binding protein-2 (27.7-fold), and studies on this gene a

subject of Chapter 7. Other molecules with decreased expression include 3 major urin
proteins, 2 proteasome components, and 2 DNA binding proteins (Statl and NF-kB).

Interestingly, targeted knockout of aromatase, which is downregulated 3.2-fold, lead
obesity and other metabolic abnormalities (Murata et al. 2002).
To assess the reliability of the microarray data, a number of Northern blots were
performed on differentially expressed genes (Figure 4.1). All genes found to be

differentially expressed by the microarrays were confirmed as being altered by North

blotting. In fact, Northern blot analysis suggested that the GeneChip 3.1 Software m

underestimate the true fold change values. Based on this analysis, any gene called I

(increased or decreased) and called P (present) in at least one of the samples by th
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upregulated in ob/ob liver
Fold Change
17.5
11.8
10.2

9.7
-8.1

6.9
-6.6

6.3
-6.1
~4.9
-4.6

4.4
4.3
4.2
-4.2

4.1
3.9
3.9
3.8
3.8
3.8
-3.6
-3.6

3.5
3.4
-3.4
-3.4

3.3
3.3
3.2
-3.2
-3.1
-3.0

Avg Diff Change Genbank Accession
4414
M64250
1104
AA059763
AA073296
901
1367
W13002
X03690
202
W33415
323
M26270
473
6919
AA139907
M61737
433
X15842
202
U72881
246
J02652
611
1069
W91509
2172
W17745
X91824
169
2635
X13135
X95280
622
D10024
618
1572
D64160
W07946
488
AA048650
257
AA104086
174
X59846
134
1089
M77003
2307
Z22216
AA114781
163
AA008737
127
1355
UD0445
104696
537
AA030483
393
AA097626
149
X04123
108
AA000410
104

Name
apolipoprotein A-IV
tubulin, beta 2
ATP citrate lyase
L14 lectin
Ig heavy chain constant region mufb)
ATP citrate lyase
stearoyl-CoA desaturase-2
spotl4
adipocyte-specific FSP27
c-rel
RGS-r
malic en2yme
ATP citrate lyase
ATP citrate lyase
small proline-rich protein 1A
fatty acid synthase
G0S2-like protein
protein-tyrosine kinase substrate p36 / calpactin I heavy chain
retinoic acid early transcript 1, alpha
homologous to alpha-1-antiproteinaseF precursor
hydroxysteroid (17-beta) dehydrogenase 12
homologous to zinc finger protein 97
GAS6
glycerol-3-phosphate acyltransferase
apolipoprotein CII
homologous to UMP-CiMP kinase
peroxin 5
glucose-6- phosphatase
glutathione S-transferase class m u
homologous to insulin induced protein 2
homologous to endogenous murine leukemia virus
terminal deoxynucleotidyltransferase
ATP citrate lyase

Function
Northern Verified
i
Lipid Metabolism
Structural
Lipid Metabolism
i
Binding Protein
4
Immune
Lipid Metabolism
i
Lipid Metabolism
-1
Lipid Metabolism
-1
Unknown
D N A Binding
Signal Transduction
Lipid Metabolism
Lipid Metabolism
V
Lipid Metabolism
V
Cell Membrane
Lipid Metabolism
Unknown
Signal Transduction
Membrane Protein
V
Secreted
Steroid Metabolism
D N A Binding
Growth Arrest
Lipid Metabolism
Lipid Metabolism
V
Nucleotide Metabolism
Peroxisome Targeting
Carbohydrate Metabolism
V
Detoxification
Unknown
Unknown
D N A Repair
Lipid Metabolism
V1

Name
insulin-like growth factor binding protein 2
PACAP/VIP receptor (PACAPR-3)
angiogenin precursor
major urinary protein IV
P311
proteasome subunit Lmp2
carboxy esterase
GTP binding protein GTP2
major urinary protein HI
TDAG51
angiogenin-related protein
homologous to ERG2
statl
alpha-2 macroglobulin receptor
proteasome subunit Lmp7
Ig gamma2a-b
aromatase p450
Via arginine vasopressin receptor
NF-kappa-B D N A binding subunit
polymeric immunoglobulin receptor
complement component C2
group 1 major urinary protein

Function
Binding Protein

Downregulated in ob/ob liver
Id Change
-27.7
-8.4
-8.1
-7.5
-5.7
-5.7

4.6
-4.6

4.5
4.4
-A.l
-3.9
-3,7
-3.7
-3.4
-3.3
-3.2
-3.1
-3.1
-3.1
-3.1

•3

Avg Diff Change
-3160
-627
-2343
-1892
-244
-322
-3055
-308
-9596

470
-168
-248
-181
-1005
-285
-960
-185
-142
-274
-581
-367
-3427

Genbank Accession
L05439
D28132
U22516
M16358
X70398
L11613
L11333
U15636
M16359
U44088
U22519
AA120109
U06924
X67469
U22031
J00479
D00659
1X9730
M57999
U06431
M57891
X03208

Northern Verified

Secreted
Unknown
Protein Turnover
Detoxification
Signal Transduction
Secreted
Signal Tran^uction
Angiogenesis
Ion Channel
Signal Transduction
Receptor
Protein Turnover
Immune
Steroid Metabolism
Receptor
Immune
Inflammably
.Secreted

Table 4.1 Genes with differential expression between ob/ob and wild-type liver. All genes with more than
3-fold differential expression are shown. The average difference change is a software-derived quantitative measure
of the difference in expression. ~ indicates that expression in the other sample is undetectable. Function

apolipoprotein
A-IV
wt ob

lectin L14

spotl4

Rne-la

ThB
wt ob

apolipoprotein
C-II
wt ob

glucose-6phosphatase
wi ob

wt ob

wt ob

wt ob

1572

77

2307

1355

18SRNA

L-Ll LU LU 111 I I 1 I IJ I IJ
difference
change
fold change

4414

1367

6919

17 5

9.7

63

IGFBP-2

angiogenin
precursor

38

-3 7

34

carboxyesterase

LRG-47

regucalcin

33

corticosteroid
binding globulin

wt ob wt ob wt ob wt ob wt ob wt ob

18SRNA

III III I LI ill ill LLI
difference
change
foldchange

-3160

-2343

-3055

-221

-3604

-1234

-277

-8 1

46

40

-24

-18

Figure 4.1 Northern blots of differentially expressed genes betweeen ob/ob and wild-type liver. Northern blots were
performed to validate the microarray data using independently generated R N A . 10 g of total R N A was hybridized with a
probe specific to the indicated genes. Equal loading was confirmed by ethidium bromide stained 18S R N A The average
difference change and fold change for each gene is indicated.

software, was considered to represent a reliable difference in R N A levels if the following

criteria were also satisfied: (i) fold change > 2.0 and average difference change >

fold change > 1.5 and average difference change > 500, and (iii) fold change > -1.5

average difference change > 100 (the average difference change is a computational v
of the magnitude of difference in expression). These thresholds were chosen
conservatively to minimize the inclusion of false-positives in subsequent analysis.

on these conditions, 79 genes were increased and 56 genes were decreased in ob/ob li

Leptin-specific patterns of gene expression
While binary comparisons, as described above, are a useful starting point for

analysis, making biological conclusions from this data is extremely difficult. The a
gene expression noted in ob/ob mice may result from obesity, hyperphagia, leptin
deficiency, or hormonal perturbations. Monitoring gene expression over a dynamic

process, such as a time course, can be more useful for dissecting the molecular basi
complex physiological pathway (Soukas et al. 2000; Soukas et al. 2001).
In order to better understand the basis for leptin's unique metabolic effects, we

used microarrays to identify genes that are differentially regulated by leptin vs. p

feeding in liver. To this end, ob/ob mice were followed over a time course of weight

induced by either leptin administration or pair-feeding, as previously described (S
et al. 2000). Liver RNA was isolated from groups of ob/ob mice treated with

subcutaneous leptin (infusion rate of 4.8 ,ug/24 hours) for 2, 4, and 12 days and f

ob/ob mice that received saline. This dose of leptin has been shown to produce plasm
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levels of the hormone comparable to those in wild-type mice (Shimomura et al. 1999c).

RNA was also isolated from ob/ob mice that were pair-fed to the leptin treated group

2, 4, and 12 days of treatment. Adipose RNA was isolated from the same time course t

analyze leptin-specific patterns of gene expression in this tissue (Soukas et al. 20

change in body weight and food intake of these groups of mice is shown in Figure 4.2

and b). As previously shown, leptin treated ob/ob mice lost significantly more weigh
than pair-fed mice indicating that leptin has metabolic actions that are not purely
its effects on food intake (Levin et al. 1996).
Leptin replacement preferentially corrected the liver pathology in ob/ob mice.

Leptin reduced hepatomegaly, significantly more so than pair-feeding (p < 0.05 lepti

pair-fed at days 2, 4, and 12) (Figure 4.2c). Leptin also caused a significant decre

liver triglyceride levels, with far greater potency than pair-feeding (Figure 4.2d).
was further evident in histological sections showing a greater reduction in hepatic

vacuolation following 12 days of leptin treatment than after an equivalent period of
restriction (Figure 4.2e).
RNA from the livers of these mice was hybridized to Affymetrix Murine 6500
GeneChips. Data were analyzed using a AT-means clustering algorithm (Hartigan 1975;
Kohonen 1997; Soukas et al. 2000). This computational method groups genes with

similar patterns of expression over the time course experiment. For inclusion in the

cluster analysis, a gene had to meet pre-established selection criteria, based on wh

genes were included in the analysis (See Materials and Methods, Chapter 2) (Soukas e
al. 2000; Soukas et al. 2001).
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Figure 4.2 Leptin treatment produces novel metabolic effects. (A) Percent change in body
weight and (B) daily food intake in o b o b mice treated with leptin (green circles), P B S with
pair-feeding (red triangles), and P B S withfree-feeding(blue squares). Liver R N A was isolated
from .animals sacrificed at days 2, 4, and 12 of the time course, n = 4 per group, error bars denote
S E M , *, p < 0.05 pair-fed vs. leptin. At all time points, except tO, both pair-fed and leptin
values were significantly different from pbs values (p < 0.01). (C) Liver weight and (D) liver
triglyceride content at day 12 of treatment and in untreated wild-type liver. For (C) and (D),
P B S is in blue, pair-fed is in red, and leptin is in green; error b.ars denote S E M . For (C) n =4,
', p < 0.05 pair-fed vs. leptin, for (D) n =3, *, p < 0.05 leptin vs. pbs and *, p = 0.07 pair-fed vs.
leptin. (E) Hematoxylin and eosin stained liver sections from representative mice sacrificed after
12 days of pbs, pair-feeding, or leptin. Images are 200x magnifications; scale bars denote 100 |am
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Figure 4.3 Leptin elicits a specific program of gene expression in ob/ob liver. K-means cluster analysis
of genes from the time course. In the colorgram on the left, each row represents a gene and each column
represents a group. The color denotes the expression level of each gene relative to wild type. The graphs on
the right .are another means of representing the data. In these curves, the expression profile of the average
gene in each cluster is depicted relative to untreated lean littermate controls for which expression is given a
value of zero. The expression levels in leptin treated and pair-fed mice are shown in green -and blue
respectively. 15 clusters of genes with distinct patterns of expression were identified, six of which correspond
* ;
i^~L
:c--"y regulated by leptin relative to pair-feeding.

15 clusters of genes with distinct patterns of expression were identified, six of
which corresponded to genes specifically regulated by leptin, but not pair-feeding (Figure
4.3). These clusters were likely to include genes that are either functional components or
markers of leptin's metabolic effects. These six clusters were further subdivided into two
classes: (a) genes that were overexpressed in ob/ob liver and specifically reduced by
leptin (clusters 10, 11, 13, and 14) and (2) genes that were underexpressed in ob/ob liver
and preferentially induced by leptin (clusters 7 and 12). In addition, several clusters of
genes showed similar patterns of expression with both leptin treatment and pair-feeding,
suggesting that these profiles represented a more general response to reduced food intake
and weight loss or to experimental manipulation (Figure 4.3, clusters 2, 3, 5, 6, and 15).
A complete list of the genes in all of the clusters can be found on the worldwide web

(http://hal.rockefeller.edu/arrays/leptin/liver/). In aggregate, these data confirm that lept
elicits a novel program of gene expression in liver. As the genes in each of these clusters
are specifically regulated by leptin (as compared to pair feeding), they could, in certain
cases, mediate some of the effects of the hormone.

Transcriptional control of leptin-regulated clusters of genes
The leptin-regulated clusters, particularly those whose expression was specifically
repressed by leptin (clusters 10, 11, 13, and 14), were enriched in genes involved in lipid
and carbohydrate metabolism. Genes with roles in lipid metabolism included molecules
involved in lipogenesis (SCD-1, SCD-2, malic enzyme, ATP citrate lyase, fatty acid
synthase, spotl4, and glycerophosphate dehydrogenase), lipid transport (CD36, PMP70),
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and apolipoprotein metabolism (plasma phospholipid transfer protein, apolipoprotien A-

IV, apolipoprotein C-II). Genes with functions in carbohydrate metabolism included th
three rate-limiting enzymes of gluconeogenesis, glucose-6-phosphatase fructose
bisphosphatase 1, and phosphoenolpyruvate carboxykinase 1 (PEPCK) (all members of

cluster 10, Figure 4.3). The transcriptional regulation of lipogenesis and gluconeog

are both well characterized. Since leptin specifically repressed genes involved in t

processes, we examined whether leptin regulated the transcription factors coordinati
these metabolic pathways.
Sterol regulatory element-binding proteins (SREBPs) are a family of basic helixloop-helix transcription factors that regulate the entire program of fatty acid and

cholesterol biosynthesis (Horton et al. 2002). In their inactive form, SREBPs are bo
the endoplasmic reticulum membrane. In reponse to sterol depletion, SREBPs are

proteolytically cleaved from the ER membrane and translocate to the nucleus, where t

activate the transcription of genes containing sterol response elements (SREs)(Horto
al. 2002). Studies in transgenic mice have shown that SREBP-la and -lc primarily

activate transcription of fatty acid biosynthetic molecules, while SREBP-2 preferent
activates cholesterol biosynthetic genes (Shimano et al. 1996; Shimano et al. 1997;
Horton et al. 1998). SREBP-lc RNA levels and nuclear protein were shown to be
increased in diabetic, leptin deficient ob/ob and aP2-SREBP-lc transgenic mice
(Shimomura et al. 1999a; Shimomura et al. 2000). Microarray analysis of SREBP
expression, however, found only a small, unreliable increase in SREBP RNA levels in

ob/ob mice and no substantial alterations upon either leptin administration or pairfeeding, a finding that was confirmed by Northern blot analysis (Figure 4.4a) and
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Figure 4.4 Transcriptional regulation of leptin-specific cluster of gene
expression. ( A ) Northern blot analysis (top) of S R E B P - 1 R N A levels using
a probe that hybridizes with both S R E B P - l a and -lc. Ethidium bromide stained
18S R N A w a s used to confirm equal loading. Western blot analysis (bottom) of
6 8 k D nuclear S R E B P protein. The upper band likely represents an intermidate
of proteioytic cleavage. Nuclear protein w a s prepared as described in Chapter 2.
(B) Northern blot analysis of P G C - 1 R N A levels using a probe that hybridizes
to all three splice variants, indicated by an * T h e blot w a s hybridized with a
cyclophilin probe to confirm equal loading.

ribonuclease protection assays (data not shown). Furthermore, Western blotting detected
no increase in nuclear SREBP-1 protein in ob/ob mice, and a minor, but equivalent
repression following either leptin treatment or pair-feeding (Figure 4.4a).
Gluconeogenic gene expression is regulated by a number of factors, including the

transcriptional cofactor PGC-1. This molecule was originally identified as a cold-in
transcriptional coactivator of PPARy and thyroid hormone receptor in brown fat
(Puigserver et al. 1998). Subsequent studies showed that the cAMP-regulated
transcription factor CREB induced PGC-1, which in turn, coactivated HNF4cc and
induced gluconeogenic gene expression (Herzig et al. 2001; Yoon et al. 2001). In

addition, in animal models of hepatic insulin resistance, including ob/ob mice, whic

to downregulate hepatic gluconeogenesis in response to elevated insulin, liver PGC-1

expression was elevated (Yoon et al. 2001). Northern blot analysis demonstrated lepti
specific repression of the RNA levels of all three PGC-1 splice variants, with no
alteration observed in response to pair-feeding (Figure 4.4b). The pattern of PGC-1

expression in response to leptin treatment mirrored the expression profiles of gluco
phosphatase, fructose bisphosphatase 1, and phosphoenolpyruvate carboxykinase 1
(cluster 10, Figure 4.3). Thus, leptin-mediated repression of PGC-1 may be the
mechanism by which leptin suppresses gluconeogenic gene expression.

Discussion

A number of reports have examined gene expression and its involvement in

obesity and metabolic diseases. Differential display was done to identify alteration
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gene expression in ob/ob skeletal muscle, and global analysis of expression was

performed in multiple tissues of ob/ob mice using the GeneCalling technology (Vicent
al. 1998; Renz et al. 2000). Oligonucleotide microarrays were used to characterize
expression profiles in white adipose tissue in response to leptin treatment or over

gradient of increasing obesity and worsening diabetes (Nadler et al. 2000; Soukas et

2000). Microarrays were also used to study gene expression in ob/ob liver in respons

leptin therapy, with similar findings to those described here (Ferrante et al. 2001;
and Tall 2001).
The liver is central to whole body metabolism and plays an important role in the

determination to follow either an anabolic or catabolic fate. Lipogenic gene express

was elevated in ob/ob liver and was previously shown to be suppressed in ob/ob adipo

tissue, an observation that was also noted in obese humans, and indicates that hepat

fatty acid biosynthesis may contribute substantially to the development and maintena
of obesity (Nadler et al. 2000; Soukas et al. 2000; Diraison et al. 2002). Livers of

mice are massively enlarged and steatotic, and contain elevated lipid and glycogen i

keeping with an anabolic process. Weight loss and depletion of hepatic lipid require
shift to a catabolic program, which appears to be specifically modulated by leptin.

Understanding the molecular basis for these programs could provide a marker for lept
unique effects and could ultimately explain how body composition is determined.
The effects of leptin cannot be accounted for by a reduction in food intake alone,

as leptin treated ob/ob mice lose significantly more weight than pair-fed controls (

et al. 1996). In addition, leptin replacement completely corrects the hyperinsulinemi

ob/ob mice, which is likely associated with enhanced hepatic insulin sensitivity, wh
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pair-feeding only reduces insulin levels by 5 0 % (Levin et al. 1996). Thus, leptin-specific
modulation of gene expression and the depletion of hepatic lipid may, in fact, be
secondary to the correction of diabetes and neuroendocrine abnormalities of ob/ob mice.
Leptin-deficient, lipodystrophic aP2-SREBP-lc transgenic mice also manifest
hyperinsulinemia, diabetes, and hepatic steatosis, all of which can be corrected by leptin
administration (Shimomura et al. 1999c). The alterations in gene expression and patterns
of expression following leptin treatment of these mice demonstrate a striking similarity to
those of ob/ob mice (E. Asilmaz, unpublished results). These findings suggest that leptindeficiency accounts for a significant component of the abnormalities in both of these
animal models and that the leptin-specific programs of gene expression observed in ob/ob
and aP2-SREBP-lc transgenic mice may be secondary to the correction of
hyperinsulinemia and other endocrine defects.
To study the effects of leptin, independent of its correction of the obese
phenotype, gene expression was also analyzed in wild-type liver at several time points of
leptin administration and pair-feeding. In wild-type mice, neither leptin treatment nor
pair-feeding significantly affect insulin levels or other endocrine parameters (Levin et al.
1996). Only a small number of genes were specifically modulated by leptin in wild-type
liver, further indicating that the leptin-specific transcriptional signature in ob/ob mice
might be largely secondary to correction of the obese condition (data not shown). These
genes are more likely to be specifically modulated by quantitative changes in circulating
leptin levels.
Data presented earlier in this thesis (Chapter 3) suggested that a significant
proportion of leptin's effects on hepatic gene expression were the result of central action.
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In addition, i.c.v. leptin enacted a markedly similar program of gene expression to

peripherally administered leptin in lipodystrophic mice (E. Asilmaz, unpublished res

The efferent pathways responsible for leptin's effects on gene expression and metabo
are not known, but are likely to involve the combined modulation of the autonomic
nervous system and the hypothalamic-pituitary axis. Central administration of NPY

stimulates peripheral lipogenic gene expression (Billington et al. 1991; Zarjevski e

1993). Leptin decreases NPY levels in the hypothalamus, suggesting that the modulatio
of a neuronal circuit downstream of NPY may be responsible for leptin's effects on
lipogenic gene expression (Stephens et al. 1995). Genetically modified pseudorabies

viruses have been used to trace the leptin circuitry within the brain (DeFalco et al
Similar studies are in progress to identify the neuronal sites from which efferents
to peripheral metabolic organs such as adipose tissue and liver.
Understanding the transcriptional mechanisms underlying leptin-specific patterns

of gene expression may help identify the efferent signal(s) underlying leptin's peri

effects. Based on the membership of leptin-regulated gene clusters, we examined whet

leptin regulated the levels of known, candidate transcription factors. While previou
reports indicated that levels of SREBP-lc RNA and nuclear protein were elevated in
ob/ob mice, experiments performed here did not detect any alterations (Shimomura et
1999a; Shimomura et al. 2000). SREBP expression and cleavage are stimulated by
insulin, and the discrepancy between our results and those previously published may
reflect differences in insulin levels (Foretz et al. 1999; Shimomura et al. 1999a;

Shimomura et al. 1999b). Specifically, the previous studies used older mice in the m
of the dark cycle, when insulin levels should be at their peak, whereas we studied
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younger mice in the middle of the light cycle, when insulin levels are likely to be at their
nadir (Shimomura et al. 1999a; Shimomura et al. 2000). Leptin was found to regulate
SREBP RNA levels and cleavage in adipose tissue (Soukas et al. 2000). However, in

adipose tissue a far more comprehensive list of SREBP-target genes than identified h

were found to co-cluster, perhaps indicating that the lipogenic genes regulated by l

in the liver could be targets of another transcription factor. We did find that lept
specifically downregulated the RNA levels of PGC-1 a transcriptional cofactor, that

regulates gluconeogenic gene expression (Herzig et al. 2001; Yoon et al. 2001). As ob

mice are diabetic and have elevated hepatic gluconeogenesis, leptin-specific modulat

of PGC-1 might contribute to the correction of diabetes associated with leptin treat

Further studies are required to determine the role of this molecule in the transcrip

response to leptin. In addition to these molecules, leptin may also regulate the lev
and/or activity of PPARa, PPARy, ChREBP, HNFs, LXRs, or yet to be identified

transcription factors (Bocher et al. 2002; Edwards et al. 2002; Schrem et al. 2002; U
et al. 2002).
In aggregate, these data demonstrate the induction of a novel, distinct

transcriptional signature characteristic of the unique metabolic program of weight l
induced by leptin. These data distinguish leptin treatment from food restriction at

molecular level, and may ultimately provide new insight into the nature of the lepti

stimulated efferent signals from the hypothalamus. A subset of these leptin-regulate

genes may play a functional role in the obese phenotype and the unique metabolic act
of leptin.
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Chapter 5: Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated W e i g h t
Loss

Introduction

Leptin regulates energy balance, metabolism, and the neuroendocrine response to
altered nutrition (Zhang et al. 1994; Friedman 2000a). The metabolic program that leptin
elicits is not explained by its effects on food intake alone (Levin et al. 1996; Kamohara et
al. 1997). Leptin replacement in leptin-deficient (ob/ob) mice and humans leads to the
depletion of lipid in adipose tissue, liver, and other tissues (Campfield et al. 1995; Halaas
et al. 1995; Pelleymounter et al. 1995; Farooqi et al. 1999). Leptin treatment also
improves insulin sensitivity and reduces fat content in lipodystrophic mice and humans
(Shimomura et al. 1999c; Oral et al. 2002).
To elucidate the mechanism whereby leptin reduces hepatic lipid content, w e
used microarrays to identify genes that were differentially regulated by leptin vs. pairfeeding in liver. Leptin treated ob/ob mice lose significantly more weight than pair-fed
mice, indicating that leptin stimulates energy expenditure (Figure 4.2). Liver R N A from
these animals was hybridized to microarrays and the data were analyzed using a AT-means
clustering algorithm (Soukas et al. 2000). 15 clusters of genes with distinct patterns of
expression were identified, six of which correspond to genes specifically regulated by
leptin, but not pair- feeding (Figure 4.3).
W e used a more directed computational approach to identify genes that are
particularly repressed during leptin-mediated weight loss. Leptin was found to
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specifically repress R N A

levels and enzymatic activity of hepatic stearoyl-CoA

desaturase-1 (SCD-1), which catalyzes the biosynthesis of monounsaturated fatty acids
Mice lacking SCD-1 were lean and hypermetabolic. ob/ob mice with mutations in SCD-1
were significantly less obese than ob/ob controls and had markedly increased energy

expenditure, ob/ob mice with mutations in SCD-1 had histologically normal livers wit

significantly reduced triglyceride storage and VLDL production. These findings sugge

that down-regulation of SCD-1 is an important component of leptin's metabolic action

Results

Identifying and ranking leptin-repressed genes.
In order to prioritize leptin-regulated genes for detailed functional analysis, we

developed an algorithm to identify and rank genes that are specifically repressed by

leptin. This algorithm ranked genes based on the extent to which their expression wa

increased in ob/ob liver compared to wild type (2) repressed by leptin treatment, an
different between leptin treatment and pair-feeding. Such genes are candidates as

contributing to the obese phenotype. Specifically, we selected genes whose expressio

was increased in ob/ob relative to wild-type and corrected by leptin administration.
with the lowest scores are those most strongly leptin-regulated. The specific

characteristics of this algorithm are described in more detail in Chapter 2. The res
this analysis are shown in Table 5.1. The gene encoding SCD-1 ranked the highest in
analysis.
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L e p t i n - r e p r e s s e d g e n e e x p r e s s i o n i n o b / o b liver
Accesion Numter
M21285
W29265
AA059763
J04696
U00445
J02652
AA030483
AA139907
W17745
D10024
AA108647
M16465
X62940
W13002
M26270
W83337
X13135
AA028398
AA108166
M64250
W33721
W13646
X61940
L28836
D64160
Z22216
W15891
U37226
U29396
D12618
M61737
M13366
1.23108
AA063800
W62918
L09104

Name
stearoyl-CoA desaturase-1
glutathione S-transferase, alpha 1
tubulin, beta
glutathione S-transferase class m u
glucose-6-phosphatase
malate N A D P oxidoreductase
est, similar to human insulin induced protein 2
spot 14
ATP citrate lyase
calpactin I heavy chain
fructose bisphosphatase 1
calpactin 1 light chain
TSC-22
lectin, galactose binding, soluble 1
stearoyl-CoA desaturase-2
glutathione peroxidase 4
fatty acid synthase
tubulin, beta
fructose bisphosphatase 1
apolipoprotein A-IV
enolase 1, alpha
ubiquitin C
protein tyrosine phosphatase, non-receptor type 16
peroxisome membrane protein (PMP70)
retinoic acid early transcript 1, alpha
apolipoprotein CII
ketohexokinase
plasma phospholipid transfer protein
annexin V
nucleosome assembly protein-1
adipocyte-specific FSP27
glycerophosphate dehydrogenase
CD36
phosphoenolpyruvate carboxykinase 1
Epstein-Barr virus induced gene 3
glucose phosphate isomerase

Function
Score
Lipid Metabolism
2.00
Detoxification
4.00
Structural
5.50
Detoxification
6.00
Carbohydrate Metatolism 7.75
Lipid Metabolism
9.00
Unknown
9.00
Lipid Metabolism
10.00
Lipid Metabolism
14.50
Signal Transduction
14.75
Carbohydrate Metabolism 14.00
Signal Transduction
15.00
Unknown
16.00
Binding Protein
14.50
Lipid Metabolism
17.00
Detoxification
18.50
Lipid Metabolism
20.00
Structural
20.00
Carbohydrate Metabolism 20.00
Lipid Metabolism
20.50
Carbohydrate Metabolism 21.50
Protein Turnover
18.50
Signal Transduction
19.50
Lipid Metabolism
23.00
Membrane Protein
23.00
Lipid Metabolism
24.50
Carbohydrate Metabolism 23.00
Lipid Metabolism
25.50
Signal Transduction
25.00
Chromatin Structure
23.50
Unknown
28.00
Lipid Metabolism
29.00
Lipid Metabolism
31.50
Carbohydrate Metabolism 33.50
Unknown
34.50
Carbohydrate Metabolism 37.00

T a b l e 5.1 Leptin-repressed g e n e expression in ob/ob liver. In order to prioritize leptin-regulated
genes for detailed functional analysis, a n algorithm w a s developed to identify and rank genes that
are specifically repressed b y leptin. This algorithm ranked genes based o n the extent to w h i c h thenexpression w a s (1) increased in ob/ob liver c o m p a r e d to wild type (2) repressed b y leptin treatment,
a n d (3) different b e t w e e n leptin treatment a n d pair-feeding. S u c h genes are candidates as contributing
to the obese phenotype. G e n e s w e r e selected w h o s e expression w a s increased in ob/ob relative to
wild-type a n d corrected b y leptin administration. G e n e s with the lowest scores are m o s t strongly
leptin-repressed.

Leptin-specific regulation of SCD-1
SCD-1 is a microsomal enzyme that is required for the biosynthesis of the

monounsaturated fats palmitoleate and oleate from saturated fatty acids (Ntambi et a
1988; Ntambi 1999). SCD-1 RNA levels were highly elevated in untreated ob/ob liver

(Figure 5.1a). SCD-1 RNA levels in leptin treated ob/ob mice were normalized at 2 da

and by 4 days fell to levels below that of lean controls, a result consistent with p
studies (Ferrante et al. 2001; Liang and Tall 2001). Pair-fed mice showed a smaller
delayed decrease in SCD-1 gene expression.
SCD enzymatic activity was elevated 7.2-fold in livers of untreated ob/ob mice

relative to wild type (p < 0.0005) and remained significantly elevated in saline-tr
free-fed ob/ob controls (Figure 5.1b). Leptin treatment normalized SCD enzymatic

activity, while pair-feeding reduced enzymatic activity to a lesser extent (p < 0.0
vs. free fed, p < 0.02 leptin vs. pair-fed at each time point). Levels of hepatic
monounsaturated 16:1 and 18:1 fatty acids, the products of SCD-1, were elevated in

ob/ob mice and normalized by 12 days of leptin treatment, but not by pair-feeding (T

5.2). Leptin also preferentially normalized desaturation indices (ratio of 16:1/16:0
18:1/18:0 levels), which are an indicator of SCD enzymatic activity.

Reduced fat mass in mice lacking SCD-1
To investigate whether SCD-1 might mediate some of leptin's metabolic effects,
we studied asebia mice (abJ/ab ), which carry mutations in SCD-1 (Gates and Karasek

1965). These mice have a spontaneous deletion of the first four exons of the SCD-1 g
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Figure 5.1 Leptin-specific down-regulation of S C D - 1 R N A levels and enzymatic
activity. (A) Northern blot of liver R N A samples from an independent time course
experiment probed with radioactively labeled c D N A probes specific for S C D - 1 and
the small mitochondrial R N A p A L - 1 5 (loading control). (B) S C D enzymatic activity
assays measure the conversion of [1-14C] stearoyl-CoA to [l-l4C] oleate, as described in
Chapter 2. Activity is expressed as nmol min"1 mg"1 protein. Error bars indicate the
S E M , n = 3 for each group. *, p < 0.05 vs. saline treated, *, p < 0.02 vs. p.air fed,
" p < 0.0005 untreated lean vs. untreated ob/ob. (C) Ratios of 16:1/16:0 and 18:1/
18:0 triglycerides, as an indicator of S C D enzymatic activity. Values were determined
from lipid composition analysis (Table 5.2). Error bars indicate the S E M , n = 3 for each
group.", p < 0.05 vs. saline treated, *, p < 0.05 vs. pair fed.
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T a b l e 5.2 Liver fatty acid composition. Liver lipid composition w a s determined
in untreated lean a n d ob/ob liver a n d following 12 days o f pbs, pair-feeding, or leptin.
Total lipids w e r e extracted from liver with Folch solvent (chloroform/methanol 2:1).
A t the start o f the liver extraction, internal standards o f C 17:0 triglyceride, cholesteryl
ester, a n d phosphatidyl choline w e r e added to quantitate each lipid class. T h e lipid
classes in the liver extract w e r e separated b y thin layer chromatography using silica gel
G a n d a developing solvent o f hexane/diethyl ether/acetic acid (60:40:1). T h e fatty acids
in each lipid class w e r e methylated with fresh 5 % methanolic H C I a n d analyzed with a
gas chromatograph. N u m b e r s in the table are averaged from 3 m i c e per group. F o r clarity,
S E M is not s h o w n , but all error values w e r e within acceptable limits. *, p < 0.05 lean vs. ob/ob
or p < 0.05 pair-fed or leptin vs. saline, *, p < 0.05 leptin vs. p.air-fed.

and express no SCD-1 R N A or protein, though expression of SCD-2 is not altered (Zheng
et al. 1999). SCD-1 is highly expressed in the sebaceous glands of the skin and the

harderian and meibomian glands of the eye. Consequently, abJ/abJ mice have cutaneou

and ocular defects. The phenotype of these mice is identical to that of mice with an
induced mutation in SCD-1 (Miyazaki et al. 2001).
The weight of male abJ/abJ mice was indistinguishable from that of littermates
i„iJ mice weighed significantly more than littermates (Figure 5.2a, p <
and female abU /ab
0.005 at all ages after 6 weeks). However, abJ/abJ mice had significantly reduced fat
mass relative to controls (from 12.7% to 8.3% in females, p < 0.005; from 13.5% to

in males, p < 0.0005, Figure 5.2b) and plasma leptin levels (females: 2.3±0.4 ng/ml
5.0±0.9 ng/ml, males: 2.7±0.5 ng/ml vs. 7.8±1.4 ng/ml, p < 0.01 for both sexes).
To explore the effects of SCD-1 deficiency on the ob/ob phenotype, we
intercrossed ob/+ and abJ/+ or abJ/ abJ mice. abJ/abJ; ob/ob mice showed a dramatic
reduction in body weight at all ages compared to ob/ob littermate controls (Figure
< 0.0001 from 5 weeks of age). At 16 weeks of age, weight was reduced by 29% in

females (p < IO"6) and 34% in males (p < IO"4). A photograph of a representative ob/
and an abJ/abJ; ob/ob mouse is shown in Figure 5.2c. Fat mass in 16 week-old double
mutant females was 32.1% vs. 51.0% in ob/ob (p < IO"4) and 28.1% in double mutant

males vs. 49.9% in ob/ob (p < 10"5) (Figure 5.2b). abJ/abJ; ob/ob mice of both sexes

showed a significant increase in percent lean mass relative to ob/ob littermates (f
15.3% to 18.5% in females, p < 0.005; from 15.3% to 20.1% in males, p < 0.05)
indicating that double mutants do not suffer from a generalized growth defect.
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Figure 5.2 Attenuation of the obese phenotype in mice with a mutation in SCD-1 (abJ/abJ).
Weight curves of o b o b (blue squares), at/ 'at/; ob ob (green diamonds), at/ at/ (gold circles),
and control (magenta tri,angles) mice. Error b.ars indicate the S E M , n > 9 for each group.
*, p < 0.01 at/ at/ vs. control orp < 0.0001 at/ at/; ob ob vs. ob ob. (B) Carcass analysis of
female and male ob ob (blue), at/ at/; ob ob (green), at/ at/ (gold), and control (magenta) mice
was performed as in Chapter 2. Error bars indicate the S E M , n > 8 for each group. ', p < 0.005 vs.
lean control, \ p < 0.05 vs. ob ob. (C) Photograph of a representative ob ob and at/ at/; ob ob
mouse.

Mechanism for reduced adiposity in mice lacking SCD-1
To analyze energy balance, we measured food intake and energy expenditure in
ob/ob and lean littermates with and without homozygous SCD-1 mutations, ob/ob mice

were hyperphagic compared to lean controls (Figure 5.3a,b). Despite being significan
leaner, abJ/abJ; ob/ob mice consumed 35% more food than ob/ob littermates (9.0±0.9
g/day vs. 6.6±0.4 g/day, p < 0.05) (Figure 5.3a,b). abJ/abJ mice consumed 53% more

lean controls (6.3±0.2 g/day vs. 4.2±0.2 g/day, p < IO"6) with an average food inta

indistinguishable from that of ob/ob mice (Figure 5.3a,b). Relative to ob/ob control

abJ/abJ; ob/ob mice showed increases of 96% (female) and 56% (male) in total V02 an
increases of 174% (female) and 71% (male) in resting V02 (Figure 5.3c,d, p < 0.02).

Total and resting oxygen consumption in female double mutants were indistinguishabl
from those of lean controls and in male double mutants they were even greater than
of lean controls (p < 0.05 for resting V02). Lean abJ/abJ mice expended more energy
with increases of 30% and 46% in total oxygen consumption and increases of 43% and

62% in resting oxygen consumption for females and males respectively (Figure 5.3c,d

< 0.02). Double mutant abJ/abJ; ob/ob mice had increased plasma levels of ketone bod
(P-hydroxybutyrate) relative to ob/ob littermates, suggesting increased fatty acid

oxidation (females: 6.6±1.2 mg/dl vs. 3.4±0.6 mg/dl, p < 0.05; males: 4.5±1.4 mg/dl
3.5±0.7mg/dl,NS).
ob/ob mice have massively enlarged livers that are engorged with lipid. Gross
inspection revealed that the hepatomegaly and the steatosis of ob/ob mice were

normalized in abJ/abJ; ob/ob mice. Histological sections of ob/ob liver showed large
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Figure 5 3 Increased energy expenditure, despite persistent hyperphagia, accounts for
reduced adiposity in abJ/abJ;ob/ob a n d abJ/abJ mice. (A) Average daily food intake by group
and (B) scatterplot of average daily food intake for individual mice in each group of oft ob (blue),
abJ abJ; ob ob (green), abJ at/ (gold), and control (magenta) mice. Mice were acclimated m
individual cages and 2 4 hour food consumption w a s measured for 8 consecutive days Food intake
for each m o u s e w a s averaged over the 8 days and these values were averaged for the mice m each
group. M i c e were 12-18 w e e k s of age. F o o d intake for males and females w a s indistinguishable and
has been pooled. Error bars indicate S E M , n > 4 for each group. * p < 0.05 vs. lean control,", p < 0 05
vs. ob ob (C) Total and ( D ) resting oxygen consumption of female and male ob ob (blue), a f a f ; ob ob
(green), abJ/abJ (gold), and control (magenta) mice. 14-16 w e e k old mice were placed m an indirect
calorimeter and allowed 2 hours to acclimate to the n e w environment Measurements were taken for
5 hours during the middle of the light cycle T h e total V 0 2 is the average of these readmgs. T h e resting
V 0 2 is the average of all readmgs that are one standard deviation below the total V 0 2 , as these readings
represent periods of inactivity Error bars mdicate S E M , n > 3 for each group * p < 0.05 vs. lean control,
*, p < 0.05 vs. ob ob

lipid-filled vacuoles, while those of abJ/abJ; ob/ob mice showed little or no vacuolation

and were indistinguishable from those of wild-type mice (Figure 5.4a). The levels of

liver triglyceride were substantially increased in ob/ob mice (p < 0.005 vs. all ot

groups), whereas triglycerides in abJ/abJ; ob/ob mice were reduced to levels compara

to lean controls (Figure 5.4b). As previously shown, triglyceride levels in lean abJ

mice were reduced below those of lean controls (Figure 5.4b) (Miyazaki et al. 2000).
Palmitoleate and oleate in triglycerides and cholesterol esters are major

constituents of very low density lipoprotein (VLDL) particles, which transport fatty

from liver to adipose tissue and other sites. We assayed the rate of hepatic lipid e
mice injected with tyloxapol, an inhibitor of VLDL hydrolysis, permitting the
measurement of VLDL production (Merkel et al. 1998). VLDL production was increased

2.4-fold in ob/ob mice relative to lean controls (Figure 5.4c, p < 0.05). Compared t
ob/ob controls, VLDL production was reduced 3.6-fold in abJ/abJ; ob/ob mice (8.2
mg/dl/min vs. 2.3 mg/dl/min, p < 0.02) (Figure 5.4c).
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Figure 5.4 Reduced hepatic lipid storage and V L D L production in af/af;ob/ob mice. (A) Hematoxylin
and eosin ( H & E ) stained liver sections from representative o b o b .and a f a f ; ob ob mice. Images are 200x
magnifications; scale bars denote 100 (im. (B) Liver triglyceride content ofob ob (blue), a f a f ; ob ob (green),
a f a f (gold), .and control (magenta) mice. Levels were determined as described in Chapter 2. Error bars indicate
S E M , n > 4 for each group. *, p < 0.0005 vs. obob. (C) V L D L production in ob ob (blue), a f a f ; ob ob (green),
a f a f (gold), and control (magenta) mice. Mice fasted for 5 hours were injected with 0.5 mg/kg tyloxapol
(Triton-1339) (Sigma, St. Louis, M O ) via the tail vein as described m Chapter 2. Tail bleeds were done at 0, 45,
and 90 min .and plasma triglycerides were assayed using an enzymatic reagent. The slope of the line mdicates the
rate of V L D L production. Error bars indicate S E M , n > 3 for each group. For a f a f ; ob ob and control, p < 0.05
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Discussion

These data show that SCD-1 is required for the fully developed obese phenotype

of ob/ob mice and suggest that a significant proportion of leptin's metabolic effec

result from inhibition of this enzyme. Mice with a targeted knockout of SCD-1 (SCDhave also been generated, and they resemble abJ/abJ mice in all respects (Miyazaki

2001). These mice also have reduced fat mass and are resistant to increased adiposit

after long-term consumption of a high-fat diet (Ntambi et al. 2002). SCD-1"7" mice a

have enhanced glucose and insulin tolerance. Microarray analysis of gene expression
these mice detected increased expression of genes involved in fatty acid oxidation
decreased expression of lipogenic genes in SCD-17" mice (Ntambi et al. 2002).
The basis for the metabolic effects of SCD-1 deficiency is not known. One

possibility is that in the absence of SCD-1, a reduced rate of triglyceride and VLDL
synthesis increases the intracellular pool of saturated fatty acyl CoAs leading to

increase in fatty acid oxidation. Monounsaturated fats are necessary for normal rat
triglyceride and cholesterol ester synthesis, which are required for hepatic lipid
and VLDL synthesis (Miyazaki et al. 2000). Saturated fatty acyl CoAs, but not

monounsaturated fatty acyl CoAs, potently allosterically inhibit acetyl CoA carboxyl

(ACC), reducing cellular levels of malonyl CoA (Volpe and Vagelos 1976; Lunzer et al

1977; Nikawa et al. 1979). Malonyl CoA is required for fatty acid biosynthesis and a

inhibits the mitochondrial carnityl palmityl transferase shuttle system, the rate-l

step in the import and oxidation of fatty acids in mitochondria (McGarry et al. 1977
Reduced activity of SCD-1 may decrease adiposity by decreasing cellular levels of
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malonyl C o A thereby reducing fatty acid biosynthesis and de-repressing fatty acid
oxidation. Figure 5.5a shows a schematic of this potential mechanism. Moreover,

preliminary data indicates that levels of saturated fatty acyl CoAs are, in fact, in
3-fold or more in mice lacking SCD-1 (Figure 5.5b). Whether or not the increased
saturated fatty acyl CoAs inhibit ACC and lead to reduced malonyl CoA and increased
fatty acid oxidation remains to be tested.
These findings are similar to those described in mice lacking acetyl-CoA

carboxylase 2, which also have increased fatty acid oxidation in skeletal muscle and

lean phenotype (Abu-Elheiga et al. 2001). The mechanism by which leptin increases fat

acid oxidation in liver may be similar to that in skeletal muscle in that both may o
by reducing ACC activity. However, in skeletal muscle, leptin, acting directly and
indirectly via the CNS, inhibits ACC via a2 AMP-kinase, which phosphorylates and

inhibits ACC (Minokoshi et al. 2002). Recent studies have shown that leptin stimulat

fatty acid oxidation in liver and heart does not activate oc2 AMP-kinase, indicating
other mechanisms may be involved, perhaps involving changes in SCD-1 activity
(Atkinson et al. 2002; Lee et al. 2002).
Alternative mechanisms could also account for the metabolic effects of SCD-1
deficiency. Changes in SCD-1 activity could alter the levels of ligands for PPARa,

PPARy, or other nuclear hormone receptors. Changes in the ratio of saturated:unsatur

fatty acids in phospholipids can also alter membrane fluidity, which could affect si
transduction. The observed increase in energy expenditure associated with SCD-1
deficiency also suggests that uncoupling activity and/or futile cycles are induced.
Reactive oxygen species are a byproduct of elevated oxidative metabolism and can
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Figure 5.5 Basis for increased energy expenditure in mice lacking SCD-1. (A) Hypothetical
mechanism for the metabolic effects of SCD-1 deficency In the absence of SCD-1, synthesis
of triglycerides and V L D L is blocked, leading to decreased hepatic lipid storage and export.
A lack of SCD-1 causes an increase in the pool of saturated fatty acyl CoAs, which allosterically
inhibit acetyl C o A carboxylase ( A C C ) . Inhibition of A C C reduces levels of malonyl C o A , a
metabolite which normally inhibits the mitochondrial carnityl palmitoyl shuttle system, the
rate-limiting step in the import and oxidation of fatty acids in mitochondria. Decreased malonyl
C o A thus de-represses fatty acid oxidation, leadmg to mcreased burning of fat. (B) Liver fatty
acyl C o A levels were measured as decribed in Chapter 2 in ob ob (blue), atr atr: ob ob (green),
atr atr (gold), .and control (magenta) mice. Mice were scanficed in the mid-light cycle after a
6-10 hour fast. Error bars indicate S E M , n > 3 for each group, except control n= 2. p < 0.05
atr atr vs. lean control or atr atr; ob ob vs. ob ob control.

increase cellular oxidative stress, thereby increasing the risk of cancer, atherosclerosis,
and other diseases (Droge 2002). Future studies are necessary to determine whether
increased oxidative stress is an unwanted side effect of SCD-1 deficiency.

The effects of leptin on SCD-1 in liver are likely to require central action, as mic

lacking the leptin receptor in brain have enlarged, fatty livers, while livers of mi

liver-specific knockout of the leptin receptor appear normal (Cohen et al. 2001). Le

also reduces hepatic SCD-1 activity when administered intracerebroventricularly, at

dose that has no effect when delivered peripherally (E. Asilmaz, unpublished results
The CNS signals that modulate liver metabolism in response to leptin are unknown.
SCD-1 deficiency also appears to modulate CNS pathways that regulate food intake,
perhaps secondary to the increased oxygen consumption.
Leptin may also modulate the production of monounsaturated fatty acids in
tissues other than liver. Down-regulation of SCD enzyme activity by leptin in other

tissues, including brain, could contribute to some of the observed metabolic effects
Although SCD-1 is the only isoform normally expressed in liver, both SCD-1 and SCD-

2, a similar enzyme, are expressed in most other tissues. While both enzymes catalyz

same reaction, their cellular distribution and substrate preferences may be differen
In summary, a deficiency of SCD-1 ameliorates the obesity of ob/ob mice and

completely corrects the hypometabolic phenotype of leptin deficiency. These findings
suggest that leptin-specific down regulation of SCD-1 is an important component of

novel metabolic response to leptin and suggests that inhibition of SCD-1 could be o

benefit for the treatment of obesity, hepatic steatosis, and other metabolic disorde
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Chapter 6: Role for Stearoyl-CoA Desaturase-1 in Fatty Liver Disease

Introduction

Hepatic steatosis, or fatty liver, is the earliest manifestation of both alcoholic a

nonalcoholic liver disease. Both types of fatty liver disease are marked by the hist

presence of steatosis and a mixed inflammatory cell infiltrate, and as disease worse

the appearance of hepatocyte necrosis and fibrosis (Angulo 2002). In fact, the two ty

of disease are histologically indistinguishable, and the differential diagnosis is l

based on the presence or absence of alcohol abuse (Yu and Keeffe 2002). Fatty livers

particularly susceptible to endotoxin-mediated damage, which in turn, accelerates th
progression of disease to steatohepatitis, fibrosis, cirrhosis, and end-stage liver
(Yang et al. 1997; Diehl 2001; Yang et al. 2001). Nonalcoholic fatty liver disease
(NFLD) is now recognized as the most common form of liver disease in the United

States, and alcoholic fatty liver disease is a major cause of morbidity and mortalit
(Menon et al. 2001; McCullough 2002). Furthermore, both forms of disease are largely

untreatable. Thus, understanding the molecular basis for fatty liver disease is requ
develop effective treatments.
While alcoholic fatty liver disease is, by definition, a result of chronic alcohol

abuse, NFLD has a diverse set of etiologies. Both obesity and type 2 diabetes mellit

markedly increase the risk and severity of NFLD (Silverman et al. 1990; Wanless and

Lentz 1990; Bellentani et al. 2000). While NFLD is estimated to affect 10-24% of the
population, the prevalence among obese individuals has been estimated to be as high

74% (Angulo 2002). Both types of disease are characterized, in their early stages, by
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presence of hepatic steatosis. Lipid can accumulate in hepatocytes due to either increased

fatty acid uptake or biosynthesis or decreased fatty acid export or oxidation (Kotei
Diehl 2001).
Alcoholic fatty liver was originally thought to result from the generation of
NADH during ethanol oxidation, which then inhibits NAD+-dependent enzymes of the
citric acid cycle and ft-oxidation, thereby inhibiting hepatic fatty acid oxidation
and Kondrup 1986; Crabb 1993). However, increased lipogenesis is being increasingly

appreciated as underlying alcoholic fatty liver (Lieber et al. 1966; Muramatsu et al

Carrasco et al. 2001). A number of studies have demonstrated increased RNA levels and

enzymatic activity of lipogenic enzymes in ethanol fed rodent models (Joly et al. 19
Arakawa et al. 1975; Muramatsu et al. 1981; You et al. 2002).
Increased rates of hepatic lipogenesis have also been demonstrated in obese rodents
humans, who are more prone to NFLD (Godbole and Yotk 1978; Kaplan and Leveille
1981; Diraisonetal. 2002).
Stearoyl-CoA desaturase-1 (SCD-1) is the rate-limiting enzyme in the conversion

of saturated to monounsaturated fatty acids (Ntambi 1995). SCD-1 is required for norm

rates of hepatic triglyceride and cholesterol ester biosynthesis (Miyazaki et al. 200

SCD-1 RNA levels and enzymatic activity are increased in ob/ob mice, and SCD-1 plays
a role in leptin-mediated weight loss, as ob/ob mice lacking SCD-1 (abJ/abJ; ob/ob)

demonstrate a significant correction of obesity (Chapter 5)(Cohen et al. 2002). abJ/a

ob/ob mice also have a dramatic correction in the hepatic steatosis typical of ob/ob

This suggested that SCD-1 may play a more general role in fatty liver disease. Here,
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examine the role of SCD-1 in alcoholic fatty liver disease and in N F L D secondary to
lipodystrophy.

Results

SCD-1 and alcoholic fatty liver disease
To explore the role of SCD-1 in alcohol-induced fatty liver, we studied asebia

mice (abJ/abJ), an inbred, naturally occurring mutant with a mutation in SCD-1 (Gate

and Karasek 1965; Zheng et al. 1999). After an acclimation period, abJ/abJ and litte
control mice (abJ/+ or +/+) were given a 10% ethanol solution as their sole source
fluid. Mice will consume alcohol at this concentration, and this treatment induces
liver in a number of mouse models (Furuno et al. 1975; Wood 1976; Watabiki et al.
2000).
abJ/abJ and littermate controls were sacrificed after 3 and 5 weeks of alcohol

consumption. As an additional control, age-matched mice of each genotype that were n

exposed to alcohol were also studied. After 3 weeks of alcohol intake, livers from b

abJ/abJ and control mice appeared grossly normal. In addition, liver triglyceride co

was equivalent to that of untreated control mice (Fig. 6.1a). After 5 weeks of ethan

however, littermate controls developed grossly steatotic livers, while livers from a

mice appeared normal. Quantitation of liver triglycerides revealed a 2-fold increas

littermate controls mice relative to abJ/abJ (17.4 mg/g vs. 8.6 mg/g, p = 0.0009) (

6.1a). Furthermore, even after five weeks of alcohol consumption, triglyceride level
abJ/abJ mice remained indistinguishable from mice not given alcohol.
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In order to confirm that the absence of fatty liver disease in abJ/ab mice was not

due to reduced alcohol consumption, we measured alcohol intake. Surprisingly, abJ/ab
mice actually consumed more alcohol than littermate controls. To quantitate alcohol

consumption more exactly, 5 male abJ/abJ and 5 littermate controls were individually
caged, and food and alcohol intake were recorded weekly. abJ/abJ mice consumed more

food than littermate controls, at all time points (Figure 6.2b). While they also con

more alcohol within the first few weeks, alcohol intake was comparable between the t

groups thereafter (Figure 6.2b). Thus, despite consuming more food and an equivalent

amount of alcohol abJ/abJ mice remained resistant to the development of alcoholic fa
liver.

SCD-1 and nonalcoholic fatty liver disease secondary to lipodystrophy
Transgenic overexpression of nuclear sterol regulatory element-binding proteinic (aP2-SREBP-lc tg) in white adipose tissue produces mice with a near complete
absence of adipose tissue, along with marked hepatic steatosis, insulin resistance,

hyperglycemia (Shimomura et al. 1998a). The livers in these mice closely resemble th

of ob/ob mice, and in both cases, treatment with physiological doses of leptin for 1
corrects the hepatic steatosis, along with the hyperglycemia and hyperinsulinemia
(Chapter 4) (Shimomura et al. 1999c). A number of human lipodystrophy syndromes

have also been described, and treatment of these patients with leptin also reverses
steatosis and insulin resistance (Oral et al. 2002; Petersen et al. 2002).
To study the role of SCD-1 in the fatty liver disease of lipodystrophy, abJ/abJ
mice were crossed to aP2-SREBP-lc tg mice to generate lipodystrophic mice lacking
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Figure 6.1 Resistance to alcoholic fatty liver in mice lacking SCD-1. (A) 5-7 week
old, male and female a f a f (gold) and littermate control mice (magenta) were offered
a 1 0 % E t O H solution for one week. After this acclimation period (time 0), mice were
provided with 1 0 % E t O H as the only liquid source. Groups of animals were sacrificed
after 3 .and 5 weeks of alcohol consumption. A s a control, similarly aged mice, that were
not exposed to alcohol were also studied (untreated). Error bars indicate S E M , n > 3 for
each group. *, p = 0.0009. (B) 8-10 week old a f a f and littermate control mice were
individually caged and given a few days to acclimate to a 1 0 % EtOh solution. Then,
regular drinking water was removed (time 0) and weekly food and alcohol intake were
recorded. Error bars indicate S E M , n = 5 for each group. *, p < 0.05 a f a f vs. control.

SCD-1 (abJ/abJ;aP2-SREBP-lc tg). Analysis of these mice confirmed that aP2-SREBP-

lc tg mice had massively enlarged steatotic livers. Livers from abJ/abJ;aP2-SREBP-lc

mice, on the other hand, remained enlarged, but were no longer grossly steatotic (Fi
6.2a). Histological sections showed hepatic vacuolation consistent with fatty liver
in aP2-SREBP-lc tg mice, while abJ/abJ;aP2-SREBP-lc tg sections showed a nearly

normal histological appearance (Figure 6.2b). Measurement of liver triglyceride leve

revealed a 4-fold increase in triglyceride levels in aP2-SREBP-Ic tg livers relativ
double mutant livers (34.0 ± 8.9 mg/g vs. 8.2 ± 1.2 mg/g, p = 0.02) (Figure 6.2c).

Triglyceride levels in abJ/abJ;aP2-SREBP-lc tg livers were comparable to those in wi
type littermate controls.

Discussion

The data presented here indicate that the absence of SCD-1 can not only correct

the fatty liver of obesity (Chapter 5), but can also block the development of alcoho

fatty liver disease and nonalcoholic fatty liver disease associated with lipodystrop

Elevated lipogenesis has been postulated to cause both types of fatty liver disease,

mice lacking SCD-1 have decreased rates of hepatic triglyceride production (Miyazaki

al. 2000). Reduced hepatic fatty acid oxidation can also contribute to fatty liver d

Evidence suggests that the absence of SCD-1 indirectly leads to increased liver fatt

oxidation (Cohen et al. 2002; Ntambi et al. 2002). Enhanced fatty acid oxidation coul

also underlie the resistance to hepatic steatosis in mice lacking SCD-1. Elevated fa

acid oxidation can be associated with increased levels of reactive oxygen species (D
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Figure 6.2 Resistance to fatty liver associated with lipodystrophy in mice lacking
S C D - 1 . (A) Photograph offreshlydissected livers from mice with the genotypes
+/+;nontg (ctrl), a f +;aP2-SREBP-lc tg (tg), and a f af;aP2-SREBP-lc tg (ab;tg).
(B) Hematoxylin and eosin stained liver sections from a representative aP2-SREBP-lc tg
.and an a f a f ; a P 2 - S R E B P - l c tg mouse. Images are 200x magnifications; scale bars
denote 100 (im. (C) Liver triglyceride content of control (+ +;nontg and a f -;nontg)
(magenta) a f a f ; a P 2 - S R E B P - l c tg (green), and transgenic { a f +;aP2-SREBP-lc tg
and +/+;aP2-SREBP-lc tg) (blue). Error bars indicate S E M , n > 4 for each group.
*, p < 0.05 vs transgenic.

2002). Since increased (ROS) contribute to fatty liver disease as well as to other disease

processes, it will be important to test whether this is a sequella of SCD-1 deficien
(Pessayre et al. 2002).

Increased lipogenesis is a recognized feature of alcoholic fatty liver (Lieber et a
1966; Muramatsu et al. 1981; Carrasco et al. 2001). Expression analysis of liver RNA
from alcohol fed mice found a 3-fold increase in SCD-1 RNA levels (data not shown).
Real-time quantitative PCR confirmed this increase in SCD-1 expression (data not
shown). A number of studies have demonstrated increased RNA levels and enzymatic

activity of lipogenic enzymes in ethanol fed rodent models (Joly et al. 1973; Araka

al. 1975; Muramatsu et al. 1981). A recent study showed that the levels of SREBP tar

genes, including SCD-1, are upregulated in alcoholic fatty liver, due to increased l
of cleaved, nuclear SREBP (You et al. 2002). In addition, ethanol-fed rodents have a
dramatic increase in hepatic levels of palmitoleic and oleic acid, the products of
(Tsukamoto et al. 1984). Further study is required to determine whether abJ/abJmice

remain resistant to alcoholic fatty liver disease after more chronic ethanol admini

In addition, longer exposure to alcohol is associated with a progression to hepatiti

fibrosis, and ultimately cirrhosis, and it will be interesting to see whether mice l
SCD-1 are also resistant to further liver damage.
Lipodystrophic mice also demonstrate increased hepatic lipogenesis, due to
increased expression of fatty acid biosynthetic enzymes, including SCD-1 (Shimomura

al. 1998a). Leptin administration corrects diabetes and hepatic steatosis, and is as
with a normalization in the expression of SCD-1 and other lipogenic molecules (E.
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Asilmaz, unpublished results) (Shimomura et al. 1999c). Since these mice lack adipose

tissue, they also deposit triglyceride in a number of other peripheral tissues, such

muscle, heart, kidney, and spleen (Garg 2000; Reitman et al. 2000). abJ/abJ;aP2-SREBP
Ic tg mice appear to be resistant to triglyceride accumulation in these tissues as

not shown). While hepatic steatosis was prevented, livers remain grossly enlarged in

double mutant animals, and the cause for this remains unknown. In addition, it is no

clear whether abJ/abJ;aP2-SREBP-lc tg mice have any improvement in insulin resistan
or hyperglycemia.
Mice with transgenic overexpression of nuclear sterol regulatory element-binding

protein-la (PEPCK-SREBP-la tg) in liver also have massively enlarged livers, engorge

with lipid (Shimano et al. 1996). These mice have increased expression of genes invo
in the entire program of monounsaturated fatty acid biosynthesis (Shimomura et al.
1998b). In addition, Ay mice, which develop severe adult onset obesity, also have

increased hepatic lipogenesis and NFLD (Yen et al. 1976). Both of these mutants have

been crossed to abJ/abJ mice, and studies are underway to examine whether the absenc
of SCD-1 can prevent fatty liver disease in these models.
In the absence of SCD-1, two different forms of fatty liver disease could be
largely prevented. The incidence of NFLD has been steadily rising in parallel with

rise in obesity and diabetes. At present, there is no effective treatment other than
correction of the underlying condition (Angulo 2002). Based on these results, the
inhibition of SCD-1 may be of benefit in treating fatty liver disease.
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Chapter 7: Role for Insulin-like G r o w t h Factor Binding Protein-2 in Leptinmediated Weight Loss

Introduction

Leptin has metabolic actions that are distinct from its effects on food intake
(Levin et al. 1996). Transcriptional profiling of ob/ob liver during a time course of weight
reduction demonstrated a program of gene expression that is specific to leptin-mediated
weight loss (Chapter 4). Cluster analysis identified several groups of genes whose
expression was uniquely modulated by leptin as compared to pair-feeding. These clusters
were broadly divided into two classes: (i) genes with increased expression that were
preferentially reduced with leptin treatment and (ii) genes with decreased expression that
were preferentially induced with leptin treatment.
To prioritize thefirstclass of genes for functional study, an algorithm was
developed to identify and rank genes in ob/ob liver that were specifically reduced by
leptin administration. This list served as a molecular signature of leptin action and could
contain genes that are functionally important in energy homeostasis. SCD-1, the gene that
ranked at the top of this list, was found to play an important role in obesity and fatty liver
disease (Chapters 5 and 6)(Cohen et al. 2002; Ntambi et al. 2002).
While ob/ob mice lacking SCD-1 showed a marked improvement in adiposity and
other components of the obese phenotype, the absence of this gene alone did not
completely correct the abnormalities of ob/ob mice. This suggested that other alterations
in gene expression, typical of ob/ob mice, remained and contributed to the residual
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phenotype in these mice. T o identify additional genes involved in leptin's metabolic

effects, we used an algorithm to prioritize the second class of genes, those that we

reduced in ob/ob liver and specifically induced by leptin. Insulin-like growth facto
binding protein-2 (IGFBP-2) ranked at the top of this list and studies on the role
molecule in leptin-mediated weight loss are presented here.

Results

Modulation of IGFBP-2 R N A levels
The algorithm described in Chapter 5 (and more fully in Chapter 2) was modified

to rank genes based on the extent to which their expression was (1) decreased in ob

liver compared to wild type (2) induced by leptin treatment, and (3) different betw

leptin treatment and pair feeding. Genes with the lowest scores are those most stro
leptin-regulated. Such genes may be functionally involved in the metabolic effects
leptin. The results of this analysis are shown in Table 7.1.
The list of leptin-induced genes included a diverse number of functional
categories. Unlike the list of leptin repressed genes (Table 5.1), the majority of

function in lipid and carbohydrate metabolism, nearly half of the leptin-induced ge

secreted. The identification of such factors may reflect a normalization of impaire

function, secondary to leptin-deficiency, insulin resistance, and hepatic steatosis.

Alternatively, some of these genes could also be directly involved in the unique pr
of leptin-mediated weight loss.
The genes in Table 7.1 included a number of molecules that are components of
the growth hormone (GH) / insulin-like growth factor (IGF) pathway. Growth hormone
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L e p t i n - i n d u c e d G e n e E x p r e s s i o n in o b / o b L i v e r
Accesion Number
L05439
L11333
U29762
X64263
M16358
X00496
U22516
U66900
M57891
L11613
M75721
M16359
X70533
X03208
J00479
V01527
U06924
L29006
X70398
U19119
U44088
X95685
D16492
X04653
U22031
Y00964
U28937
D45850
L07645
X70391
AA002504
U00674
J04766
X04480
M81447
U36993
X58426
U15636
AA120109

Name
Function
insulin-like growth factor binding protein 2
Binding Protein
carboxyesterase
Detoxification
albumin gene D-Box binding protein
D N A Binding
apolipoprotein A-I
Lipid Metabolism
major urinary protein IV
Secreted
la-associated invariant chain
Immune
angiogenin precursor
Angiogenesis
acid labile subunit
Binding Protein
complement component C2
Inflammatory
20S proteasome subunit Lmp2
Protein Turnover
alpha-1 protease inhibitor 1
Secreted
major urinary protein III
Secreted
corticosteroid-binding globulin
Binding Protein
group 1 for major urinary protein
Secreted
Ig gamma2a-b
Immune
M H C class II antigen, I-A-beta
Immune
statl
Signal Transduction
solute carrier family 7
Transport
P311
Unknown
interferon inducible protein 1
Inflammatory
Signal Transduction
TDAG51
Steroid Metabolism
17-beta-hydroxysteroid dehydrogenpise type II
mannan-binding lectin serine protease 1
Secreted
Ly-6 alloantigen
Membrane Protein
Protein Turnover
20S proteasome subunit Lmp7
Secreted
beta-hexosaminidase
regucalcin
Signal Transduction
Steroid Metabolism
17-beta-hydroxysteroid dehydrogenase 5
Amino Acid Metabolism
histidine ammonia lyase
inter-alpha trypsin inhibitor, heavy chain 1
Secreted
est, similar to human hyaluronan binding protein 2 Unknown
Secreted
syndecan 2
Clotting
plasminogen
preproinsulin-like growth factor IA
Growth
Structural
connexin 32
Steroid Metabolism
cytochrome P450, 7bl
Lipid Metabolism
hepatic triglyceride lipase
Signal Transduction
G T P binding protein GTP2
Unknown
est, similar to rat E R G 2

Score
4.50
4.50
4.50
6.00
6.00
8.00
9.00
10.00
11.00
13.50
13.50
14.50
16.00
16.50
17.00
18.00
19.50
21.00
22.00
22.50
23.00
24.50
25.00
25.00
25.50
25.75
26.25
27.00
27.00
28.00
28.50
28.50
29.50
31.00
32.50
33.50
34.50
37.00
38.50

T a b l e 7.1 Leptin-induced g e n e expression in ob/ob Liver. G e n e s w e r e ranked based
o n the extent to w h i c h their expression w a s (1) decreased in ob/ob liver c o m p a r e d to
wild-type, (2) induced b y leptin treatment, a n d (3) m a x i m a l l y different b e t w e e n leptin
treatment a n d pair-feeding. G e n e s with the lowest scores are m o s t strongly leptin-induced.

secreted into the bloodstream by the pituitary gland and stimulates the production of IGF-

I, particularly from the liver. IGF-I then circulates in a complex with any of a num

binding proteins, known as insulin-like growth factor binding proteins (IGFBPs), whi

modulate IGF-I action. IGF-I has pleiotropic actions on multiple target tissues, gen

stimulating cell growth and division (Le Roith et al. 2001). The list of leptin-induc

genes included prepro-IGF-Ia itself, insulin-like growth factor binding protein-2 (I

2) and acid labile subunit (ALS), which bind IGF-I in the circulation, and three diff

major urinary proteins, the levels of which are positively regulated by GH (Knopf et
1983; Clemmons 1998).
One of the three genes sharing the top rank for being most strongly leptin-induced
was IGFBP-2, a member of a family of IGF binding proteins, which has endocrine
functions by modulating serum IGF half-life and transport, as well as autocrine and
paracrine functions by blocking or enhancing the availability of IGFs to bind their

receptors (Binkert et al. 1989; Schuller et al. 1994; Ranke and Elmlinger 1997). Nort
blot analysis showed that IGFBP-2 RNA levels were undetectable in ob/ob mice, and

were induced to wild-type levels with leptin replacement (Figure 7.1a). Pair-feeding

the other hand, had a negligible effect on IGFBP-2 expression. Leptin also specifica

induced ALS, which circulates as a ternary complex with IGFs and IGFBP-3, stabilizin

this complex and thereby increasing the half-life of IGFs (Boisclair et al. 1996). Wi
exception of IGFBP-2 and ALS, based on microarray analysis, the other known IGFBPs
were not found to be leptin-induced.
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T o gain further insight into the role of IGFBP-2, its R N A levels were also
measured in a number of other rodent models of obesity (Figure 7.1b). IGFBP-2 was

expressed at equivalent levels in livers of C57B1/6J and AKR/J, two inbred strains o
wild-type mice. IGFBP-2 was markedly suppressed in mice lacking leptin or totally

resistant to its actions (ob/ob, dbKls/dbKls, and db3J/db3J). In addition, IGFBP-2 ex

was drastically decreased in moderately obese transgenic mice, constitutively expres

a low level of leptin (ob/ob tg)(Ioffe et al. 1998). Interestingly, IGFBP-2 levels w

reduced far less in Ay and New Zealand obese (NZO) mice, which manifest partial lept

resistance (Halaas et al. 1997). IGFBP-2 expression was also measured in each of the

models following a 48 hour fast (Figure 7.1b). In every case, fasting led to a marke
upregulation in IGFBP-2, confirming previous studies in wild-type rodents (Tseng et
1992). The modulation of IGFBP-2 levels by leptin, its alteration in numerous rodent

obesity models, and its regulation by fasting support a role for this molecule in en
homeostasis.

Attenuated response to leptin in ob/ob mice lacking IGFBP-2
In order to examine the functional role of IGFBP-2 induction by leptin, we

studied IGFBP-2 knockout mice. Aside from reduced spleen size and increased liver si

IGFBP-2 null mice have no obvious abnormalities, possibly due to redundancy within t

IGFBP family (Wood et al. 1993; Pintar et al. 1995; Wood et al. 2000). To test wheth

IGFBP-2 induction is important in leptin-mediated weight loss, we crossed IGFBP-2'''

mice to ob/ob mice to generate double mutant animals. These mice were then treated w
leptin, and their response was compared to that of ob/ob mice. We hypothesized that
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Figure 7.1 Regulation of I G F B P - 2 R N A levels by leptin and nutritional status.
Northern blots of 10 (ig of liver R N A were hybridized with radioactively labeled probes
specific for IGFBP-2, 18S R N A , or P-actin. IGFBP-2 R N A levels in (A) time course
experiment and (B) different mouse models of obesity in either the fed state or after a
48 hour fast.

IGFBP-2 is involved in leptin's metabolic effects, then ob/ob mice lacking IGFBP-2
might have a diminished response to leptin.
After ten days of subcutaneous leptin administration, IGFBP-2''';ob/ob and ob/ob

mice showed marked differences in the amount of weight loss (Figure 7.2a). ob/ob mic

lost nearly twice as much weight as IGFBP-2'';ob/ob mice (28% vs. 15% weight loss, p

= 0.008), with significant differences between these mice detectable as early as fiv

after initiating leptin treatment. This is consistent with the time course of IGFBP-

induction in leptin-treated ob/ob mice (Figure 7.1a). Leptin also had a significantl
potent anorectic effect in ob/ob than on IGFBP-2'';ob/ob mice (Figure 7.2b).
These data suggest that leptin can reach higher circulating levels and/or produce

more potent effects in obese mice capable of inducing IGFBP-2. While leptin levels i

both groups of mice were close to the physiological range, levels in ob/ob mice were

greater than those in IGFBP-2'1';ob/ob mice (17.2 ng/ml vs. 11.9 ng/ml, p = 0.04) (F

7.2d). In addition, as shown before, leptin completely corrected hyperglycemia in ob/

mice (glucose: 91.5 mg/dl) (Halaas et al. 1995; Pelleymounter et al. 1995). IGFBP-2''
;ob/ob mice, on the other hand, showed a more modest reduction in hyperglycemia,

though glucose levels were substantially higher in these mice than in ob/ob control
(glucose: 174 mg/dl, p = 0.01 vs. leptin treated ob/ob) (Figure 7.2c).
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Figure 7.2 Attenuated response to leptin in I G F B P Z ; o b / o b mice, o b o b and
IGFBP2~~;ob/ob mice were treated with subcutaneous pbs or leptin (4.8 |j.g/day) for
10 days. (A) percent change in body weight, *, p < 0.05 o f o b vs. I G F B P 2 ' ; o b o b
leptin treated. (B) daily food intake averaged over days 3-10 of treatment. *, p < 10"5
pbs vs. leptin;", p < IO"5 ob/ob vs. IGFBP2";ob/ob (C) plasma glucose levels,
*, p < IO"5 pbs vs. leptin; *, p < 10"5 o f o b vs. IGFBP2"";o6'ob and (D) plasma leptin,
', p < 0.05 ob/ob vs. IGFBP2';ob/ob. n > 4 for each group, error bars indicate S E M .

Discussion

The data presented here indicate that IGFBP-2 is necessary for the full

complement of leptin's metabolic effects. Double mutant mice lost significantly less

weight than ob/ob counterparts. IGFBP-2''';ob/ob mice were also observed to be lept

resistant in a separate time course experiment (data not shown). Although the IGFBP-

;ob/ob mice were older than the ob/ob mice studied here, in seaprate experiments old

ob/ob mice also lost approximately 30% of their body weight following leptin therap
opposed to 15% in IGFBP-2'';ob/ob mice). In addition, IGFBP-2'';ob/ob mice have less

marked reductions in hyperglycemia. This could point to a specific function of IGFBP

or may simply be due to the more modest weight loss in these mice. Further study, in

inbred mice is required to determine whether double mutant mice have other phenotyp
alterations relative to ob/ob mice.
Despite the lack of any dramatic phenotype in IGFBP-2 knockout mice, perhaps
due to functional redundancy, data from transgenic mice and obese humans support a
for this molecule in body weight physiology (Wood et al. 1993; Pintar et al. 1995;
et al. 2000). Transgenic mice expressing IGFBP-2 under the control of the CMV

promoter expressed IGFBP-2 in every tissue, but liver, and had a 3-fold increase in
IGFBP-2 levels (Hoeflich et al. 1999). These mice developed normally, but from

weaning onward showed a significant reduction in body weight (approximately 10%) at

all ages (Hoeflich et al. 1999) (Schneider et al. 2000). In addition, transgenic mice
reduced glucose levels relative to non-transgenic controls. When outbred mice were
selectively bred to generate lines of mice with either low or high body weight, low
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weight was associated with elevated hepatic IGFBP-2 expression, while high body

weight was associated with reduced hepatic IGFBP-2 expression (Hoeflich et al. 1998)
IGFBP-2 levels were also suppressed in obese humans, and this suppression was

accentuated by the concomitant presence of diabetes (Nam et al. 1997; Frystyk et al.
1999).

The findings in leptin treated IGFBP-2'1' ;ob/ob mice are highly similar to those in

pair-fed ob/ob mice. Since ob/ob mice have undetectable IGFBP-2 expression, which is

not induced at all by pair-feeding, the induction of IGFBP-2 upon leptin treatment c

be responsible for many of the differences observed between leptin treated and pair-

mice. Pair-fed mice also lose significantly less weight than leptin-treated ob/ob mi
show a less dramatic correction of the diabetic phenotype (Levin et al. 1996). Since

fed mice lose both fat mass and lean mass, whereas leptin treated mice only lose fat
body composition analysis of leptin treated IGFBP-2''';ob/ob mice is necessary to

determine which body compartments contribute to their weight loss (Halaas et al. 199
Pelleymounter et al. 1995).
The mechanism by which IGFBP-2 contributes to leptin-mediated weight loss is
currently unknown. Numerous studies have shown that the growth hormone (GH) axis is
perturbed in human obesity (Scacchi et al. 1999). In humans, plasma GH is inversely

related to measures of adiposity, and obesity is associated with reduced plasma IGFwhich is downstream of GH (Rudman et al. 1981) (Copeland et al. 1990). Treatment of
patients with growth hormone results in increased lean mass and decreased adiposity

(Rudman et al. 1990). In rodents, central leptin infusion stimulates spontaneous puls
GH secretion, as well as secretion in response to GHRH (Tannenbaum et al. 1998). In
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addition, leptin reverses the starvation-induced fall in serum G H (LaPaglia et al. 1998).
Thus, the leptin-specific induction of IGFBP-2 expression may be related to the
normalization of the GH/IGF axis, and could thereby account for the role of IGFBP-2
leptin-mediated weight loss.
Alternatively, the effects of IGFBP-2 may be independent of its role in the
GH/IGF pathway. Recent reports have shown that IGFBP-s can also mediate actions

independent of IGF, initiating signal transduction and acting as growth factors on t
own (Mohan and Baylink 2002). IGFBP-s may also bind other circulating molecules,

perhaps stabilizing them and increasing their half-life. IGFBP-4 can bind circulatin
leptin as part of a macromolecular complex (Sui and Wilson 2000). Since the IGFBP-s

share a high degree of structural homology, IGFBP-2 could also bind leptin and stabi

it in the plasma, a possibility that is being explored. This would explain the highe
levels achieved in ob/ob mice capable of inducing IGFBP-2, and could ultimately

account for the greater potency of leptin in these mice relative to IGFBP-2'1';ob/ob
IGFBP-2 is part of a complex endocrine system with multiple levels of regulation.
Its activity can be modulated by proteolysis, phosphorylation, and adherence to the

membrane or extracellular matrix (Clemmons 1998). IGFBP-2 also has a specific patter

of temporal and tissue-type expression (Schneider et al. 2000). Finally, IGFBP-2 leve

are altered in numerous disease states including obesity, diabetes, glioma, prostate

(Cohen et al. 1993; Nam et al. 1997; Frystyk et al. 1999; Zhang et al. 2002). Thus, f

studies of animal models with tissue-specific deletion and overexpression of IGFBP-2
necessary to dissect its pleiotropic physiological roles.
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While the mechanism is not yet known, the data presented here indicate that

IGFBP-2 induction plays an important role in leptin-mediated weight loss. While IGFB
2 expression is completely suppressed in ob/ob and db/db mice, it is only partially
suppressed in Ay and NZO mice, models of severe and moderate leptin resitance

respectively. The presence of tonic IGFBP-2 expression in these mice may underlie th

partial response to leptin therapy and suggests that co-administration of leptin and
IGFBP-2 may augment their weight loss response. Leptin resistance appears to be a

feature of the majority of human obesity, and obese humans also have suppressed leve

of IGFBP-2 levels (Nam et al. 1997; Frystyk et al. 1999). These findings suggest that

IGFBP-2 could be useful as a leptin adjuvant in the therapy of obesity and metabolic
diseases.
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C h a p t e r 8: C o n c l u s i o n

S u m m a r y of findings

T h e studies in this thesis explore the molecular basis for the metabolic effects of

leptin. We specifically studied the effects of leptin on the liver, due to its prominent role
in carbohydrate and lipid metabolism. Leptin-deficient ob/ob mice manifest a mixed form
of hepatic insulin sensitivity and resistance, resulting in increased lipogenesis along with
elevated gluconeogenesis, which contributes to both obesity and diabetes (Shimomura et
al. 2000). In the absence of effective leptin action, triglyceride is deposited in peripheral

sites such as liver, skeletal muscle, heart, and pancreatic islets. This build-up of lipid in
non-adipose tissues causes lipotoxicity, which contributes to insulin resistance and organ
dysfunction in the obese state (Unger 2002) (McGarry 1992; Shulman 2000). Leptin
replacement in leptin-deficient (ob/ob) mice and humans leads to the specific depletion of

lipid in adipose tissue, liver, and other tissues (Campfield et al. 1995; Halaas et al. 1995;
Pelleymounter et al. 1995; Farooqi et al. 1999). The metabolic program that leptin elicits
is not explained by its effects on food intake alone (Levin et al. 1996; Kamohara et al.
1997; Shimomura et al. 1999c). Leptin, with significantly greater potency than pairfeeding, rapidly reduces lipid in non-adipose tissues by decreasing triglyceride formation
and increasing free fatty acid oxidation (Shimabukuro et al. 1997a). The goal of this
thesis was to dissect the molecular basis for leptin's effects on hepatic metabolism in
order to better understand the unique program of leptin-mediated weight loss.
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A s an entry point to this question, w efirstexamined whether leptin's effects on

liver were the result of direct action on heptocytes or secondary to action on the b

(Chapter 3). While data from intracerebroventricular administration of leptin sugges

that it has direct effects on brain, the leptin receptor is broadly expressed, and l

also been shown to act directly to deplete triglycerides (Campfield et al. 1995; Ghi

al. 1996; Fei et al. 1997; Halaas et al. 1997; Shimabukuro et al. 1997a; Minokoshi e
2002). The relative importance of leptin's effects on brain vs. peripheral sites was

untested as was the contribution of these actions to body weight homeostasis, deposi

of lipid in peripheral sites, and neuroendocrine function. Therefore, we generated a
studied mice with either neuronal (ObRSynIKO) or hepatocyte-specific (ObRAlbKO)
deletions of ObR (Cohen et al. 2001). Among the ObRSynIKO mice, animals with the

lowest levels of ObR exhibited an obese phenotype with elevated plasma levels of lep

glucose, insulin, and corticosterone. These data demonstrated that leptin has direct

on neurons and that a significant proportion, or perhaps the majority, of its weight

reducing and neuroendocrine effects result from its actions on the brain. ObRA bKO m

on the other hand, weighed the same as controls with no alterations in body composit
Moreover, while db/db and ObRSynIKO mice had enlarged fatty livers, ObRAlbKO mice

did not. While these findings do not exclude a functional role for the hepatic lepti

receptor, they do indicate that the severe liver abnormalities of ob/ob and db/db mi
secondary to defective leptin signaling in the brain.
The demonstration that the brain is a critical site of leptin action suggested that

leptin modulates a neuronal circuit regulating peripheral metabolism. The components

this neuronal circuit and the nature of the efferent signals from the central nervou
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that regulate metabolism in response to leptin are unknown. Since leptin elicits a
metabolic response that cannot be explained by its effects on food intake alone, we
hypothesized that leptin causes weight loss via a novel program, distinct from food

restriction on both a physiological and molecular basis (Levin et al. 1996). This pr

was presumed to involve modulation of gene expression in metabolically active organs

such as liver, adipose tissue, and muscle, associated with the depletion of peripher

(Soukas et al. 2000). In order to more fully characterize this metabolic response, we

examined leptin-specific gene expression in liver (Chapter 4). We identified a novel

distinct transcriptional signature characteristic of the unique metabolic program of

loss induced by leptin. These data distinguish leptin treatment from food restrictio

molecular level, and may ultimately provide new insight into the nature of the lepti
stimulated efferent signals from the brain.
We also presumed that a subset of these leptin-regulated genes might play a

functional role in the obese phenotype and the unique metabolic actions of leptin. T

prioritize such genes for further analysis, we developed an algorithm to identify ge

that were repressed during leptin-mediated weight loss (Chapter 5). Leptin was shown
specifically repress RNA levels and enzymatic activity of hepatic stearoyl-CoA

desaturase-1 (SCD-1), which catalyzes the biosynthesis of monounsaturated fatty acids
Mice lacking SCD-1 were hypermetabolic and lean, ob/ob mice with mutations in SCD-1
(abJ/abJ; ob/ob) were significantly less obese than ob/ob controls and demonstrated
markedly increased energy expenditure, ob/ob mice with mutations in SCD-1 had

histologically normal livers with significantly reduced triglyceride storage and VLD
production. These data suggested that down-regulation of SCD-1 is an important
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component of leptin's metabolic actions and that inhibition of this enzyme m a y be
beneficial for the treatment of obesity and other metabolic diseases.
SCD-1 is required for normal rates of hepatic triglyceride and cholesterol ester
biosynthesis and ob/ob mice lacking SCD-1 (abJ/abJ; ob/ob) displayed a dramatic

correction in the hepatic steatosis typical of ob/ob mice (Miyazaki et al. 2000). The
we examined whether SCD-1 plays a more general role in fatty liver disease (Chapter

Hepatic steatosis is the earliest sign of both alcoholic and nonalcoholic fatty live

SCD-1 expression is elevated in livers of mice with alcoholic fatty liver and in mic

nonalcoholic fatty liver disease (NFLD) secondary to lipodystrophy. Mice lacking SCD

(abJ/abJ) were resistant to the development of alcoholic steatosis, while littermate

controls accumulated significant amounts of liver triglyceride. In addition, lipodys
mice lacking SCD-1 (abJ/abJ;aP2-SREBP-lc tg) showed a marked correction in the
NFLD associated with this condition. Millions of people worldwide are affected by

alcoholic fatty liver disease or NFLD and no effective treatment is currently availa

Our findings suggest that targeted inhibition of SCD-1 may be therapeutically useful
these disorders.
The important role demonstrated for SCD-1 suggested that other leptin-regulated

genes might also be functionally involved in leptin's unique metabolic effects. Whil
ob/ob mice lacking SCD-1 showed a marked correction of obesity and other components
of the obese phenotype, the absence of this gene alone did not completely eliminate
abnormalities of ob/ob mice. We therefore assumed that other alterations in gene

expression, typical of ob/ob mice, persisted and contributed to the residual phenoty

these mice. Using a computational approach, we identified a group of genes that were
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reduced in ob/ob liver and specifically induced by leptin. W e reasoned that the induction

of some of these genes might be required for leptin's metabolic effects. Insulin-lik

growth factor binding protein-2 (IGFBP-2) expression was uniquely induced by leptin

administration and not by pair-feeding, ob/ob mice lacking IGFBP-2 (IGFBP-2''';ob/o
showed markedly attenuated weight loss following leptin treatment.

Directions for future research

The findings presented here have generated a number of questions which remain

to be answered. With regard to leptin's central vs. peripheral action, more detailed
using metabolic tracers may yet uncover a role for the hepatic leptin receptor in
modulating lipid metabolism. Furthermore, hepatic ObR may only be functionally

relevant in altered physiological states such as genetic or dietary obesity or marke
or hyperleptinemia, possibilities that are currently being evaluated. However, the

enlarged fatty liver in ObRSynIKO mice and the absence of steatosis in ObRAlbKO mice
clearly indicates that defective central leptin action is responsible for the liver

of ob/ob and db/db mice. Therefore, it will be important to define the neuronal circ

to determine the nature of the efferent signal from the CNS that modulates the metab

effects of leptin in liver. Given that most obese humans are leptin resistant and th

sites of resistance are in the transport across the blood-brain-barrier and downstre

pathways, identifying the efferent signal(s) emanating from the brain in response to

could have great therapeutic benefits (Maffei et al. 1995b; Caro et al. 1996; Consid
al. 1996).
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The efferent signal is part of a homeostatic pathway, in which elevated leptin

levels signal nutritional abundance to the brain, which then activates thermogenesis
increase energy expenditure and maintain stable body weight (Lowell and Spiegelman
2000). The CNS efferent is likely to involve the autonomic system and/or the
hypothalamic pituitary axis. The presence of obesity in mice lacking all three
P-adrenergic receptors (P-less mice) indicates that the sympathetic nervous system
critical component of the CNS efferent pathway activated by leptin (Bachman et al.

2002). Testing the response of these mice to leptin should allow the contribution of
limb of the CNS efferent pathway enacted by leptin to be evaluated.
The leptin-specific programs of liver gene expression identified in Chapter 4 may
be valuable for further dissecting the CNS efferent pathways activated by leptin.
Regardless of their functional role, these patterns of expression can be used as a

molecular marker of leptin action. In addition to treating P-less mice with leptin,

mice can be also be bred on to the ob/ob background and treated with leptin (Bachma

al. 2002). Comparison of liver gene expression between these mice (P-less; ob/ob) an
ob/ob mice might show that certain clusters of genes with leptin-specific patterns

expression in ob/ob liver were no longer modulated in a leptin-dependent manner. The

clusters would likely contain genes that are regulated by leptin-dependent sympathe
activation. In theory, the role of any candidate efferent signal could be similarly

genetic models or determined by treating ob/ob mice with an agonist or antagonist o
pathway and monitoring leptin-specific gene expression.

Further understanding of the transcriptional regulation of leptin-specific patterns

of gene expression can also be used to trace backwards to identify the efferent sig
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emanating from the C N S . If a leptin-regulated transcription factor were identified, the
next goal would be to determine the mechanism by which leptin modulates this factor.
Such studies could elucidate post-translational modifications, signal transduction
pathways, and even extracellular signals that are stimulated or repressed by leptin. It
should be noted that in this discussion, the term leptin-regulated is used rather loosely.
The transcriptional machinery regulating metabolism is highly complex and could be
modulated by a multitude of factors. In addition, leptin may only regulate this pathway
secondary to its effects on other hormones, such as insulin. In any case, the identification
of such a factor would help elucidate the mechanism for leptin's novel metabolic actions.
A number of transcription factors regulate metabolic gene expression, and
whether or not these factors are regulated by leptin remains untested. In addition, clusters
of gene expression can also be used to computationally study transcriptional regulation.
With the completion of the human and murine genomes, in prinicipal, the transcriptional
start sites and upstream promoter sequence of every clustered gene can be obtained.
Computational methods can then query these sequences and determine whether either
known or novel promoter motifs are enriched in particular clusters. This could lead to the
identification of a "leptin-regulated element" which could then be used to biochemically
purify the transcription factor which binds it. Such an approach has been successfully
applied to identify a novel circadian regulated transcription factor in mice (Ueda et al.
2002).
The more detailed characterization of leptin-specific regulation of SCD-1 and
IGFBP-2 suggests that these genes may be useful for studying the transcriptional control
of leptin-repressed and leptin-induced gene expression, respectively. Of interest, both of
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the R N A levels of both of these genes also appear to regulated by leptin administration in
wild-type mice (data not shown). As discussed in Chapter 4, very few genes were

specifically modulated by leptin in wild-type liver, and these genes are more likely

specifically modulated by quantitative changes in circulating leptin levels. Prior t
beginning these studies, nuclear run-on assays will be performed to test whether

regulation of these genes is at the level of transcription and not at the level of R

stability. If regulation does prove to be transcriptional, constructs fusing differe

portions of the promoter to a CAT or luciferase indicator will be made. The human SC
1 promoter has been cloned and a number of different luciferase-promoter constructs

have already been studied in vitro (Bene et al. 2001). Generation of transgenic mice

harboring these constructs will allow in vivo analysis of leptin-dependent regulatio

gene expression. These studies will permit the delineation of promoter regions requi
for leptin-dependent gene expression. The identification of these sequences will be

useful reagent for studying the signal transduction pathways and transcription facto
regulate these genes.
The data presented suggests one possible mechanism by which leptin regulates
SCD-1 expression. The transcriptional modulation of SCD-1 is complex, with a number

of factors known to stimulate and repress transcription (Ntambi 1995). Polyunsaturate
fatty acids (PUFAs) repress SCD-1 transcription through a defined promoter element,

independent of their reported ability to inhibit SREBP cleavage and nuclear transloc
(Yahagi et al. 1999; Bene et al. 2001; Ntambi and Bene 2001). Fatty acid composition

ob/ob livers demonstrated that leptin-specifically increased the levels of PUF As, w
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are otherwise repressed in ob/ob liver (Table 5.2). These increased P U F A levels could, in
turn, account for the leptin-dependent suppression of SCD-1 RNA levels.
As well as being used as molecular markers of leptin's effects, SCD-1 and
IGFBP-2 have functional roles in metabolism and energy homeostasis. With regard to
SCD-1, future studies on inbred abJ/abJ;ob/ob mice will determine whether other

metabolic abnormalities of the obese phenotype such as insulin resistance and diabet
are corrected in the absence of SCD-1. Neuroendocrine, thermoregulatory, immune, and

reproductive function will also be examined. In addition, the phenotype of these mic

will be characterized at an older age to determine whether there are any undesirable
effects of eliminating SCD-1.
Understanding the mechanism underlying the effects of SCD-1 deficiency will

also be a focus of future studies. Figure 5.5a proposed one possible mechanism by wh

the absence of SCD-1 could lead to increased fatty acid oxidation and increased ener
expenditure. While Figure 5.5b presented preliminary data illustrating that abJ/abJ
ab'/ab"r;ob/ob mice have elevated saturated fatty acyl CoAs, other elements of this

hypothesis require further testing. Measurement of malonyl CoA levels is necessary t

confirm whether these saturated fatty acyl CoAs might inhibit ACC. In addition, abJ/

and abJ/abJ;ob/ob mice will be treated with etomoxir, an inhibitor of CPT-1, to dete

whether the increased oxygen consumption is blunted when fatty acid translocation in
the mitochondria and subsequent oxidation is blocked (Esser et al. 1993). Finally,
measurement of tissue-specific fatty acid oxidation in these mice is necessary to

determine whether increased fatty acid oxidation, or another mechanism altogether, i
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responsible for the increased energy expenditure and resistance to obesity in mice lacking
SCD-1.
These same studies will also be performed in alcohol fed abJ/abJ mice and in
ab /ab ;aP2-SREBP-lc tg mice to see if similar mechanisms are operative in their

apparent resistance to fatty liver disease. In addition, abJ/abJ mice have been bred

other mouse models of fatty liver disease including mice with transgenic overexpress
of nuclear sterol regulatory element-binding protein-la (PEPCK-SREBP-la tg) and Ay

mice (Yen et al. 1976; Shimano et al. 1996). In addition to assessing resistance to h

steatosis, all of these models will be followed over time to see if they are similar

resistant to fibrosis and other advanced pathology of fatty liver disease. Furthermo

mice lacking SCD-1 will be treated with carbon tetrachloride and thioacetamide, indu

of hepatic fibrosis, to determine whether their resistance to hepatic lipid accumula
renders them resistant to more severe liver pathology as well (Friedman 2000b).
Future studies will also explore whether SCD-1 and SCD-2 expression, activity,

and enzymatic products, are modulated by leptin in tissues other than liver. While t

effects of SCD-1 deficiency described are attributable to an increased rate of energ
expenditure, the full complement of tissues contributing to this increased energy

expenditure are as yet unknown, ob/ob mice were followed over a time course of lepti

administration, saline with pair-feeding, and saline with free-feeding (identical to
experiment described in Chapter 4) and liver, fast and slow twitch skeletal muscle,
and brown adipose tissue, heart, hypothalamus, and other tissues were harvested for

analysis. Leptin was recently shown to activate fatty acid oxidation in heart, indep
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of a 2 AMP-kinase activation, suggesting that another pathway, potentially involving
regulation of SCD-1 could be relevant (Atkinson et al. 2002).
In addition, analysis of SCD-1 regulation in hypothalamus and other brain regions

will be important to determine whether there is a direct role for SCD-1 and its prod

the neuronal pathways controlling feeding. Central administration of C75, an inhibit

fatty acid synthase, has indicated that alterations in hypothalamic malonyl CoA leve

associated with reduced levels of NPY, leading to reduced food intake and weight los

(Loftus et al. 2000). ab /ab ;ob/ob mice are hyperphagic relative to ob/ob mice, perh

secondary to increased energy expenditure or possibly due to a compensatory increase
SCD-2 expression and/or activity in the brain. Understanding the mechanism for the

hyperphagia in abJ/abJ;ob/ob mice and its consequent blunting, could lead to an even

greater correction of the obese phenotype in these animals. To explore whether there
compensatory increase in other SCD isoforms in mice lacking SCD-1, SCD-2 and SCD-3
expression, SCD activity, and enzymatic products will also be measured in multiple
tissues from abJ/abJ;ob/ob mice. Data generated thus far indicates that there is no
compensation by other SCD isoforms in the liver, as SCD activity in abJ/abJ and

abJ/abJ;ob/ob mice could not be detected. Similar studies are underway in other tiss
including the hypothalamus.
Generation of mice with tissue-specific overexpression of different SCD isoforms

is another means to dissect the role of this molecule in individual tissues. Constru
directing hepatocyte-specific overexpression of SCD-1 and SCD-2 are currently being
generated. The demonstration of markedly elevated hepatic SCD-1 expression and

activity in the hyperlipidemic, hyplip mutant mouse suggests that hypertriglyceridem
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and hypercholesterolemia could be one consequence of hepatic overexpression of SCD-1

(Attie et al. 2002; Bodnar et al. 2002). Based on the analysis of leptin-specific SCD

regulation in other tissues, described above, transgenic overexpression could also b
targeted to other relevant sites.
The data demonstrating a role for IGFBP-2 in leptin-mediated weight loss are

more preliminary than that for SCD-1, and therefore require further experimentation.

data presented here suggest that IGFBP-2''";ob/ob mice have a more severe phenotype
than ob/ob controls. A complete analysis of the metabolic and other alterations

characteristic of the obese phenotype need to be performed in inbred IGFBP-2''';ob/
mice. As IGFBP-2 is widely expressed, further studies are necessary to determine

whether leptin-dependent induction of IGFBP-2 RNA is unique to liver or whether oth

tissues are also involved. To further dissect the effects of liver-specific inducti
IGFBP-2, transgenic mice overexpressing IGFBP-2 exclusively in heptocytes and an
adenovirus producing IGFBP-2 are currently being generated.
The mechanism for the apparent leptin resistance in IGFBP-2''';ob/ob mice and
the role for IGFBP-2 induction in leptin-mediated weight loss are unknown.
Administration of recombinant IGFBP-2 and infection of mice with an IGFBP-2

adenovirus (currently being made) will allow for further study of the effects of in

levels of this molecule. The findings presented here could be due to an indispensabl

for IGFBP-2 in the induction of the GH / IGF axis or could be due to an IGF indepen

role of IGFBP-2. Future experiments will be necessary to assay the effects of leptin
other components of the GH / IGF axis in ob/ob mice with and without IGFBP-2. One

possible IGF-independent role for IGFBP-2 may be to stabilize circulating leptin, th
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increasing its half-life and potentiating its actions. This possibility can be tested by
comparing the leptin dose-response curves of ob/ob and IGFBP-2''';ob/ob mice.

Alternatively, this hypothesis could be explored by treating mice with different do

recombinant IGFBP-2 and leptin or by co-infecting mice with different titers of IGF

and leptin adenoviruses. If the observed effects of IGFBP-2 are, in fact, independen
IGF, then the role for this molecule may be further dissected by analyzing gene

expression in mice following IGFBP-2 administration or adenoviral infection. Perhaps

IGFBP-2 initiates a signaling pathway that represses anabolic gene expression and /
induces catabolic gene expression.

A common biochemical pathway determining nutrient partitioning
Analysis of leptin-specific gene expression in the liver has identified two
molecules, SCD-1 and IGFBP-2 with functions in energy metabolism. SCD-1, and

perhaps IGFBP-2 as well, is involved in determining whether calories are partitioned

fat or burned. Based on the findings in abJ/abJ;ob/ob mice, SCD-1 joins a list of ot

genes, that when either deleted or overexpressed confer leanness. Thus far, approxim
50 such genes have been described and the mechanisms underlying their effects have
been divided into eight major categories: (1) peripherally driven increased energy

expenditure in muscle, (2) peripherally driven increased energy expenditure via adip
tisse, (3) increased energy expenditure via multiple or unknown tissues, (4) CNSmediated, (5) peripherally decreased energy availability, (6) abnormal adipocyte
biochemistry, (7) white fat ablation, and (8) unknown (Reitman 2002). SCD-1 could be
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placed in the third grouping, pending elucidation of the tissue(s) driving increased energy
expenditure in mice lacking this gene.

Further analysis of genetic alterations conferring leanness indicates that a number
of other molecules in the same biochemical pathway as SCD-1 are also involved in

energy partitioning (Figure 8.1). Deletion of acetyl-CoA carboxylase 2 produces a l

phenotype, secondary to decreased malonyl CoA and increased fatty acid oxidation (Ab

Elheiga et al. 2001). Inhibition of fatty acid synthase by the compound C75 also lea
reduced adiposity (Loftus et al. 2000). This molecule was originally thought to act

centrally to decrease food intake, but has been subsequently found to increase energ

expenditure and peripheral fatty acid oxidation (Thupari et al. 2002). The finding o

increased fat oxidation in the setting of elevated malonyl CoA was paradoxical. Howe

studies have suggested that C75 competes with malonyl CoA, thereby disinhibiting it

actions on CPT-1 (Thupari et al. 2002). As described in this work, in the absence of
SCD-1, animals demonstrate resistance to obesity and increased energy expenditure,

perhaps also due to effects on malonyl CoA and fatty acid oxidation (Chapter 5)(Coh
al. 2002). Furthermore, mice with a targeted deletion of acyl CoA:diacylglycerol

transferase (DGAT), which catalyzes the final step in triglyceride biosynthesis, hav

increased energy expenditure and are protected from obesity (Smith et al. 2000). DGA

null mice also have sebaceous gland defects very similar to those in asebia mice (C
al. 2002). Interestingly, a promoter polymorphism in this gene leading to decreased
expression is associated with reduced BMI in Turkish women (Ludwig et al. 2002).
Modulation of the above gene products may prevent obesity by a similar mechanism to
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Figure 8.1 S C D - 1 is part of a biochemical pathway regulating energy partitioning
and adiposity. A s described in the text, modulation of the gene targets in bold print
affect body weight. In all cases (except for Apo-Cl, which exerts its effects w h e n overexpressed), inhibition of the gene target protects mice from obesity. A C C : acetyl-CoA
carboxylase 2, F A S : fatty acid synthase, SCD-1: stearoyl C o A desaturase-1, D G A T :
acyl CoA:diacylglycerol transferase, V L D L r : very low density lipoprotein receptor,
L P L : lipoprotein lipase, A P O - C 1 : apolipoprotein Cl.

that proposed for SCD-1 in Figure 5.5a. Therefore, it will be important to determine the
common and unique features of each of these models.
In the liver, the triglycerides formed through this pathway can be packaged in

VLDL and exported to adipose tissue and other sites. A number of genetic alterations
inhibiting hydrolysis and consequently delivery of VLDL triglyceride, also lead to

reduced adiposity (Figure 8.1). Mice lacking the VLDL receptor are lean, and breedin
this mutation on to the ob/ob background leads to a marked correction in obesity

(Frykman et al. 1995; Goudriann et al. 2001). In addition, ob/ob mice lacking adipose

tissue lipoprotein lipase (LPL), an enzyme required for triglyceride hydrolysis, als
diminished weight and fat mass (Weinstock et al. 1997). Finally, ob/ob mice
overexpressing of apolipoprotein Cl (apo-Cl), which has been proposed to inhibit

hydrolysis of VLDL triglyceride, demonstrate a nearly total correction in obesity (J
al. 2001).
Analysis of other leptin-regulated genes in Table 5.1 and Table 7.1 may identify
other molecules that can protect from obesity, operating through the aforementioned
pathway or through an entirely different mechanism. One such gene may already exist

corticosteroid binding globulin (CBG), which is reduced in ob/ob liver and specifica
induced by leptin (Figure 4.1, Table 7.1). Obese Zucker rats have reduced levels of

which binds corticosterone in the circulation and limits its tissue availability (Gr

2001). Increased tissue corticosterone levels lead to visceral obesity and metabolic

defects in mice (Masuzaki et al. 2001). In addition, an obese human proband has been
identified with total genetic deficiency in CBG (Roitman et al. 1984).
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The continued study of SCD-1, IGFBP-2, and other leptin-regulated genes in liver

should help further elucidate the mechanism for leptin's effects on metabolism and t

means by which these genes modulate body weight. In addition, microarray analysis of

liver gene expression in abJ/abJ;ob/ob mice should also be of value in determining w
expression alterations in ob/ob mice are corrected and which remain dysregulated.
Functional study of both groups of genes may identify other molecules involved in
energy homeostasis.

Conclusion

Overweight and obesity are a pressing public health problem. With increased

prosperity and development, obesity is gradually replacing starvation and malnutriti

the world's most common metabolic disease. The discovery of leptin confirmed that bo
weight and appetite are under molecular control. Identification of other molecules
involved in leptin's endocrine loop has demonstrated other control points for body
weight, some of which may be amenable to pharmacologic manipulation. The polygenic

nature of obesity and the complex interplay of genes and environment in this disorde
make it unlikely that a single gene product or drug will be found to cure all human

obesity. However, targeted manipulation of numerous points in the molecular machiner
regulating energy homeostasis may alleviate this condition. Therefore, the complete

elucidation of leptin's circuit and the identification of the full complement of mol
involved in its unique metabolic effects may provide novel therapeutic targets. The
oligonucleotide microarrays to identify such genes coupled with functional analysis
these molecules should contribute to this effort.

149

References

Abu-Elheiga, L., M . M . Matzuk, K. A. H. Abo-Hashema and S. J. Wakil (2001).
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetylC o A carboxylase 2. Science 291: 2613-6.
Ahima, R. S., J. Dushay, S. N. Flier, D. Prabakaran and J. S. Flier (1997). Leptin
accelerates the onset of puberty in normal female mice. Journal of Clinical
Investigation 99(3): 391-5.
Ahima, R. S., D. Prabakaran, C. Mantzoros, D. Qu, B. Lowell, E. Maratos-Flier and J. S.
Flier (1996). Role of leptin in the neuroendocrine response to fasting. Nature 382:
250-2.
al-Adsani, H., L. J. Hoffer and J. E. Silva (1997). Resting energy expenditure is sensitive
to small dose changes in patients on chronic thyroid hormone replacement. J Clin
Endocrinol Metab 82: 111 8-25.
Angulo, P. (2002). Nonalcoholic fatty liver disease. N EnglJ M e d 346: 1221-31.
Aoyama, T., J. M . Peters, N . Iritani, T. Nakajima, K. Furihata, T. Hashimoto and F. J.
Gonzalez (1998). Altered constitutive expression of fatty acid-metabolizing
enzymes in mice lacking the peroxisome proliferator-activated receptor alpha
(PPARalpha). J Biol Chem 273: 5678-84.
Arakawa, M., S. Taketomi, K. Furuno, T. Matsuo and H. Iwatsuka (1975). Metabolic
studies on the development of ethanol-induced fatty liver in K K - A y mice. J Nutr
105: 1500-8.
Atkinson, L. L., M . A. Fischer and G. D. Lopaschuk (2002). Leptin Activates Cardiac
Fatty Acid Oxidation Independent of Changes in the AMP-activated Protein
Kinase-Acetyl-CoA Carboxylase-Malonyl-CoA Axis. J Biol Chem 111: 2942430.
Artie, A. D., R. M . Krauss, M . P. Gray-Keller, A. Brownlie, M . Miyazaki, J. J. Kastelein,
A. J. Lusis, A. F. H. Stalenhoef, J. P. Stoehr, M . R. Hayden and J. M . Ntambi
(2002). Relationship between stearoyl-CoA desaturase activity and plasma
triglycerides in human and mouse hypertriglyceridemia. J Lipid Res in press.
Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith and K.
Struhl (1999). Current protocols in molecular biology. N e w York, John Wiley and
Sons.
Bachman, E. S., H. Dhillon, C-Y. Zhang, S. Cinti, A. C. Bianco, B. K. Kobilka and B. B.
Lowell (2002). B A R signaling required for diet-induced thermogenesis and
obesity resistance. Science 297: 843-5.
Bado, A. (1998). The stomach is a source of leptin. Nature 394: 790-3.
Banks, W . A., A. J. Kastin, W . Huang, J. B. Jaspan and L. M . Maness (1996). Leptin
enters the brain by a saturable system independent of insulin. Peptides 17: 305-11.
Barsh, G. S., I. S. Farooqi and S. O'Rahilly (2000). Genetics of body weight regulation.
Nature 404: 644-51.
Barzilai, N., J. Wang, D. Massilon, P. Vuguin, M . Hawkins and L. Rossetti (1997).
Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin
Invest \W(12): 3105-10.

150

Baskin, D. G., B. J. Wilcox, D. P. Figlewicz and D. M . Dorsa (1988). Insulin and insulinlike growth factors in the C N S . Trends Neurosci 11: 107-11.
Baura, G. D., D. M . Foster, D. Porte, Jr., S. E. Kahn, R. N. Bergman, C. Cobelli and M .
W . Schwartz (1993). Saturable transport of insulin from plasma into the central
nervous system of dogs in vivo. J. Clin. Invest. 92: 1824-30.
Bellentani, S., G. Saccoccio, F. Masutti, L. S. Croce, G. Brandi, F. Sasso, G. Cristanini
and C. Tiribelli (2000). Prevalence of andriskfactors for hepatic steatosis in
Northern Italy. Ann Intern M e d 132: 112-7.
Bene, H., D. Lasky and J. M . Ntambi (2001). Cloning and characterization of the human
stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol
regulatory element binding protein and repression by polyunsaturated fatty acids
and cholesterol. Biochem. Biophys. Res. Commun. 284: 1194-8.
Berg, A. H., T. P. Combs, X. Du, M . Brownlee and P. E. Scherer (2001). The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat M e d 7: 947-53.
Billington, C. J., J. E. Briggs, M . Grace and A. S. Levine (1991). Effects of
intracerebroventricular injection of neuropeptide Y on energy metabolism. A m J
Physiol 260: R321-7.
Binkert, C , J. Landwehr, J. L. Mary, J. Schwander and G. Heinrich (1989). Cloning,
sequence analysis and expression of a c D N A encoding a novel insulin-like growth
factor binding protein (IGFBP-2). E M B O 8: 2497-502.
Bjorbaek, C , J. K. Elmquist, J. D. Frantz, S. E. Shoelson and J. S. Flier (1998).
Identification of SOCS-3 as a potential mediator of central leptin resistance.
Molecular Cell 1: 619-25.
Bjorbaek, C , S. Uotani, B. da Silva and J. S. Flier (1997). Divergent signaling capacities
of the long and short isoforms of the leptin receptor. J Biol Chem 272(51): 3268695.
Bocher, V., I. Pineda-Torra, J. C. Fruchart and B. Staels (2002). PP./\Rs: transcription
factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci 967: 7-18.
Bodnar, J. S., A. Chatterjee, L. W . Castellani, D. A. Ross, J. Ohmen, J. Cavalcoli, C. W u ,
K. M . Dains, J. Catanese, M . Chu, S. S. Sheth, K. Charugundla, P. Demant, D. B.
West, P. de Jong and A. J. Lusis (2002). Positional cloning of the combined
hyperlipidemia gene Hyplipl. Nat Genet 30: 110-6.
Boisclair, Y. R., D. Seto, S. Hsieh, K. R. Hurst and G. T. Ooi (1996). Organization and
chromosomal localization of the gene encoding the mouse acid labile subunit of
the insulin-like growth factor binding complex. Proc Natl Acad Sci U S A 9 3 :
10028-33.
Boissonneault, G. A., M . J. Hornshuh, J. W . Simons, R. D.R. and G. A. Leveille (1978).
Oxygen consumption and body fat content of young lean and obese (OB/OB)
mice. Proc Soc Exp Biol M e d 157: 402-6.
Bornstein, S. R., K. Uhlmann, A. Haidan, M . Ehrhart-Bornstein and W . A. Scherbaum
(1997). Evidence for a novel peripheral action of leptin as a metabolic signal to
the adrenal gland: leptin inhibits Cortisol release directly. Diabetes 46: 1235-8.
Boss, O., S. Samec, A. Paoloni-Giacobino, C. Rossier, A. Dulloo, J. Seydoux, P. Muzzin
and J. Giacobino (1997). Uncoupling protein-3: a new member of the
mitochondrial carrier family with tissue-specific expression. F E B S Lett 408: 3942.

151

Boston, B. A., K. M . Blaydon, J. Varnerin and R. D. Cone (1997). Independent and
additive effects of central P O M C and leptin pathways on murine obesity. Science
278(5343): 1641-4.
Bouchard, C , A. Tremblay, J. P. Despres, A. Nadeau, P. J. Lupien, G. Theriault, J.
Dussault, S. Moorjani, S. Pinault and G. Fournier (1990). The response to longterm overfeeding in identical twins. N Engl J M e d 322: 1477-82.
Bray, G. A. and D. A. York (1979). Integration of energy intake and expenditure in
animals and man: the autonomic and adrenal hypothesis. Physio. Rev. 59: 719809.
Bray, G. A. and D. A. York (1998). The M O N A LISA hypothesis in the time of leptin.
Recent Prog. Horm. Res. 53: 95-117.
Broberger, C , J. Johansen, C. Johansson, M . Schalling and T. Hokfelt (1998). The
neuropeptide Y/agouti gene-related protein ( A G R P ) brain circuitry in normal,
anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A 9 5 :
15043-8.
Brown, P. O. and D. Botstein (1999). Exploring the new world of the genome with D N A
microarryas. Nat. Genet. Suppl. 21: 33-7.
Bruning, J. C , D. Gautam, D. J. Burks, J. Gillette, M . Schubert, P. C. Orban, R. Klein,
W . Krone, D. Muller-Wieland and C. R. Kahn (2000). Role of brain insulin
receptor in control of body weight and reproduction. Science 289: 2122-5.
Burcelin, R., S. Kamohara, J. Li, G. Tannenbaum, M . Charon and J. Friedman (1999).
Acute intravenous leptin infusion increases glucose turnover but not skeletal
muscle glucose uptake in ob/ob mice. Diabetes 48: 1264-9.
Campfield, L. A., F. J. Smith, Y. Guisez, R. Devos and P. Burn (1995). Recombinant
mouse O B protein: Evidence for a peripheral signal linking adiposity and central
neural networks. Science 269: 546-9.
Caro, J. F., J. W . Kolaczynski, M . R. Nyce, J. P. Ohannesian, I. Opentanova, W . H.
Goldman, R. B. Lynn, P. L. Zhang, M . K. Sinha and R. V. Considine (1996).
Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism
for leptin resistance [see comments]. Lancet 348(9021): 159-61.
Carpenter, L. R., T. J. Farruggella, A. Symes, M . L. Karow, G. D. Yancopoulos and N .
Stahl (1998). Enhancing leptin response by preventing SH2-containing
phosphatase 2 interaction with ob receptor. Proc. Natl. Acad. Sci. USA 95: 60616.
Carrasco, M . P., C. Marco and J. L. Segovia (2001). Chronic ingestion of ethanol
stimulates lipogenic response in rat hepatocytes. Life Sci 68: 1295-304.
Cairo, E., R. Senaris, R. V. Considine, F. F. Casanueva and C. Dieguez (1997).
Regulation of in vivo growth hormone secretion by leptin. Endocrinology 138(5):
2203-6.
Casanueva, F. F., C. Dieguez, V. Popovic, R. Peino, R. V. Considine and J. F. Caro
(1997). Serum Immunoreactive Leptin Concentrations In Patients With Anorexia
Nervosa Before and After Partial Weight Recovery. Biochemical & Molecular
Medicine 60(2): 116-20.
Chehab, F. F., M . E. Lim and R. Lu (1996). Correction of the sterility defect in
homozygous obese female mice by treatment with the human recombinant leptin.
Nature Genetics 12: 318-20.

152

Chehab, F. F., K. Mounzih, R. Lu and M . E. Lim (1997). Early onset of reproductive
function in normal female mice treated with leptin. Science 275(5296): 88-90.
Chen, G., K. Koyama, X. Yuan, Y. Lee, Y. T. Zhou, R. O'Doherty, C. B. Newgard and R.
H. Unger (1996a). Disappearance of body fat in normal rats induced by
adenovirus-mediated leptin gene therapy. Proc. Natl. Acad. Sci. USA 93(25):
14795-9.
Chen, H., O. Charlat, L. A. Tartaglia, E. A. Woolf, X. Weng, S. J. Ellis, N. D. Lakey, J.
Culpepper, K. J. Moore, R. E. Breitbart, G. M . Duyk, R. I. Tepper and J. P.
Morgenstern (1996b). Evidence that the diabetes gene encodes the leptin receptor:
Identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:
491-5.
Chen, H. C , S. J. Smith, B. Tow, P. M . Elias and R. V. J. Farese (2002). Leptin
modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on
murine fur and sebaceous glands. J. Clin. Invest. 109: 175-81.
Cheng, A., N . Uetani, P. D. Simoncic, V. P. Chaubey, A. Lee-Loy, C. J. McGlade, B. P.
Kennedy and M . L. Tremblay (2002). Attenuation of Leptin Action and
Regulation of Obesity by Protein Tyrosine Phosphatase IB. Dev Cell 2: 497-503.
Cherradi, N., A. M . Capponi, R. C. Gaillard and F. P. Pralong (2001). Decreased
expression of steroidogenic acute regulatory protein: a novel mechanism
participating in the leptin-induced inhibition of glucocorticoid biosynthesis.
Endocrinology 142: 3302-8.
Cheung, C. C , D. K. Clifton and R. A. Steiner (1997). Proopiomelanocortin neurons are
direct targets for leptin in the hypothalamus. Endocrinology 138: 4489-92.
Chinookoswong, N., J. W a n g and Z. Shi (1999). Leptin restores euglycemia and
normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 48:
1487-92.
Chua, S. C , W . K. Chung, X. S. Wu-Peng, Y. Zhang, S. M . Liu, L. Tartaglia and L. R.L.
(1996). Phenotypes of mouse diabetes and rat fatty due to mutations in the O B
(leptin) receptor. Science 271: 994-6.
Clement, K., C. Vaisse, N . Lahlou, S. Cabrol, V. Pelloux, D. Cassuto, M . Gourmelen, C.
Dina, J. Chambaz, J. M . Lacorte, A. Basdevant, P. Bougneres, Y. Lebouc, P.
Froguel and B. Guy-Grand (1998). A mutation in the human leptin receptor gene
causes obesity and pituitary dysfunction. Nature 392(6674): 398-401.
Clemmons, D. R. (1998). Role of insulin-like growth factor binding proteins in
controlling IGF actions. M o l Cell Endocrinol 140: 19-24.
Cohen, P., M . Miyazaki, N. D. Socci, A. Hagge-Greenberg, W . Liedtke, A. A. Soukas, R.
Sharma, L. C. Hudgins, J. M . Ntambi and J. M . Friedman (2002). Role for
stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297: 240-3.
Cohen, P., D. M . Peehl, T. A. Stamey, K. F. Wilson, D. R. Clemmons and R. G.
Rosenfeld (1993). Elevated levels of insulin-like growth factor-binding protein-2
in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031-5.
Cohen, P., C. Zhao, X. Cai, P. Feinstein, J. M . Montez, C. Rohani, P. Mombaerts and J.
M . Friedman (2001). Selective deletion of leptin receptor in neurons leads to
obesity. Journal of Clinical Investigation 108: 1113-21.

153

Cohen, S., J. Werrmann and T. M R (1998). 13C N M R study of he effects of leptin
treatment on kinetics of hepatic intermediary metabolism. Proc. Nat. Acad. Sci.
USA 95: 7385-90.
Coleman, D. L. (1978). Obese and Diabetes: two mutant genes causing diabetes-obesity
syndromes in mice. Diabetologia 14: 141-8.
Coleman, D. L. (1979). Obesity genes: beneficial effects in heterozygous mice. Science
203: 663-5.
Coleman, D. L. (1982). Diabetes-obesity s y n d r o m e s in mice. Diabetes
3 1 (Suppl. 1): 1-6.
Collins, S., C. M . Kuhn, A. E. Petro, A. G. Swick, B. A. Chrunyk and R. S. Surwit
(1996). Role of leptin in fat regulation. Nature 380: 677.
Collins, S. and R. S. Surwit (1995). Pharmacologic manipulation of ob expression in a
dietary model of obesity. J Biol Chem 271: 9437-40.
Colombo, C , J. J. Cutson, T. Yamauchi, C. Vinson, T. Kadowaki, O. Gavrilova and M .
L. Reitman (2002). Transplantation of adipose tissue lacking leptin is unable to
reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 51:
2727-33.
Combs, T. P., A. H. Berg, S. Obici, P. E. Scherer and L. Rossetti (2001). Endogenous
glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin.
Invest. 108: 1875-81.
Committee, W . H. O. E. (1995). Physical Status: the Use and Interpretation of
Anthropometry. Geneva, World Health Organization.
Considine, R. V., M . K. Sinha, M . L. Heiman, A. Kriauciunas, T. W . Stephens, M . R.
Nyce, J. P. Ohannesian, C. C. Marco, L. J. M c K e e and T. L. Bauer (1996). Serum
immunoreactive-leptin concentrations in normal-weight and obese humans. N.
England J. Medicine 334: 324-5.
Cook, W . S. and R. H. Unger (2002). Protein Tyrosine Phosphatase IB: A Potential
Leptin Resistance Factor of Obesity. Dev Cell 2: 385-7.
Copeland, K. C , R. B. Colletti, J. T. Devlin and T. L. McAuliffe (1990). The relationship
between insulin-like growth factor-I, adiposity, and aging. Metabolism 39: 584-7.
Crabb, D. W . (1993). Recent developments in alcoholism:the liver. Recent Dev Alcohol
11: 207-30.
Crowley, V. E. F., G. S. H. Yeo and S. O'Rahilly (2002). Obesity therapy: altering the
energy intake-and-expenditure balance sheet. Nat Rev Drug Discov 1: 276-86.
Cummings, D. E., E. P. Brandon, J. V. Planas, K. Motamed, R. L. Idzerda and G. S.
McKnight (1996). Genetically lean mice result from targeted disruption of the
RIIP subunit of protein kinase A. Nature 382(6592): 622-6.
Cummings, D. E., D. S. Weigle, R. S. Frayo, P. A. Breen, M . K. M a , E. P. Dellinger and
J. Q. Purnell (2002). Plasma ghrelin levels after diet-induced weight loss or
gastric bypass surgery. N Engl J M e d 346: 1623-30.
Dauncey, M . J. and D. Brown (1987). Role of activity-induced thermogenesis in twentyfour hour energy expenditure of lean and genetically obese (ob/ob) mice. Q J Exp
Physiol 72: 549-59.
Davies, J. I. (1968). In vitro regulation of the lipolysis of adipose tissue. Nature 218: 34952.

154

DeFalco, J., M . Tomishima, H. Liu, C. Zho, X. Cai, J. D. Marth, L. Enquist and J. M .
Friedman (2001). Virus-assisted mapping of neural inputs to a feeding center in
the hypothalamus. Science 291: 2608-13.
Diatchenko, L., Y. F. C. Lau, A. P. Campbell, A. Chenchik, F. M o q d a m , B. Huang, S.
Lukyanov, K. Lukyanov, N . Gurskaya, E. D. Sverdlov and P. D. Siebert (1996).
Suppression subtractive hybridization: a method for generating differentially
regulated or tissue-specific c D N A probes and libraries. Proc Natl Acad Sci U S A
93: 6025-30.
Diehl, A. M . (2001). Nonalcoholic fatty liver disease: implications for alcoholic liver
disease pathogenesis. Alcohol Clin Exp Res 25(5 Suppl ISBRA): 8S-14S.
Dietz, W . H. (1994). Critical periods in childhood for the development of obesity. A m J
Clin Nutr 59: 955-9.
Diraison, F., E. Dusserre, H. Vidal, M . Sothier and M . Beylot (2002). Increased hepatic
lipogenesis but decreased expression of lipogenic gene in adipose tissue in human
obesity. A m J Physiol Endocrinol Metab 282: E46-E51.
Droge, W . (2002). Free radicals in the physiological control of cell function. Physiol Rev
82: 47-95.
Ducy, P., M . Amling, S. Takeda, M . Priemel, A. F. Schilling, F. T. Beil, J. Shen, C.
Vinson, J. M . Rueger and G. Karsenty (2000). Leptin inhibits bone formation
through a hypothalamic relay: a central control of bone mass. Cell 100(2): 197207.
Ebihara, K., Y. Ogawa, H. Masuzaki, M . Shintani, F. Miyanaga, M . Aizawa-Abe, T.
Hayashi, K. Hosoda, G. Inoue, Y. Yoshimasa, O. Gavrilova, M . L. Reitman and
K. Nakao (2001). Transgenic overexpression of leptin rescues insulin resistance
and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 505-: 1440-8.
Edwards, P. A., H. R. Kast and A. M . Anisfeld (2002). BAREing it all: the adoption of
L X R and F X R and their roles in lipid homeostasis. J Lipid Res 43: 2-12.
Elchebly, M., P. Payette, E. Michaliszyn, W . Cromlish, S. Collins, A. L. Loy, D.
Normandin, A. Cheng, J. Himms-Hagen, C. C. Chan, C. Ramachandran, M . J.
Gresser, M . L. Tremblay and B. P. Kennedy (1999). Increased insulin sensitivity
and obesity resistance in mice lacking the protein tyrosine phosphatase-IB gene.
Science 283: 544-8.
Elias, C. F., C. Lee, J. Kelly, C. Aschkenasi, R. S. jAhima, P. R. Couceyro, M . J. Kuhar,
C. B. Saper and J. K. Elmquist (1998). Leptin activates hypothalamic C A R T
neurons projecting to the spinal cord. Neuron 21: 1375-85.
Elmquist, J. E., C. F. Elias and C. B. Saper (1999). From lesions to leptin: Hypothalamic
control of food intake and body weight. Cell 22: 221-32.
Elmquist, J. K., R. S. Ahima, C. F. Elias, J. S. Flier and C. B. Saper (1998a). Leptin
activates distinct projections from the dorsomedial and ventromedial
hypothalamic nuclei. Proc Natl Acad Sci U S A 95(2): 741-6.
Elmquist, J. K., R. S. Ahima, E. Maratos-Flier, J. S. Flier and C. B. Saper (1997). Leptin
activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology
138(2): 839-42.
Elmquist, J. K., C. Bjorbaek, R. S. Ahima, J. S. Flier and C. B. Saper (1998b).
Distributions of the leptin receptor m R N A isoforms in the rat brain. J C o m p
Neurol 395(4): 535-47.

155

Enerback, S., A. Jacobsson, E. M . Simpson, C. Guerra, H. Yamashita, M . E. Harper and
L. P. Kozak (1886). Mice lacking mitochondrial uncoupling protein are coldsensitive but not obese. Nature 387: 90-4.
Erickson, J. C , G. Hollopeter and R. D. Palmiter (1996). Attenuation of the obesity
syndrome of ob/ob mice by the loss of neuropeptide Y. Science 274(5293): 17047.
Erman, M . (2002). Big Kids' Clothing Becoming Big Business. Reuters.
Esser, V., M . Kuwajima, C. H. Britton, K. Krishnan, D. W . Foster and J. D. McGarry
(1993). Inhibitors of mitochondrial carnitine palmitoyltransferase I limit the
action of proteases on the enzyme. Isolation and partial amino acid analysis of a
truncated form of the rat liver isozyme. J Biol Chem 268: 5810-6.
Estrada, V., M . Serrano-Rios, M . T. Martinez Larrad, N. G. Villar, A. Gonzalez Lopez,
M . J. Tellez and C. Fernandez (2002). Leptin and adipose tissue maldistribution in
HIV-infected male patients with predominant fat loss treated with antiretroviral
therapy. J Acquir Immune Defic Syndr 29: 32-40.
Ewart-Toland, A., K. Mounzih, J. Qiu and F. F. Chehab (1999). Effect of the genetic
background on the reproduction of leptin-deficient obese mice. Endocrinology
140(2): 732-8.
Fan, W., B. A. Boston, R. A. Kesterson, V. J. Hruby and R. D. Cone (1997). Role of
melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature
385: 165-8.
Farooqi, I., S. Jebb, G. Langmack, E. Lawrence, C. Cheetham, A. Prentice, I. Hughes, M .
McCamish and S. O'Rahilly (1999). Effects of recombinant leptin theraphy in a
child with congenital leptin deficiency. N e w England Journal ofMedicine 341:
879-84.
Farooqi, I. S., J. M . Keogh, S. Kamath, S. Jones, W . T. Gibson, R. Trussell, S. A. Jebb,
G. Y. Lip and S. O'Rahilly (2001). Partial leptin deficiency and human adiposity.
Nature 414: 34-5.
Fei, H., H. J. Okano, C. Li, G.-H. Lee, C. Zhao, R. Darnell and J. M . Friedman (1997).
Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse
brain and other tissues. Prod. Natl. Acad. Sci., USA. 94: 7001-5.
Ferrante, A. W., M . Thearle, T. Liao and R. Leibel (2001). Effects of leptin deficiency
and short-term repletion on hepatic gene expression in genetically obese mice.
Diabetes 50: 2268-78.
Field, A. E., E. H. Coakley, A. Must, J. L. Spadano, N . Laird, W . H. Dietz, E. R i m m and
G. A. Colditz (2001). Impact of overweight and obesity on theriskof developing
c o m m o n chronic diseases during a 10-year period. Arch Intern M e d 161: 1581-6.
Finkelstein, J. A., P. Jervois, M . Menadue and J. O. Willoughby (1986). Growth hormone
and prolactin secretion in genetically obese Zucker rats. Endocrinology 118:
1233-6.
Flegal, K. M., M . D. Carroll, R. J. Kuczmarski and C. L. Johnson (1998). Overweight
and obesity in the United States: prevalence and trends,
1960-1994. Int J Obes Relat Metab Disord 22: 39-47.
Fleury, C , M . Neverova, S. Collins, S. Raimbault, O. Champigny, C. Levi-Meyrueis, F.
Bouillaud, M . F. Seldin, R. S. Surwit, D. Ricquier and C. H. Warden (1997).

156

Uncopuling protein-2: a novel gene linked to obesity and hyperinsulinemia.
Nature Genetics 15: 269-76.
Foretz, M., C. Pacot, I. Dugail, P. Lemarchand, C. Guichard, X. Le Liepvre, C.
Berthelier-Lubrano, B. Spiegelman, J. B. Kim, P. Ferre and F. Foufelle (1999).
ADDl/SREBP-lc is required in the activation of hepatic lipogenic gene
expression by glucose. M o l Cell Biol 19: 3760-8.
Freedman, M . R., B. A. Horwitz and J. S. Stern (1986). Effect of adrenalectomy and
glucocorticoid replacement on development of obesity. Am. Physiological
Society: R595-R607.
Friedman, J. (2000a). Obesity in the new millennium. Nature 404: 632-4.
Friedman, J. M . and J. L. Halaas (1998). Leptin and the regulation of body weight in
mammals. Nature 395: 763-70.
Friedman, J. M . and R. L. Leibel (1992). Tackling a Weighty Problem. Cell 69: 217-20.
Friedman, S. L. (2000b). Molecular regulation of hepatic fibrosis, an integrated cellular
response to tissue injury. J Biol Chem 275: 2247-50.
Fruebis, J., T. S. Tsao, S. Javorschi, D. Ebbets-Reed, M . R. Erickson, F. T. Yen, B. E.
Bihain and H. F. Lodish (2001). Proteolytic cleavage product of 30-kDa adipocyte
complement-related protein increases fatty acid oxidation in muscle and causes
weight loss in mice. Proc Natl Acad Sci U S A 9 S : 2005-10.
Frykman, P. K., M . S. Brown, T. Yamamoto, J. L. Goldstein and J. Herz (1995). Normal
plasma lipoproteins and fertility in gene-targeted mice homozygous for a
disruption in the gene encoding very low density lipoprotein receptor. Proc. Natl.
Acad. Sci. USA 91: 8453-7.
Frystyk, J., C. Skjaerbaek, E. Vestbo, S. Fisker and H. Orskov (1999). Circulating levels
of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes.
Diabetes Metab Res Rev 15: 314-22.
Furuno, K., M . jArakawa, A. Shino and Z. Suzuoki (1975). Induction of fatty liver by
ethanol drinking in K K and K K - A y mice. J Nutr 105: 1253-62.
Galton, D. J. and G. A. Bray (1967). Studies on lipolysis in human adipose cells. J. Clin.
Invest. 46: 621-9.
Garg, A. (2000). Lipodystophies. A m J M e d 108: 143-52.
Garrison, R. J., M . Feinleib, W . P. Castelli and P. M . McNamara (1983). Cigarette
smoking as a confounder of the relationship between relative weight and longterm mortality. The Framingham Heart Study. J A M A 249: 2199-203.
Gates, A. H. and M . Karasek (1965). Hereditary absence of sebaceous glands in the
mouse. Science: 1471-3.
Gavrilova, O., B. Marcus-Samuels, D. Graham, J. K. Kim, G. I. Shulman, A. L. Castle,
C. Vinson, M . Eckhaus and M . L. Reitman (2000a). Surgical implantation of
adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105: 271-8.
Gavrilova, O., B. Marcus-Samuels, L. R. Leon, C. Vinson and M . L. Reitman (2000b).
Leptin and diabetes in lipoatrophic mice. Nature 403: 850.
Ghilardi, N., S. Ziegler, A. Wiestner, R. Stoffel, M . H. Heim and R. Skoda (1996).
Defective S T A T signaling by the leptin receptor in diabetic mice. Proc. Natl.
Acad. Sci. USA 93: 6231-5.
Gimeno, R., M . Dembski, X. Weng, N . Deng, A. Shyjan, C. Gimeno, F. Iris, S. Ellis, E.
Woolf and L. Tartaglia (1997). Cloning and characterization of an uncoupling

157

protein homolog: a potential molecular mediator of human thermogenesis.
Diabetes 46: 900-6.
Godbole, V. and D. A. Yotk (1978). Lipogenesis in situ in the genetically obese Zucker
fatty rat (fa/fa): role of hyperphagia and hyperinsulinaemia. Diabetologia 14: 1917.
Goldstein, D. J. (1992). Beneficial health effects of modest weight loss. Int J Obes Relat
Metab Disord 16: 397-415.
Gong, D. W., Y. He, M . Karas and M . Reitman (1997). Uncoupling protein-3 is a
mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic
agonsits, and leptin. J Biol Chem 272: 24129-32.
Goudriann, J. R., P. J. Tacken, V. E. H. Dahlmans, M . J. J. Gijbels, K. W . van Dijk, L.
M . Havekes and M . C. Jong (2001). Protection from obesity in mice lacking the
V L D L receptor. Arterioscler Thromb Vase Biol. 21: 1288-93.
Graham, M., J. R. Shutter, U. Sarmiento, I. Sarosi and K. L. Stark (1997).
Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 17: 273-4.
Grasa, M . M., C. Cabot, J. A. Fernandez-Lopez, X. Remesar and M . Alemany (2001).
Modulation of corticosterone availability to white adipose tissue of lean and obese
Zucker rats by corticosteroid-binding globulin. Horm Metab Res 33: 407-11.
Grobet, L., L. J. Martin, D. Poncelet, D. Pirottin, B. Brouwers, J. Riquet, A.
Schoeberlein, S. Dunner, F. Menissier, J. Massabanda, R. Fries, R. Hanset and M .
Georges (1997). A deletion in the bovine myostatin gene causes the doublemuscled phenotype in cattle. Nat Genet 17: 71-4.
Grunnet, N. and J. Kondrup (1986). The effect of ethanol on the beta-oxidation of fatty
acids. Alcohol Clin Exp Res 10: 64S-8S.
Gu, H., J. D. Marth, P. C. Orban, H. Mossmann and K. Rajewsky (1994). Deletion of a
D N A polymerase P gene segment in T cells using cell type-specific gene
targeting. Science 265: 103-6.
Gumucio, J. J., C. M . Berkowitz, S. T. Webster and A. J. Thornton (1996). Structural and
functional organization of the liver. Philadelphia, Williams and Wilkins.
Hahn, T. M., J. F. Breininger, D. G. Baskin and M . W . Schwartz (1998). Coexpression of
Agrp and N P Y in fasting-activated hypothalamic neurons. Nat Neurosci 1: 271-2.
Hakansson, M.-L., H. Brown, N . Ghilardi, R. C. Skoda and B. Meister (1998). Leptin
receptor immunoreactivity in chemically defined target neurons of the
hypothalamus. J. Neurosci. 18: 559-72.
Halaas, J. L., C. Boozer, J. Blair-West, N . Fidahusein, D. Denton and J. M . Friedman
(1997). Physiological response to long-term peripheral and central leptin infusion
in lean and obese mice. Proc. Natl. Acad. Sci. USA 94: 8878-83.
Halaas, J. L., K. S. Gajiwala, M . Maffei, S. L. Cohen, B. T. Chait, D. Rabinowitz, R. L.
Lallone, S. K. Burley and J. M . Friedman (1995). Weight-reducing effects of the
plasma protein encoded by the obese gene. Science 269: 543-6.
Haluzik, M., K. R. Dietz, J. K. Kim, B. Marcus-Samuels, G. I. Shulman, O. Gavrilova
and M . L. Reitman (2002). Adrenalectomy improves diabetes in A-ZIP/F-1
lipoatrophic mice by increasing both liver and muscle insulin sensitivity. Diabetes
51:2113-8.
Harris, R. B. S. (1990). Role of set-point theory in regulation of body weight. F A S E B J.
4:3310-8.

158

Hartigan, J. A. (1975). Clustering algorithms. N e w York, Wiley. 351.
Harvey, J., F. McKenna, P. S. Herson, D. Spanswick and M . L. Ashford (1997). Leptin
activates ATP-sensitive potassium channels in the rat insulin- secreting cell line,
CRI-G1. J Physiol (Lond) 504(Pt 3): 527-35.
Haynes, W . G., D. A. Morgan, S. A. Walsh, A. L. Mark and W . I. Sivitz (1997).
Receptor-mediated regional sympathetic nerve activation by leptin. Journal of
Clinical Investigation 100: 270-8.
Herzig, S., F. Long, U. S. Jhala, S. Hedrick, R. Quinn, A. Bauer, D. Rudolph, G. Schutz,
C. Yoon, P. Puigserver, B. Spiegelman and M . Montminy (2001). C R E B
regulates hepatic gluconeogenesis through the coactivator PGC-l. Nature 413:
179-83.
Hetherington, A. W . and S. W . Ranson (1942). The spontaneous activity and food intake
of rats with hypothalamic lesions. Am. J. ofPhysiol. 136: 609-17.
Heymsfield, S., A. Greenberg, K. Fujioka, R. Dixon, R. Kushner, T. Hunt, J. Lubina, J.
Patane, B. Self, P. Hunt and M . McCamish (1999). Recombinant leptin for weight
loss in obese and lean adults. J A M A 282: 1568-75.
Hileman, S. M., D. D. Pierroz, H. Masuzaki, C. Bjorbaek, K. El-Haschimi, W . A. Banks
and J. S. Flier (2002). Characterizaton of short isoforms of the leptin receptor in
rat cerebral microvessels and of brain uptake of leptin in mouse models of
obesity. Endocrinology 143: 775-83.
Hiller, D. V. (1981). The salience of overweight in personality characterization. J
Psychol 108: 233-40.
Himms-Hagen, J. (1989). Brown adipose tissue thermogenesis and obesity. Prog. Lipid
Res. 28: 67-115.
Hinney, A., A. Schmidt, K. Nottebom, O. Heibult, I. Becker, A. Ziegler, G. Gerber, M .
Sina, T. Gorg, H. Mayer, W . Siegfried, M . Fichter, H. Remschmidt and J.
Hebebrand (1999). Several mutations in the melanocortin-4 receptor gene
including a nonsense and aframeshiftmutation associated with dominantly
inherited obesity in humans. J Clin Endocrinol Metab 84: 1483-6.
Hodge, A. M., G. K. Dowse, P. Z. Zimmet and V. R. Collins (1995). Prevalence and
secular trends in obesity in Pacific and Indian Ocean island populations. Obes Res
Suppl2:77s-87s.
Hoeflich, A., P. Schmidt, J. Foil, O. Rottmann, M . M . Weber, H. J. Kolb, F. Pirchner and
E. Wolf (1998). Altered growth of mice divergently selected for body weight is
associated with complex changes in the growth hormone/insulin-like growth
factor system. Growth H o r m I G F Res 8: 113-23.
Hoeflich, A., M . W u , S. Mohan, J. Foil, R. Wanke, T. Froehlich, G. J. Arnold, H. Lahm,
H. J. Kolb and E. Wolf (1999). Overexpression of insulin-like growth factorbinding protein-2 in transgenic mice reduces postnatal weight gain.
Endocrinology 140: 5488-96.
Hoesche, C , A. Sauerwald, R. W . Veh, B. Krippl and M . W . Kilimann (1993). The 5'flanking region of the rat synapsin I gene directs neuron- specific and
developmentally regulated reporter gene expression in transgenic mice. J Biol
Chem 268(35): 26494-502.

159

Horton, J. D., J. L. Goldstein and M . S. Brown (2002). SREBPs: activators of the
complete program of cholesterol and fatty acid synthesis in the liver. J. Clin.
Invest. 109: 1125-31.
Horton, J. D., I. Shimomura, M . S. Brown, R. E. Hammer, J. L. Goldstein and H.
Shimano (1998). Activation of cholesterol synthesis in preference to fatty acid
synthesis in liver and adipose tissue of transgenic mice overproducing sterol
regulatory element-binding protein-2. J. Clin. Invest. 101: 2331-9.
Hotamisligil, G. S., P. Peraldi, A. Budavari, R. Ellis, M . F. White and B. M . Spiegelman
(1996). IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in
TNF-alpha- and obesity-induced insulin resistance. Science 111: 665-8.
Hotamisligil, G. S., N. S. Shargill and B. M . Spiegleman (1993). Adipose expression of
tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science
259:87-91.
Huang, L., Z. W a n g and C. Li (2001). Modulation of circulating leptin levels by its
soluble receptor. J Biol Chem 276: 6343-9.
Huang, Q., R. Rivest and D. Richard (1998). Effects of leptin on corticotropin-releasing
factor (CRF) synthesis and C R F neuron activation in the paraventricular
hypothalamic nucleus of obese (ob/ob) mice. Endocrinology 139: 1524-32.
Hubert, H. R., M . Feinleib, P. M . McNamara and W . P. Castelli (1983). Obesity as an
independentriskfactor for cardiovascular disease: a 26-year follow-up of
participants in the Framingham Heart Study. Circulation 67: 968-77.
Huszar, D., C. a. Lynch, V. Fairchild-Huntress, J. H. Dunmore, Q. Fang, L. R.
Berkemeier, W . Gu, R. A. Kesterson, B. A. Boston, R. D. Cone, F. J. Smith, L. A.
Campfied, P. Burnt and F. Lee (1997). Targeted disruption of the melanocortin-4
receptor results in obesity in mice. Cell 88: 131-41.
Ikeda, A., K. T. Chang, Y. Matsumoto, Y. Furuhata, M . Nishihara, F. Sasaki and M .
Takahashi (1997). Obesity and insulin resistance in human growth hormone
transgenic mice. Endocrinology 139: 3057-63.
Ioffe, E., B. Moon, E. Connolly and J. M . Friedman (1998). Abnormal regulation of the
leptin gene in the pathogenesis of obesity. Proc. Natl. Acad. Sci. USA 95: 118527.
Joly, J. G., L. Feinman, H. Ishii and C. S. Lieber (1973). Effect of chronic ethanol
feeding on hepatic microsomal glycerophosphate acyltransferase activity. J Lipid
Res 14: 337-43.
Jong, M . C , P. J. Voshol, M . Muurling, V. E. Dahlmans, J. A. Romijn, H. Pijl and L. M .
Havekes (2001). Protection from obesity and insulin resistance in mice
overexpressing human apolipoprotein Cl. Diabetes 50: 2779-85.
Kaestner, K. H., J. M . Ntambi, T. J. Kelly Jr. and M . D. Daniel Lane (1989).
Differentiation-induced gene expression in 3T3-L1 preadipocytes. A second
differentially expressed gene encoding stearoyl-CoA desaturase. J. Biological
Chemistry 264: 14755-61.
Kamohara, S., R. Burcelin, J. L. Halaas, J. M . Friedman and M . J. Charron (1997). Acute
stimulation of glucose metabolism in mice by leptin treatment. Nature 389: 374-7.
Kaplan, M . L. and G. A. Leveille (1981). Development of lipogenesis and insulin
sensitivity in tissues of the ob/ob mouse. A m J Physiology 240: E101-E7.

160

Kennedy, G. C. (1950). The hypothalamic control of food intake in rats. Proc. of the
Royal Soc. ofLondon 137: 535-49.
Kennedy, G. C. (1953). The role of depot fat in the hypothalamic control of food intake
in the rat. Proc. Roy. Soc. (London) (B) 140: 578-92.
Kieffer, T. J., R. S. Heller and J. F. Habener (1996). Leptin receptors expressed on
pancreatic beta-cells. Biochemical & Biophysical Research Communications
224(2): 522-7.
Kieffer, T. J., R. S. Heller, C. A. Leech, G. G. Holz and J. F. Habener (1997). Leptin
suppression of insulin secretion by the activation of ATP-sensitive K + channels in
pancreatic beta-cells. Diabetes 46: 1087-93.
Kim, K. H., K. Lee, Y. S. M o o n and H. S. Sul (2001). A cysteine-rich adipose tissuespecific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:
11252-6.
Kim, Y. B., S. Uotani, D. D. Pierroz, J. S. Flier and B. B. Kahn (2000). In vivo
administration of leptin activates signal transduction directly in insulin-sensitive
tissues: overlapping but distinct pathways from insulin. Endocrinology 141(7):
2328-39.
Knopf, J. L., J. F. Gallagher and W . A. Held (1983). Differential, multihormonal
regulation of the mouse major urinary protein gene family in the liver. M o l Cell
Biol 3: 2232-40.
Kohonen, T. (1997). Self-organizing maps. Berlin, Berlin.
Kojima, M., H. Hosoda, Y. Date, M . Nakazato, H. Matsuo and K. Kangawa (1999).
Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature
402: 656-60.
Kondo, H., I. Shimomura, Y. Matsukawa, M . Kumada, M . Takahashi, M . Matsuda, N.
Ouchi, S. Kihara, T. Kawamoto, S. Sumitsuji, T. Funahashi and Y. Matsuzawa
(2002). Association of adiponectin gene mutation with type 2 diabetes: a
candidate gene for the insulin resistance syndrome. Diabetes 51: 2325-8.
Kopecky, J., G. Clarke, S. Enerback, B. Spiegelman and L. P. Kozak (1995). Expression
of the mitochondrial uncoupling protein gene from the aP2 gene promoter
prevents genetic obesity. J. Clin. Invest. 96: 2914-23.
Kopelman, P. G. (2000). Obesity as a medical problem. Nature 404: 635-43.
Koteish, A. and A. M . Diehl (2001). Animal models of steatosis. Semin Liv Dis 21(1):
89-104.
Kowalski, T. J., S.-M. Liu, R. L. Leibel and S. C. Chua (2001). Transgenic
complementation of leptin receptor deficiency. Diabetes 50: 425-35.
Kristensen, P., M . E. Judge, L. Thim, U. Ribel, K. N . Christjansen, B. S. Wulff, J. T.
Clausen, P. B. Jensen, O. D. Madsen, N. Vrang, P. J. Larsen and S. Hastrup
(1998). Hypothalamic C A R T is a new anorectic peptide regulated by leptin.
Nature 393: 72-.
Krude, H., H. Biebermann, W . Luck, R. Horn, G. Brabant and A. Gruters (1998). Severe
early-onset obesity, adrenal insufficiency and red hair pigmentation caused by
P O M C mutations in humans. Nature Genetics 19: 155.
Kuczmarski, R. J., K. M . Flegal, S. M . Campbell and C. L. Johnson (1994). Increasing
prevalence of overweight among U S adults. The National Health and Nutrition
Examination Survey 1960 to 1991. J A M A 272: 205-11.

161

Landsberg, L., M . E. Saville and J. B. Young (1984). Sympathoadrenal system and
regulation of thermogenesis. A m J Physiol 247: E181-E9.
LaPaglia, N., J. Steiner, L. Kirsteins, M . Emanuele and N. Emanuele (1998). Leptin alters
the response of the growth hormone releasing factor-growth hormone- insulin-like
growth factor-I axis to starvation. J Endocrinol 159: 79-83.
Lasko, M., J. G. Pichel, J. R. Gorman, B. Sauer, Y. Okamoto, E. Lee, F. W . Alt and H.
Westphal (1996). Efficient in vivo manipulation of mouse genomic sequences at
the zygote stage. Proc. Natl. Acad. Sci. USA 93(12): 5860-5.
Lauderdale, D. S. and P. J. Rathouz (2000). Body mass index in a U S national sample of
Asian Americans: effects of nativity, years since immigration and socioeconomic
status. Int J Obes Relat Metab Disord 24: 1188-94.
Le Roith, D., L. Scavo and A. Butler (2001). What is the role of circulating IGF-I?
Trends Endocrinol Metab 12: 48-52.
Lee, G.-H., C. Li, J. Montez, J. Halaas, J. Darvishzadeh and J. M . Friedman (1997).
Leptin receptor mutations in 129 db3J/db3J mice and ir\IFIfacplfacp rats. Mammalian
Genome 8: 445-7.
Lee, G. H., R. Proenca, J. M . Montez, K. M . Carroll, J. G. Darvishzadeh, J. I. Lee and J.
M . Friedman (1996). Abnormal splicing of the leptin receptor in diabetic mice.
Nature 379: 632-5.
Lee, Y., H. Hirose, M . Ohneda, J. H. Johnson, J. D. McGarry and R. H. Unger (1994).
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes
mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl
Acad Sci U S A 91: 10878-82.
Lee, Y., X. Yu, F. Gonzales, D. J. Mangelsdorf, M . Y. Wang, C. Richardson, L. A.
Witters and R. H. Unger (2002). P P A R a is necessary for the lipopenic action of
hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A 9 9 :
11848-53.
Legradi, G., C. H. Emerson, R. S. Ahima, J. S. Flier and R. M . Lechan (1997). Leptin
prevents fasting-induced suppression of prothyrotropin-releasing hormone
messengerribonucleicacid in neurons of the hypothalamic paraventricular
nucleus. Endocrinology 138: 2569-76.
Leibel, R. L., M . Rosenbaum and J. Hirsch (1995). Changes in energy expenditure
resulting from altered body weight. N e w Eng. J. Med. 332(10): 621-8.
Levin, N., C. Nelson, A. Gurney, R. Vandlen and F. de Sauvage (1996). Decreased food
intake does not completely account for adiposity reduction after ob protein
infusion. Proc. Natl. Acad. Sci. USA 93: 1726-30.
Levine, J. A., N . L. Eberhardt and M . D. Jensen (1999). Role of nonexercise activity
thermogenesis in resistance to fat gain in humans. Science 283: 212-4.
Lew, E. A. (1985). Mortality and weight: insured lives and the American Cancer Society
studies. Ann Intern M e d 103: 1024-9.
Li, C. and J. M . Friedman (1998). Leptin receptor activation of SHP-2 modulates Ob-R
signal transduction. In press, Proc. Natl. Acad. Sci., USA.
Li, C , E. Ioffe, N . Fidahusein, E. Connolly and J. M . Friedman (1998). Absence of
soluable leptin receptor in plasma from db^/dfr*5 and other db/db mice. Journal of
Biological Chemistry 273: 10078-82.

162

Liang, C.-P. and A. R. Tall (2001). Transcriptional profiling reveals global defects in
energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal
by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276: 49066-76.
Lieber, C. S., N. Spritz and L. M . DeCarli (1966). Role of dietary, adipose, and
endogenously synthesized fatty acids in the pathogenesis of the alcoholic fatty
liver. J Clin. Invest. 45: 51-62.
Liu, L., G. Karkanias, J. Morales, M . Hawkins, N. Barzilai, J. W a n g and L. Rossetti
(1998). Intracerebroventricular leptin regulates hepatic but not peripheral glucose
fluxes. J. Biol. Chem. 273: 31160-7.
Livak, K. J., S. J. Flood, J. Marmaro, W . Giusti and K. Deetz (1995). Oligonucleotides
with fluorescent dyes at opposite ends provide a quenched probe system for
detecting P C R products and nucleic acid hybridization. P C R Methods Appl 4(6):
357-62.
Lockhart, D. J. and E. A. Winzeler (2000). Genomics, gene expression and D N A arrays.
Nature 405: 827-36.
Loftus, T., D. Jaworsky, G. Frehywot, C. Townsend, G. Ronnett, M . Lane and F.
Kuhajda (2000). Reduced food intake and body weight in mice treated with fatty
acid synthase inhibitors. Science 288: 2379-81.
Lord, G. (1998). Leptin modulates the T-cell immune response and reverses starvation
induced immunosuppression. Nature 394: 897-1.
Lota, L. (2002). L.A. school board bans soda sales. Associated Press.
Lowell, B. B., V. S-Susulic, A. Hamann, J. A. Lawitts, J. Himms-Hagen, B. B. Boyers, L.
P. Kozak and J. S. Flier (1993). Development of obesity in transgenic mice after
genetic ablation of brown adipose tissue. Nature 366: 740-3.
Lowell, B. B. and B. M . Spiegelman (2000). Towards a molecular understanding of
adaptive thermogenesis. Nature 404: 652-60.
Lu, D., D. Willard, I. R. Patel, S. Kadwell, L. Overton, T. Kost, M . Luther, W . Chen, R.
P. Woychik, W . O. Wilkison and R. D. Cone (1994). Agouti protein is an
antagonist of the melanocyte-stimulating-hormone receptor. Nature 371: 799-802.
Ludwig, E. H., R. W . Mahley, E. Palaoglu, S. Ozbayrakci, M . E. Balestra, I. B. Borecki,
T. L. Innerarity and R. V. J. Farese (2002). D G A T 1 promoter polymorphism
associated with alterations in body mass index, high density lipoprotein levels and
blood pressure in Turkish women. Clin Genet 62: 68-73.
Lunzer, M . A., J. A. Manning and R. K. Ockner (1977). Inhibition of rat liver acetyl
coenzyme A carboxylase by long chain acyl coenzyme A and fatty acid. J Biol
Chem 252: 5483-7.
M a , K., A. Cabrero, P. K. Saha, H. Kojima, L. Li, B. H. Chang, A. Paul and L. Chan
(2002). Increased beta-oxidation but no insulin resistance or glucose intolerance
in mice lacking adiponectin. J Biol Chem epub ahead of print.
Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M . Matsuda, H. Nagaretani, N.
Furuyama, H. Kondo, M . Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara,
Y. Tochino, K. Okutomi, M . Horie, S. Takeda, T. Aoyama, T. Funahashi and Y.
Matsuzawa (2002). Diet-induced insulin resistance in mice lacking
adiponectin/ACRP30.j/VafAfe/8: 731-7.
Maes, H. H., M . C. Neale and L. J. Eaves (1997). Genetic and environmental factors in
relative body weight and human adiposity. Behav. Genet. 27: 325-51.

163

Maffei, M., H. Fei, G. W . Lee, C. Dani, P. Leroy, Y. Zhang, R. Proenca, R. Negrel, G.
Ailhaud and J. M . Friedman (1995a). Increased expression in adipocytes of ob
R N A in mice with lesions of the hypothalamus and with mutations at the db
locus. Proc. Natl. Acad. Sci. USA 92: 6957-60.
Maffei, M., J. Halaas, E. Ravussin, R. E. Pratley, G. H. Lee, Y. Zhang, H. Fei, S. Kim, R.
Lallone, S. Ranganathan, P. A. Kern and J. M . Friedman (1995b). Leptin levels in
human and rodent: Measurement of plasma leptin and ob R N A in obese and
weight-reduced subjects. Nature Medicine 1(11): 1155-61.
Maffei, M., M . Stoffel, M . Barone, B. Moon, M . Dammerman, E. Ravussin, C. Bogardus,
D. S. Ludwig, J. S. Flier, M . Talley, S. Auerbach and J. M . Friedman (1996).
Absence of mutations in the human ob gene in obese/diabetic subjects. Diabetes
45: 679-82.
Manson, J. E., W . C. Willett, M . J. Stampfer, G. A. Colditz, D. J. Hunter, S. E.
Hankinson, C. H. Hannekens and F. E. Speizer (1995). Body weight and mortality
among women. N Engl J M e d 333: 677-85.
Mantzoros, C , J. S. Flier, M . D. Lesem, T. D. Breweton and D. C. Jimerson (1997).
Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status
and potential role in resistance to weight gain. Journal of Clinical Endocrinology
& Metabolism 82: 1845-51.
Mantzoros, C. S., D. Qu, R. C. Frederich, V. S. Susulic, B. B. Lowell, E. Maratos-Flier
and J. S. Flier (1996). Activation of beta(3) adrenergic receptors suppresses leptin
expression and mediates a leptin-independent inhibition of food intake in mice.
Diabetes 45(7): 909-14.
Marsh, D. J., G. Hollopeter, D. Huszar, R. Laufer, K. A. Yagaloff, S. L. Fisher, P. Burn
and R. D. Palmiter (1999). Response of melanocortin-4 receptor-deficient mice to
anorectic and orexigenic peptides. Nat Genet 21: 119-22.
Masuzaki, H., Y. Ogawa, N . Sagawa, K. Hosoda, T. Matsumoto, H. Mise, H. Nishimura,
Y. Yoshimasa, I. Tanaka, T. Mori and K. Nakao (1997). Nonadipose tissue
production of leptin: leptin as a novel
placenta-derived hormone in humans. Nature Medicine. 3: 1029-33.
Masuzaki, H., J. Paterson, H. Shinyama, N . M . Morton, J. J. Mullins, J. R. Seckl and J. S.
Flier (2001). A transgenic model of visceral obesity and the metabolic syndrome.
Science 294: 2166-70.
McCullough, A. J. (2002). Update on nonalcoholic fatty liver disease. J Clin
Gastroenterol 34: 255-62.
McGarry, J. D. (1992). What if Minkowski had been ageusic? ..An alternative angle on
diabetes. Science 258: 766-70.
McGarry, J. D., G. P. Mannaerts and D. W . Foster (1977). A possible role for malonyl
C o A in regulation of hepatic fatty acid oxidation and ketogenesis. J. Clin. Invest.
60: 265-70.
McKnight, G. S., D. E. Cummings, P. S. Amieux, M . A. Sikorski, E. P. Brandon, J. V.
Planas, K. Motamed and R. L. Idzerda (1998). Cyclic A M P , P K A , and the
physiological regulation of adiposity. Recent Prog. Horm. Res. 53: 139-61.
McPherron, A. C , A. M . Lawler and S. J. Lee (1997). Regulation of skeletal muscle mass
in mice by a new TGF-beta superfamily member. Nature 387: 83-90.

164

McPherron, A. C. and S. J. Lee (1997). Double muscling in cattle due to mutations in the
myostatin gene. Proc Natl Acad Sci U S A 9 4 : 12457-61.
McPherron, A. C. and S. J. Lee (2002). Suppression of body fat accumulation in
myostatin-deficientmiceA. Clin. Invest. 109: 595-601.
Menon, K. V., G. J. Gores and V. J. Shah (2001). Pathogenesis, diagnosis, and treatment
of alcoholic liver disease. M a y o Clin Proc 16: 1021-9.
Mercer, J. G., N. Hoggard, L. M . Williams, C. B. Lawrence, L. T. Hannah, P. J. Morgan
and P. Trayhurn (1996a). Coexpression of leptin receptor and preproneuropeptide
Y m R N A in arcuate nucleus of mouse hypothalamus. Journal of
Neuroendocrinology 8(10): 733-5.
Mercer, J. G., N . Hoggard, L. M . Williams, C. B. Lawrence, L. T. Hannah and P.
Trayhurn (1996b). Localization of leptin receptor m R N A and the long form splice
variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ
hybridization. F E B S Letters 387(2-3): 113-6.
Merkel, M., P. H. Weinstock, T. Chajek-Shaul, H. Radner, B. Yin, J. L. Breslow and I. J.
Goldberg (1998). Lipoprotein lipase expression exclusively in liver. Journal of
Clinical Investigation 102: 893-901.
Minokoshi, Y., M . S. Haque and T. Shimazu (1999). Microinjection of leptin into the
ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats.
Diabetes 48: 287-91.
Minokoshi, Y., Y.-B. Kim, O. D. Peroni, L. G. D. Fryer, C. Muller, D. Carling and B. B.
Kahn (2002). Leptin stimulates fatty acid oxidation by activation of A M P activated protein kinase. Nature 415: 339-43.
Miyazaki, M., Y.-C. Kim, M . P. Gray-Keller, A. D. Attie and J. M . Ntambi (2000). The
biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice
with a disruption of the gene for stearoyl-CoA desaturase I. J. Biological
Chemistry 275:30132-8.
Miyazaki, M., W . C. M a n and J. M . Ntambi (2001). Targeted disruption of stearoyl-CoA
desaturase 1 gene in mice causes atrophy of sebaceous and meibomian glands and
depletion of wax esters in the eyelid. J Nutrition 131: 2260-8.
Mohan, S. and D. J. Baylink (2002). IGF binding proteins are multifunctional and act via
IGF-dependent and IGF-independent mechanisms. J Endocrinol 175: 19-31.
Moitra, J., M . M . Mason, M . Olive, D. Krylov, O. Gavrilova, B. Marcus-Samuels, L.
Feigenbaum, E. Lee, T. Aoyama, M . Eckhaus, M . L. Reitman and C. Vinson
(1998). Life without white fat: a transgenic mouse. Genes Dev 12: 3168-81.
Montague, C. T., I. S. Farooqi, J. P. Whitehead, M . A. Soos, H. Rau, N . J. Wareham, C.
P. Sewter, J. E. Digby, S. N. M o h a m m e d , J. A. Hurst, C. H. Cheetham, A. R.
Earley, A. H. Barnett, J. B. Prins and S. O'Rahilly (1997). Congenital leptin
deficiency is associated with severe early-onset obesity in humans. Nature 387:
903-8.
M o o n , B. C. and J. M . Friedman (1997). The molecular basis of the obese mutation in
ob2J mice. Genomics 42: 152-6.
Morton, N . M., V. Emilsson, Y. L. Liu and M . A. Cawthorne (1998). Leptin action in
intestinal cells. J Biol Chem 273(40): 26194-201.

165

Muramatsu, M., K. Kuriyama, T. Yuki and S. O h k u m a (1981). Hepatic lipogenesis and
mobilization of peripheral fats in the formation of alcoholic fatty liver. Jpn J
Pharmacol 31: 931-40.
Murata, Y., K. Robertson, M . Jones and E. Simpson (2002). Effect of estrogen deficiency
in the male: the A r K O mouse model. M o l Cell Endocrinol 193: 7.
Myers, A. and J. C. Rosen (1999). Obesity stigmatization and coping: relation to mental
health symptoms, body image, and self-esteem. Int J Obes Relat Metab Disord
23: 221-30.
Nadler, S. T., J. P. Stoehr, K. L. Schueler, G. Tanimoto, B. S. Yandell and A. D. Artie
(2000). The expression of adipogenic genes is decreased in obesity and diabetes
mellitus. Proc Natl Acad Sci U S A 97: 11371-6.
Naeser, P. (1973). Effects of adrenalectomy on the obese-hyperglycemic syndrome in
mice (gene symbol ob). Diabetologia 9: 376-9.
Nakazato, M., N . Murakami, Y. Date, M . Kojima, H. Matsuo, K. Kangawa and S.
Matsukura (2001). A role for ghrelin in the central regulation of feeding. Nature
409: 194-8.
N a m , S. Y., E. J. Lee, K. R. Kim, B. S. Cha, Y. D. Song, S. K. Lim, H. C. Lee and K. B.
H u h (1997). Effect of obesity on total andfreeinsulin-like growth factor (IGF)-l,
and their relationship to IGF-binding protein (BP)-l, IGFBP-2, IGFBP-3, insulin,
and growth hormone. Int J Obes Relat Metab Disord 21: 355-9.
Neel, J. V. (1999). The "thrifty genotype" in 1998. Nutr Rev 57: S2-S9.
Neschen, S., I. Moore, W . Regittnig, C. L. Yu, Y. Wang, M . Pypaert, K. Falk Petersen
and G. I. Shulman (2002). Contrasting effects offishoil and safflower oil on
hepatic peroxisomal and tissue lipid content. A m J Physiol Endocrinol Metab 282:
E395-E401.
Nikawa, J., T. Tanabe, H. Ogiwara, T. Shiba and S. N u m a (1979). Inhibitory effects of
long-chain acyl coenzyme A analogues on rat liver acetyl coenzyme A
carboxylase. F E B S 102: 223-6.
Niswender, K. D., G. J. Morton, W . H. Stearns, C. J. Rhodes, M . G. Myers and M . W .
Schwartz (2001). Intracellular signalling. Key enzyme in leptin-induced anorexia.
Nature 413: 794-5.
Ntambi, J., S. Buhrow, K. Kaestner, R. Christy, E. Sibley, T. Kelly Jr. and M . Lane
(1988). Differentiation-induced gene expression in 3T3-L1 preadipocytes.
Characterization of a differentially expressed gene encoding stearoyl-Co A
desaturase. J. Biological Chemistry 263: 17291-300.
Ntambi, J. M . (1995). The regulation of stearoyl-CoA desaturase (SCD). Prog. Lipid Res.
34: 139-50.
Ntambi, J. M . (1999). Regulation of stearoyl-CoA desaturase by polyunsaturated fatty
acids and cholesterol. J Lipid Research 40: 1549-58.
Ntambi, J. M . and H. Bene (2001). Polyunsaturated fatty acid regulation of gene
expression. J M o l Neurosci 16: 273-8.
Ntambi, J. M., M . Miyazaki, J. P. Stoehr, H. Lan, C. M . Kenziorski, B. S. Yandell, Y.
Song, P. Cohen, J. Friedman and A. D. Artie (2002). Loss of stearoyl-CoA
desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A
99: 11482-6.

166

O'Gorman, S., N. A. Dagenais, M . Qian and Y. Marchuk (1997). Protamine-cre
recombinase transgenes efficiently recombine target sequences in the male germ
line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. USA 94:
14602-7.
O'Rourke, L., S. J. Yeaman and P. R. Shepherd (2001). Insulin and leptin acutely regulate
cholesterol ester metabolism in macrophages by novel signaling pathways.
Diabetes 50(5): 955-61.
Obici, S., Z. Feng, G. Karkanias, D. G. Baskin and L. Rossetti (2002). Decreasing
hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats.
Nat Neurosci 5: 566-72.
Ogawa, Y., H. Masuzaki, K. Hosoda, M . Aizawa-Abe, J. Suga, M . Suda, K. Ebihara, H.
Iwai, N . Matsuoka, N . Satoh, H. Odaka, H. Kasuga, Y. Fujisawa, G. Inoue, H.
Nishimura, Y. Yoshimasa and K. Nakao (1999). Increased glucose metabolism
and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes
48: 1822-9.
Oliff, A., D. Defeo-Jones, M . Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe and
S. H. Socher (1987). Tumors secreting human TNF/cachectin induce cachexia in
mice. Cell 50: 555-63.
Ollmann, M . M., B. D. Wilson, Y. Yang, J. A. Kerns, Y. Chen, I. Gantz and G. S. Barsh
(1997). Antagonism of central melanocortin receptors in vitro and in vivo by
agouti-related protein. Science 278: 135-8.
Oral, E. A., V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A. J. Wagner, A.
M . DePaoli, M . L. Reitman, S. I. Taylor, P. Gordon and A. Garg (2002). Leptinreplacement therapy for lipodystrophy. N e w England Journal ofMedicine 346:
570-8.
Organization, W . H. (1997). Obesity: Preventing and Managing the Global Epidemic.
Geneva, World Health Organization.
Pelleymounter, M . A., M . J. Cullen, M . B. Baker, R. Hecht, D. Winters, T. Boone and F.
Collins (1995). Effects of the obese gene product on body weight regulation in
ob/ob mice. Science 269: 540-3.
Pessayre, D., A. Mansouri and B. Fromenty (2002). Nonalcoholic steatosis and
steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. A m J Physiol
Gastrointest Liver Physiol 282: G193-G9.
Petersen, K. F., E. A. Oral, S. Dufour, D. Befroy, C. Ariyan, C. Yu, G. W . Cline, A. M .
DePaoli, S. I. Taylor, P. Gorden and G. I. Shulman (2002). Leptin reverses insulin
resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin.
Invest. 109: 1345-50.
Philips, M . S., Q. Liu, H. A. H a m m o n d , V. Dugan, P. J. Hey, C. T. Caskey and J. F. Hess
(1996). Leptin receptor missense mutation in the fatty Zucker rat. Nature Genetics
13: 18-9.
Pinkert, C. A., D. M . Ornitz, R. L. Brinster and R. D. Palmiter (1987). A n albumin
enhancer located 10 kb upstream functions along with its promoter to direct
efficient, liver-specific expression in transgenic mice. Genes Dev. 1: 268-76.
Pintar, J. E., A. Schuller, J. A. Cerro, M . Czick, A. Grewal and B. Green (1995). Genetic
ablation of IGFBP-2 suggests functional redundancy in the IGFBP family. Prog
Growth Factor Res 6: 437-45.

167

Popkin, B. M . (1994). The nutrition transition in low-income countries: an emerging
crisis. Nutr Rev 52: 285-98.
Popkin, B. M . and J. R. Udry (1998). Adolescent obesity increases significantly in second
and third generation U.S. immigrants: the National Longitudinal Study of
Adolescent Health. J Nutr 128: 701-6.
Powley, T. L. and R. E. Keesey (1970). Relationship of body weight to the lateral
hypothalamic feeding syndrome. J C o m p Physiol Psychol 70: 25-36.
Project, W . H. O. M . (1988). Geographical variation in the majorriskfactors of coronary
heart disease in m e n and w o m e n aged 35-64 years. World Health Stat Quart 41:
115-40.
Puhl, R. and K. D. Brownell (2001). Bias, discrimination, and obesity. Obes Res 9: 788805.
Puigserver, P., Z. W u , C. W . Park, R. Graves, M . Wright and B. M . Spiegleman (1998).
A cold-inducible coactivator of nuclear receptors linked to adaptive
thermogenesis. Ce//92: 829-39.
Qu, D., D. S. Ludwig, S. Gammeltoft, M . Piper, M . A. Pelleymounter, M . J. Cullen, W .
F. Mathes, R. Przypek, R. Kanarek and E. Maratos-Flier (1996). A role for
melanin-concentrating hormone in the central regulation of feeding behavior.
Nature 380: 243-7.
Ranke, M . B. and M . Elmlinger (1997). Functional role of insulin-like growth factor
binding proteins. H o r m Res 48 Suppl 4: 9-15.
Ravussin, E., S. Lillioja, W . C. Knowler, P. H. Dr., L. Christin, D. Freymond, W . G. H.
Abbott, V. Boyce, B. Howard and C. Bogardus (1988). Reduced rate of energy
expenditure as ariskfactor for body-weight gain. N. Eng. J. Med. 318(8): 467-72.
Ravussin, E., R. E. Pratley, M . Maffei, H. Wang, J. M . Friedman, P. H. Bennett and C.
Bogardus (1997). Relatively low plasma leptin concentrations precede weight
gain in Pima Indians. Nature Medicine 3(2): 238-40.
Reaves, J. (2002). A Lawsuit to Choke on. Time.com.
Reitman, M . L. (2002). Metabolic lessons from genetically lean mice. Ann Rev Nutr 22:
459-82.
Reitman, M . L., E. Arioglu, O. Gavrilova and S. I. Taylor (2000). Lipoatrophy revisited.
Trends Endocrinol Metab 11: 410-6.
Renz, M., E. Tomlinson, B. Hultgren, N. Levin, Q. Gu, R. A. Shimkets, D. A. Lewin and
T. A. Stewart (2000). Quantitative expression analysis of genes regulated by both
obesity and leptin reveals a regulatory loop between leptin and pituitary-derived
A C T H . J Biol Chem 275: 10429-36.
Rissanen, A. M., M . Heliovaara, P. Knekt, A. Reunanen and A. Aromaa (1991).
Determinants of weight gain and overweight in adult Finns. Eur J Clin Nutr 45:
419-30.
Robinson, T. N. (2001). Television viewing and childhood obesity. Pediatr Clin North
A m 48: 1017-25.
Roitman, A., S. Bruchis, B. Bauman, H. Kaufman and Z. Laron (1984). Total deficiency
of corticosteroid-binding globulin. Clin Endocrinol (Oxf) 21: 541-8.
Rosenbaum, M., E. M . Murphy, S. B. Heymsfield, D. E. Matthews and R. L. Leibel
(2002). L o w dose leptin administration reverses effects of sustained weight-

168

reduction on energy expenditure and circulating concentrations of thyroid
hormones. J Clin Endocrinol Metab 87: 2391-4.
Rossetti, L., D. Massillon, N . Barzilai, P. Vuguin, W . Chen, M . Hawkins, J. W u and J.
W a n g (1997). Short term effects of leptin on hepatic gluconeogenesis and in vivo
insulin action. J. Biol. Chem. 272: 27758-63.
Ruderman, N . B., A. K. Saha, D. V a w a s and L. A. Witters (1999). Malonyl-CoA, fuel
sensing, and insulin resistance. A m J Physiol 276: E1-E18.
Rudman, D., A. G. Feller, H. S. Nagraj, G. A. Gergans, P. Y. Lalitha, A. F. Goldberg, R.
A. Schlenker, L. Cohn, I. W . Rudman and D. E. Mattson (1990). Effects of
human growth hormone in m e n over 60 years old. N Engl J M e d 323: 1-6.
Rudman, D., M . H. Kutner, C. M . Rogers, M . F. Lubin, G. A. Fleming and R. P. Bain
(1981). Impaired growth hormone secretion in the adult population: relation to
age and adiposity. J. Clin. Invest. 67: 1361-9.
Saladin, R., P. D e Vos, M . Guerre-Millo, A. Leturque, J. Girard, B. Staels and J. Auwerx
(1995). Transient increase in obese gene expression after food intake or insulin
administration. Nature 377: 527-9.
Sambrook, J., E. F. Fritsch and T. Maniatis (1989). Molecular Cloning: A Laboratory
Manual. Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press.
Satoh, N., Y. Ogawa, G. Katsuura, T. Tsuji, H. Masuzaki, J. Hiraoka, T. Okazaki, M .
Tamaki, M . Hayase, Y. Yoshimasa, S. Nishi, K. Hosoda and K. Nakao (1997).
Pathophysiological significance of the obese gene product, leptin, in ventromedial
hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in
VMH-lesioned rats. Endocrinology 138(3): 947-54.
Scacchi, M., A. I. Pincelli and F. Cavagnini (1999). Growth hormone in obesity. Int J
Obes Relat Metab Disord 23: 260-71.
Scarpace, P. J. and M . Matheny (1998). Leptin induction of U C P 1 gene expression is
dependent on sympathetic innervation. A m J Physiol 275(2 Pt 1): E259-64.
Scarpace, P. J., M . Matheny, B. H. Pollock and N. Turner (1997). Leptin increases
uncoupling protein expression and energy expenditure. A m J Physiol 273: E226E30.
Scherer, P. E., S. Williams, M . Fogliano, G. Baldini and H. F. Lodish (1995). A novel
serum protein similar to Clq, produced exclusively in adipocytes. /. Biol. Chem.
270(45): 26746-9.
Schneider, M . R., H. Lahm, M . W u , A. Hoeflich and E. Wolf (2000). Transgenic mouse
models for studying the functions of insulin-like growth factor-binding proteins.
F A S E B J14: 629-40.
Schrem, H., J. Klempnauer and J. Borlak (2002). Liver-enriched transcription factors in
liver function and development. Part I: the hepatocyte nuclear factor network and
liver-specific gene expression. Pharmacol Rev 54: 129-58.
Schreyer, S. A., S. C. J. Chua and R. C. LeBoeuf (1998). Obesity and diabetes in TNFalpha receptor- deficient mice. A Clin. Invest. 102: 402-11.
Schuller, A. G., C. Groffen, J. W . van Neck, E. C. Zwarthoff and S. L. Drop (1994).
c D N A cloning and m R N A expression of the six mouse insulin-like growth factor
binding proteins. M o l Cell Endocrinol 104: 57-66.

169

Schwartz, M . W., E. Peskind, M . Raskind, E. J. Boyko and D. Porte, Jr. (1996).
Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in
humans. Nature Medicine 2: 589-93.
Schwartz, M . W., R. J. Seeley, S. C. Woods, D. S. Weigle, L. A. Campfield, P. Burn and
D. G. Baskin (1997). Leptin increases hypothalamic pro-opiomelanocortin m R N A
expression in the rostral arcuate nucleus. Diabetes 46(12): 2119-23.
Schwartz, M . W., S. C. Woods, D. Porte, R. J. Seeley and D. G. Baskin (2000). Central
nervous system control of food intake. Nature 404: 661-71.
Serdula, M . K., A. H. Mokdad, D. F. Williamson, D. A. Galuska, J. M . Mendlein and G.
W . Heath (1999). Prevalence of attempting weight loss and strategies for
controlling weight. J A M A 282: 1353-8.
Seufert, J., T. J. Kieffer and J. F. Habener (1999a). Leptin inhibits insulin gene
transcription and reverses hyperinsulinemia in leptin-deficient ob/ob islets. Proc
Natl Acad Sci U S A 9 6 : 674-9.
Seufert, J., T. J. Kieffer, C. A. Leech, G. G. Holz, W . Moritz, C. Ricordi and J. F.
Habener (1999b). Leptin suppression of insulin secretion and gene expression in
human pancreatic islets: implications for the development of adipogenic diabetes
mellitus. J Clin Endocrinol Metab 84: 670-6.
Shibata, H. and L. J. Bukowiecki (1987). Regulatory alterations of daily energy
expenditure induced by fasting or overfeeding in unrestrained rats. J Appl Physiol
63: 465-70.
Shimabukuro, M., M . Higa, Y.-T. Zhou, M.-Y. Wang, C. B. Newgard and R. H. Unger
(1998a). Lipoapoptosis in cells of obese prediabetic fa/fa rats. Role of serine
palmitoyltransferase overexpression. J. Biol. Chem 273: 32487-90.
Shimabukuro, M., K. Koyama, G. X. Chen, M . Y. Wang, F. Trieu, Y. Lee, C. B.
Newgard and R. H. Unger (1997a). Direct antidiabetic effect of leptin through
triglyceride depletion of tissues. Proc. Natl. Acad. Sci. USA 94(9): 4637-41.
Shimabukuro, M., M . Ohneda, Y. Lee and R. H. Unger (1997b). Role of nitric oxide in
obesity-induced beta cell disease. J- Clin. Invest. 100: 290-5.
Shimabukuro, M., M . Y. Wang, Y. T. Zhou, C. B. Newgard and R. H. Unger (1998b).
Protection against lipoapoptosis of beta cells through leptin-dependent
maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A 95: 9558-61.
Shimabukuro, M., Y. T. Zhou, M . Levi and R. H. Unger (1998c). Fatty acid-induced |3
cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 9 5 :
2498-502.
Shimano, H., J. D. Horton, R. E. Hammer, I. Shimomura, M . S. Brown and J. L.
Goldstein (1996). Overproduction of cholesterol and fatty acids causes massive
liver enlargement in transgenic mice expressing truncated SREBP-la. J. Clin.
Invest. 98: 1575-84.
Shimano, H., J. D. Horton, I. Shimomura, R. E. Hammer, M . S. Brown and J. L.
Goldstein (1997). Isoform lc of sterol regulatory element binding protein is less
active than isoform la in livers of transgenic mice and in cultured cells. J. Clin.
Invest. 99: 846-54.
Shimomura, I., Y. Bashmakov and J. D. Horton (1999a). Increased levels of nuclear
SREBP-lc associated with fatty livers in two mouse models of diabetes mellitus.
J Biol Chem 274(42): 30028-32.

170

Shimomura, I., Y. Bashmakov, S. Ikemoto, J. D. Horton, M . S. Brown and J. L.
Goldstein (1999b). Insulin selectively increases SREBP-lc m R N A in the livers of
rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 9 6 : 1365661.
Shimomura, I., R. Hammer, S. Ikemoto, M . Brown and J. Goldstein (1999c). Leptin
reverses insulin resistance and diabetes mellitus in mice with congenital
lipodystrophy. Nature 401: 73-6.
Shimomura, I., R. E. Hammer, J. A. Richardson, S. Ikemoto, Y. Bashmakov, J. L.
Goldstein and M . S. Brown (1998a). Insulin resistance and diabetes mellitus in
transgenic mice expressing nuclear SREBP-lc in adipose tissue: model for
congenital generalized lipodystrophy. Genes Dev 12: 3182-94.
Shimomura, I., M . Matsuda, R. E. Hammer, Y. Bashmakov, M . S. Brown and J. L.
Goldstein (2000). Decreased IRS-2 and increased SREBP-lc lead to mixed
insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice.
Molecular Cell 6: 77-86.
Shimomura, I., H. Shimano, B. S. Korn, Y. Bashmakov and J. D. Horton (1998b).
Nuclear sterol regulatory element-binding proteins activate genes responsible for
the entire program of unsaturated fatty acid biosynthesis in transgenic mouse
liver. J Biol Chem 273: 35299-306.
Shmulewitz, D., S. B. Auerbach, T. Lehner, M . Blundell, J. D. Winick, L. D. Youngman,
V. Skilling, S. C. Heath, J. Ott, M . Stoffel, J. L. Breslow and J. M . Friedman
(2001). Epidemiology and factor analysis of obesity, type II diabetes,
hypertension, and dyslipidemia (Syndrome X ) on the island of Kosrae, Federated
States of Micronesia. H u m a n Heredity 51: 8-19.
Shulman, G. I. (2000). Cellular mechanisms of insulin resistance. Journal of Clinical
Investigation 106: 171-6.
Shutter, J. R., M . Graham, A. C. Kinsey, S. Scully, R. Luthy and K. L. Stark (1997).
Hypothalmic expression of A R T , a novel gene related to agouti, is up-regulated in
obese and diabetic mutant mice. Genes & Development 11: 593-602.
Sierra-Honigmann, M., A. Nath, C. Murakami, G. Garcia-Cardena, A. Papapetropoulos,
W . Sessa, L. Madge, J. Scheduler, M . Schwabb, P. Polverini and J. FloresRiveros (1998). Biologic action of leptin as an angiogenic factor. Science 281:
1683-6.
Silverman, J. F., K. F. O'Brien, S. Long, N. Leggett, P. G. Khazanie, W . J. Pories, H. T.
Norris and J. F. Caro (1990). Liver pathology in morbidly obese patients with and
without diabetes. A m J Gastroenterol 85: 1349-55.
Sims, E. A. and A. Danforth (1987). Expenditure and storage of energy in man. J. Clin.
Invest. 79: 1019-25.
Sinha, R., G. Fisch, B. Teague, W . V. Tamborlane, B. Banyas, K. Allen, M . Savoye, V.
Rieger, S. Taksali, G. Barbetta, R. S. Sherwin and S. Caprio (2002). Prevalence of
impaired glucose tolerance among children and adolescents with marked obesity.
N Engl J M e d 346: 802-10.
Sipols, A. J., D. G. Baskin and M . W . Schwartz (1995). Effect of intracerebroventricular
insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide
expression. Diabetes 44: 147-51.

171

Smith, S. J., S. Cases, D. R. Jensen, H. C. Chen, E. Sande, B. Tow, D. A. Sanan, J. Raber,
R. H. Eckel and R. V. Farese Jr. (2000). Obesity resistance and multiple
mechanisms of triglyceride synthesis in mice lacking D G A T . Nature Genetics 25:
87-90.
Soukas, A., P. Cohen, N . D. Socci and J. M . Friedman (2000). Leptin-specific patterns of
gene expression in white adipose tissue. Genes Dev 14(8): 963-80.
Soukas, A., N. D. Socci, B. Saatkamp, S. Novelli and J. M . Friedman (2001). Distinct
transcriptional profiles of adipogenesis in vivo and in vitro. Journal of Biological
Chemistry 276: 34167-74.
Spiegelman, B. M . and J. S. Flier (2001). Obesity and the regulation of energy balance.
Cell 104(4): 531-43.
Stanley, B. G., S. E. Kyrkouli, S. Lampert and S. F. Leibowitz (1986). Neuropeptide Y
chronically injected into the hypothalamus: a powerful neurochemical inducer of
hyperphagia and obesity. Peptides 7: 1189-92.
Stephens, T. W., M . Bashinski, P. K. Bristow, J. M . Bue-Valleskey, S. G. Burgett, H.
Hale, J. Hoffmann, H. M . Hsiung, A. Krauciunas, W . Mackellar, P. R. Rosteck,
B. Schoner, D. Smith, F. C. Tinsley, X. Y. Zhang and M . Heiman (1995). The
role of neuropeptide Y in the antiobesity action of the obese gene product. Nature
377: 530-4.
Steppan, C. M., S. T. Bailey, S. Bhat, E. J. Brown, R. R. Banerjee, C. M . Wright, H. R.
Patel, R. S. Ahima and M . A. Lazar (2001). The hormone resistin links obesity to
diabetes. Nature 409: 307-12.
Strobel, A., T. I. L. Camoin, M . Ozata and A. D. Strosberg (1998). A leptin missense
mutation associated with hypogonadism and morbid obesity. Nature Genetics 18:
213-5.
Stunkard, A. J., J. R. Harris, N . L. Pedersen and G. E. McClearn (1990). The body-mass
index of twins w h o have been reared apart. N. Engl. J. Med. 322: 1483-7.
Sui, D. and J. E. Wilson (2000). Interaction of insulin-like growth factor binding protein4, Miz-1, leptin, lipocalin-type prostaglandin D synthase, and granulin precursor
with the N-terminal half of type III hexokinase. Arch Biochem Biophys 382: 26274.
Sum, F. W., A. Gilbert, A. M . Venkatesan, K. Lim, V. W o n g , M . O'Dell., G. Francisco,
Z. Chen, G. Grosu, J. Baker, J. Ellingboe, M . Malamas, I. Gunawan, J. Primeau,
E. Largis and K. Steiner (1999). Prodrugs of CL316243: a selective beta3adrenergic receptor agonist for treating obesity and diabetes. Bioorg M e d Chem
Let 9: 1921-6.
Susulic, V. S., R. C. Frederich, J. Lawitts, E. Tozzo, B. B. Kahn, M . E. Harper, J.
Himms-Hagen, J. S. Flier and B. B. Lowell (1995). Targeted disruption of the
beta 3-adrenergic receptor gene. J Biol Chem 270: 29483-92.
Tannenbaum, G. S., W . Gurd and M . Lapointe (1998). Leptin is a potent stimulator of
spontaneous pulsatile growth hormone ( G H ) secretion and the G H response to
GH-releasing hormone. Endocrinology 139: 3871-5.
Tannenbaum, G. S., M . Lapointe, W . Gurd and J. A. Finkelstein (1990). Mechanisms of
impaired growth hormone secretion in genetically obese Zucker rats: roles of
growth hormone-releasing factor and somatostatin. Endocrinology 127: 3087-95.

172

Tartaglia, L. A., M . Dembski, X. Weng, N. Deng, J. Culpepper, R. Devos, G. J. Richards,
L. A. Campfield, F. T. Clark, J. Deeds, C. Muir, S. Sanker, A. Moriarty, K. J.
Moore, J. S. Smutko, G. G. Mays, E. A. Woolf, C. A. Monroe and R. I. Tepper
(1995). Identification and expression cloning of a leptin receptor, OB-R. Cell 83:
1263-71.
Taubes, G. (1998). A s obesity rates rise, experts struggle to explain why. Science 280:
1367-8.
Thornton, J. E., C. C. Cheung, D. K. Clifton and R. A. Steiner (1997). Regulation of
hypothalamic proopiomelanocortin m R N A by leptin in ob/ob mice.
Endocrinology 138(11): 5063-6.
Thupari, J. N., L. E. Landree, G. V. Ronnett and F. P. Kuhajda (2002). C75 increases
peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc
Natl Acad Sci U S A 99(9498-9502).
Trayhurn, P. and J. H. Beattie (2001). Physiological role of adipose tissue: white adipose
tissue as an endocrine and secretory organ. Proc Nutr Soc 60: 329-39.
Troiano, R. P., K. M . Flegal, R. J. Kuczmarski, S. M . Campbell and C. L. Johnson
(1995). Overweight prevalence and trends for children and adolescents. The
National Health and Nutrition Examination Surveys, 1963 to 1991. Arch Pediatr
Adolesc M e d 149: 1085-91.
Tschop, M., D. L. Smiley and M . L. Heiman (2000). Ghrelin induces adiposity in
rodents. Nature 407: 908-13.
Tseng, L. Y., G. T. Ooi, A. L. Brown, D. S. Straus and M . M . Rechler (1992).
Transcription of the insulin-like growth factor-binding protein-2 gene is increased
in neonatal and fasted adult rat liver. M o l Endocrinol 6: 1195-201.
Tsukamoto, H., G. Lew, E. C. Larkin, C. Largman and G. A. Rao (1984). Hepatic origin
of triglycerides in fatty livers produced by the continuous intragastric infusion of
an ethanol diet. Lipids 19: 419-22.
Ueda, H. R., W . Chen, A. Adachi, H. Wakamatsu, S. Hayashi, T. Takasugi, M . Nagano,
K. Nakahama, Y. Suzuki, S. Sugano, M . lino, Y. Shigeyoshi and S. Hashimoto
(2002). A transcription factor response element for gene expression during
circadian night. Nature 418: 534-9.
Unger, R. H. (2002). Lipotoxic diseases. Annu Rev M e d 53: 319-36.
Uyeda, K., H. Yamashita and T. Kawaguchi (2002). Carbohydrate responsive elementbinding protein (ChREBP): a key regulator of glucose metabolism and fat storage.
Biochem Pharmacol 63: 2075-80.
Uysal, K. T., S. M . Wiesbrock, M . W . Marino and G. S. Hotamisligil (1997). Protection
from obesity-induced insulin resistance in mice lacking TNF-alpha function.
Nature 389: 610-4.
Vaisse, C , K. Clement, B. Guy-Grand and P. Froguel (1998). A frameshift mutation in
human M C 4 R is associated with a dominant form of obesity. Nat. Genet. 20: 1134.
Vaisse C , J. L. Halaas, C. M . Horvath, J. E. Darnell, Jr., M . Stoffel and J. M . Friedman
(1996). Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob
mice but not db/db mice. Nature Genetics 14(1): 95-7.
V a n Heek, M., D. S. Compton, C. F. France, R. P. Tedesco, A. B. Fawzi, M . P. Graziano,
E. J. Sybertz, C. D. Strader and H. R. Davis, Jr. (1997). Diet-induced obese mice

173

develop peripheral, but not central, resistance to leptin. Journal of Clinical
Investigation 99(3): 385-90.
Ventre, J., T. Doebber, M . W u , K. MacNaul, K. Stevens, M . Pasparakis, G. Kollias and
D. E. Moller (1997). Targeted disruption of the tumor necrosis factor-alpha gene:
metabolic consequences in obese and nonobese mice. Diabetes 46: 1526-31.
Vicent, D., M . Piper, S. Gammeltoft, E. Maratos-Flier and C. R. Kahn (1998). Alterations
in skeletal muscle gene expression of ob/ob mice by m R N A differential display.
Diabetes 47: 1451-8.
Vidal-Puig, A., G. Solanes, D. Grujic, J. S. Flier and B. B. Lowell (1997). U C P 3 : an
uncoupling protein homologue expressed preferentially and abundantly in skeletal
muscle and brown adipose tissue. Biochem Biophys Res C o m m u n 235: 79-82.
Volpe, J. J. and P. R. Vagelos (1976). Mechanisms and regulation of biosynthesis of
saturated fatty acids. Physiol Rev 56: 339-417.
W a n g , J. (1998). A nutrient-sensing pathway regulates leptin gene expression in muscle
and fat. Nature 393: 384-8.
Wanless, I. R. and J. S. Lentz (1990). Fatty liver hepatitis (steatohepatitis) and obesity: an
autopsy study with analysis ofriskfactors. Hepatology 12: 1106-10.
Watabiki, T., Y. Okii, T. Tokiyasu, S. Yoshimura, M . Yoshida, A. Akane, N. Shikata and
A. Tsubura (2000). Long-term ethanol consumption in ICR mice causes
m a m m a r y tumor in females and liver fibrosis in males. Alcohol Clin Exp Res 24:
117S-22S.
Weibel, E. R., W . Staubli, H. R. Gangi and F. A. Hess (1969). Correlated morphometric
and biochemical studies on the liver cell. I. Morphometric model, stereologic
methods, and normal morphometric data for rat liver. J Cell Biol 42: 68-91.
Weigle, D. S. (1994). Appetite and the regulation of body composition. F A S E B J S : 30210.
Weinstock, P. H., S. Levak-Frank, L. C. Hudgins, H. Radner, J. M . Friedman, R. Zechner
and J. L. Breslow (1997). Lipoprotein lipase controls fatty acid entry into adipose
tissue, but fat mass is preserved by endogenous synthesis in mice deficient in
adipose tissue lipoprotein lipase. Proc. Natl. Acad. Sci. USA 94: 10260-6.
West, D. B., C. N . Boozer, D. L. M o o d y and R. L. Atkinson (1992). Obesity induced by a
high fat diet in nine strains of inbred mice. Am. J. Physiol. 262: R1025-R32.
Weyer, C , T. Funahashi, S. Tanaka, K. Hotta, Y. Matsuzawa, R. E. Pratley and P. A.
Tataranni (2001). Hypoadiponectinemia in obesity and type 2 diabetes: close
association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab
86: 1930-5.
Wickelgren, I. (1998). Obesity: h o w big a problem? Science 280: 1364-7.
Willett, W . C , W . H. Dietz and G. A. Colditz (1999). Guidelines for healthy weight. N
Engl J M e d 341: 427-34.
W o o d , T. L., L. Rogler, R. D. Streck, J. Cerro, B. Green, A. Grewal and J. E. Pintar
(1993). Targeted disruption of IGFBP-2 gene. Growth Regul 3: 5-8.
W o o d , T. L., L. E. Rogler, M . E. Czick, A. G. Schuller and J. E. Pintar (2000). Selective
alterations in organ sizes in mice with a targeted disruption of the insulin-like
growth factor binding protein-2 gene. Molecular Endocrinology 14: 1472-82.
W o o d , W . G. (1976). Ethanol preference in C57BL/6 and BALB/c mice at three ages and
eight ethanol concentrations. Exp Aging Res 2: 425-34.

174

Woods, A. J. and M . J. Stock (1996). Leptin activation in hypothalamus. Nature 381:
745.
Woods, S., E. Lotter, L. M c K a y and D. J. Porte (1979). Chronic intracerebroventricular
infusion of insulin reduces food intake and body weight of baboons. Nature 282:
503-5.
Wren, A. M., C. J. Small, C. R. Abbott, W . S. Dhillo, L. J. Seal, M . A. Cohen, R. L.
Batterham, S. Taheri, S. A. Stanley, M . A. Ghatei and S. R. Bloom (2001).
Ghrelin causes hyperphagia and obesity in rats. Diabetes 50: 2540-7.
Wren, A. M., C. J. Small, H. L. Ward, K. G. Murphy, C. L. Dakin, S. Taheri, A. R.
Kennedy, G. H. Roberts, D. G. Morgan, M . A. Ghatei and S. R. Bloom (2000).
The novel hypothalamic peptide ghrelin stimulates food intake and growth
hormone secretion. Endocrinology 141: 4325-8.
Yahagi, N., H. Shimano, A. H. Hasty, M . Amemiya-Kudo, H. Okazaki, Y. Tamura, Y.
Iizuka, F. Shionoiri, K. Ohashi, J. Osuga, K. Harada, T. Gotoda, R. Nagai, S.
Ishibashi and N. Yamada (1999). A crucial role of sterol regulatory elementbinding protein-1 in the regulation of lipogenic gene expression by
polyunsaturated fatty acids. J Biol Chem 274: 35840-4.
Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K.
Murakami, N . Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C.
Vinson, M . L. Reitman, H. Kagechika, K. Shudo, M . Yoda, Y. Nakano, K. Tobe,
R. Nagai, S. Kimura, M . Tomita, P. Froguel and T. Kadowaki (2001). The fatderived hormone adiponectin reverses insulin resistance associated with both
lipoatrophy and obesity. Nat M e d 7: 941-6.
Yang, S., H. Lin and A. M . Diehl (2001). Fatty liver vulnerability to endotoxin-induced
damage despite NF-kappaB induction and inhibited caspase 3 activation. A m J
Physiol Gastrointest Liver Physiol 281: G382-G92.
Yang, S. Q., H. Z. Lin, M . D. Lane, M . Clemens and A. M . Diehl (1997). Obesity
increases sensitivity to endotoxin liver injury: implications for the pathogenesis of
steatohepatitis. Proc Natl Acad Sci U S A 94: 2557-62.
Yanovski, S. Z. and J. A. Yanovski (2002). Obesity. N Engl J M e d 346: 591-602.
Yen, T. T., J. A. Allan, P.-L. Yu, M . A. Acton and D. V. Pearson (1976). Triacylglycerol
contents and in vivo lipogenesis of ob/ob, db/db, and A^/a mice. Biochimica et
Biophysica Acta 441: 213-20.
Yeo, G., I. Farooqi, S. Aminian, D. Halsall, R. Stanhope and S. O'Rahilly (1998). A
frameshift mutation in M C 4 R associated with dominatly inherited human obesity.
Nat. Genet. 20: 111-2.
Yoon, J. C , P. Puigserver, G. Chen, J. Donovan, Z. W u , J. Rhee, G. Adelmant, J.
Stafford, C. R. Kahn, D. K. Granner, C. B. Newgard and B. M . Spiegelman
(2001). Control of hepatic gluconeogenesis through the transcriptional coactivator
PGC-1. Nature 413: 131-8.
You, M., M . Fischer, M . A. Deeg and D. W . Crabb (2002). Ethanol Induces Fatty Acid
Synthesis Pathways by Activation of Sterol Regulatory Element-binding Protein
(SREBP). J Biol Chem 277: 29342-7.
Young, J. B. and L. Landsberg (1983). Diminished sympathetic nervous system activity
in genetically obese (ob/ob) mice. A m J Physiol 245: E148-E54.

175

Yu, A. S. and E. B. Keeffe (2002). Nonalcoholic fatty liver disease. Rev Gastroenterol
Disord 2: 11-9.
Y u , W . H., M . Kimura, A. Walczewska, S. Karanth and S. M . M c C a n n (1997). Role of
leptin in hypothalamic-pituitary function. Proc. Nat. Acad. Sci., USA 94(3): 10238.
Zabolotny, J. M., K. K. Bence-Hanulec, A. Stricker-Krongrad, F. Haj, Y. Wang, Y.
Minokoshi, Y. B. Kim, J. K. Elmquist, L. A. Tartaglia, B. B. Kahn and B. G. Neel
(2002). P T P 1 B regulates leptin signal transduction in vivo. Dev Cell 2: 489-95.
Zarjevski, N., I. Cusin, R. Vettor, F. Rohner-Jeanrenaud and B. Jeanrenaud (1993).
Chronic intracerebroventricular neuropeptide-Y administration to normal rats
mimics hormonal and metabolic changes of obesity. Endocrinology 133: 1753-8.
Zhang, W., H. Wang, S. W . Song and G. N. Fuller (2002). Insulin-like growth factor
binding protein 2: gene expression microarrays and the hypothesis-generation
paradigm. Brain Pathol 12: 87-94.
Zhang, Y., P. Proenca, M . Maffei, M . Barone, L. Leopold and J. M . Friedman (1994).
Positional cloning of the mouse obese gene and its human homologue. Nature
372: 425-32.
Zheng, Y., K. Eilertsen, L. Ge, L. Zhang, J. Sundberg, S. Prouty and P. S (1999). Scdl is
expressed in sebaceous glands and is disrupted in the asebia mouse. Nature
Genetics 23: 268-70.
Zhou, X., J. D e Schepper, D. D e Craemer, M . Delhase, G. Gys, J. Smitz and E. L.
Hooghe-Peters (1998a). Pituitary growth hormone release and gene expression in
cafetaria-diet-induced obese rats. J Endocrinol 159: 165-72.
Zhou, Y. T., M . Shimabukuro, K. Koyama, Y. Lee, M . Y. Wang, F. Trieu, C. B.
Newgard and R. H. Unger (1997). Induction by leptin of uncoupling protein-2 and
enzymes of fatty acid oxidation. Proc. Natl. Acad. Sci., USA 94: 6386-90.
Zhou, Y. T., M . Shimabukuro, M . Y. Wang, Y. Lee, M . Higa, J. L. Milburn, C. B.
Newgard and R. H. Unger (1998b). Role of peroxisome proliferator-activated
receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A 95:
8898-903.
Zhou, Y. T., Z. W . Wang, M . Higa, C. B. Newgard and R. H. Unger (1999). Reversing
adipocyte differentiation: Implications for treatment of obesity. Proc Natl Acad
Sci U S A 96: 2391-5.
Zhu, Y., M . I. Romero, P. Ghosh, Z. Ye, P. Charnay, E. J. Rushing, J. D. Marth and L. F.
Parada (2001). Ablation of N F 1 function in neurons induces abnormal
development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15:
859-76.
Zimmers, T. A., M . V. Davies, L. G. Koniaris, P. Haynes, A. F. Esquela, K. N.
Tomkinson, A. C. McPherron, N . M . Wolfinan and S. J. Lee (2002). Induction of
cachexia in mice by systemically administered myostatin. Science 296: 1486-8.

176

